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Abstract 
Gaucher disease is a lysosomal storage disorder caused by mutations in the GBA1 gene 
encoding the enzyme glucocerebrosidase (GCase). Deficiency of GCase causes the 
accumulation of its substrate glucosylceramide in both visceral organs and the brain. 
Enzyme replacement therapy is successfully used to ameliorate the visceral pathology, 
however there is no treatment available for the lethal neurodegeneration. This research 
focuses on Gaucher disease type II, the most acute neuronopathic form, in which the 
neuropathology results in death during early infancy. The aim of this project is to 
intravenously administer adeno-associated viral vector (AAV) based gene therapy to a 
GCase-deficient mouse model of acute neuronopathic Gaucher disease and assess 
improvement in lifespan, behaviour, brain and visceral pathology. 
The untreated Gba1 knock-out mice die 12-14 days after birth following severe 
neurodegeneration. The AAV vector carrying the functional human GBA1 gene under 
control of a ubiquitous promoter was intravenously administered to neonatal knock-out 
mice, with treated animals showing a significant increase in their lifespan (p=0.0081). 
Since the animals did not develop any evident pathological symptoms, they were 
sacrificed at 55 days of age for a short-term study. The neuropathology was ameliorated 
and several of the most affected areas of the brain were partially rescued. The analysis 
of liver, spleen, lung and heart tissues revealed promising improvements in the visceral 
pathology. A consequent long-term study was performed on 180-day-old treated mice, 
with the aim to compare intravenous and intracranial administration of the viral vector. 
In order to enhance the therapeutic effects of the treatment and improve gene expression 
in the central nervous system, a novel construct where the GBA1 gene is controlled by a 
neuron-specific promoter was administered to neonatal knock-out mice. The severe 
neurodegeneration was further rescued and the life span of treated animals increased. 
Together, these encouraging results demonstrate that gene therapy could provide an 
effective treatment for the neuronopathic form of Gaucher disease, for which 
therapeutic needs are currently unmet. 
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Impact statement 
The clinical impact of gene therapy is rapidly growing, as this field has the potential to 
provide treatment for a wide spectrum of diseases. Gaucher disease, although rare, is the 
most common lysosomal storage disorder (Belmatoug, 2012). Enzyme replacement 
therapy and substrate reduction therapy are effective in treating the visceral pathology 
of type I patients; however there is no cure for the neuronopathic forms of Gaucher 
disease. Gene therapy has shown the potential to address this unmet need. In the light of 
our promising findings, in 2015 the European Medicine Agency granted the Orphan 
Drug designation for AAV9-based gene therapy for neuronopathic Gaucher disease as a 
novel possible treatment. 
Furthermore, systemic gene therapy could not only ameliorate the neuropathology but 
also be beneficial for type I cases. These patients present a wide range of symptoms 
with severe complications in different organs. Although enzyme replacement therapy 
has revolutionised the treatment of type I Gaucher disease (Pastores and Hughes, 2015), 
it has a number of drawbacks. This includes the need for repeated and regular infusions 
for the duration of the patient’s life, which is both difficult and expensive and may fail 
to treat some tissues, such as the bones. Gene therapy has the potential to offer an 
alternative and unified treatment strategy that could overcome these issues through a 
single administration. 
One of the principal limitations is the price of gene therapy trials, as the GMP vector 
manufacturing costs are extremely high. However, from a long-term economic 
perspective, gene therapy for Gaucher disease could be significantly less costly than a 
lifetime of enzyme replacement treatments. Nevertheless, as part of the gene therapy 
community we are confident that, as with all new technologies, further developments in 
research will ultimately decrease the cost of developing novel treatments.
5 
Acknowledgements 
After I graduated, I followed with great interest Dr. Rahim and Dr. Waddington 
research, hoping to move to London one day and join their team. Unfortunately, at that 
time the UCL Institute for Women’s Health did not advertise any new PhD position and 
I was not able to find a suitable studentship. So I gave up, convinced I had lost my 
chance. However my brother, who I could not thank enough for his love and help, 
persuaded me to contact Dr. Rahim and Dr. Waddington despite the odds. Luckily I was 
the right person at the right time, and after a few months of uncertainty I got the 
position. So all my gratitude goes to Ahad and Simon that welcomed me in their office 
that morning and believed in my potential when they passed over to me their precious 
‘Gaucher project’. Over the course of the last three years they have constantly supported 
me, helping me to produce this work.  
I would also like to thank the Gauchers Association for funding my PhD studentship 
and accepting me in their community, as well as all the collaborators who helped me 
along the way. 
I would like to acknowledge everyone from the Waddington’s group, and in particular 
Dany Perocheau for his invaluable patience and assistance. A big thank goes to 
Michael, who helped me infinite times bearing me in the lab and bearing with me at 
home. And of course thanks to Sam, Archie and everyone from the Pharmacology 
department, in whom I found great friends and fellows adventurers.   
I thank from the bottom of my heart my family, who loves my unconditionally and 
without whose advices and sacrifices I would not be here. Grazie. 
Last, but not least, I would like to honour the sacrifice of my animals to further the 
advancements of this scientific research, with the hope that our contribution will help 
Gaucher patients in the future.
6 
Table of contents 
Abstract .................................................................................................................. 3 
Impact statement ................................................................................................... 4 
Acknowledgements................................................................................................ 5 
Table of contents ................................................................................................... 6 
List of figures ....................................................................................................... 11 
List of tables ......................................................................................................... 13 
Abbreviations ...................................................................................................... 14 
1. Introduction ..................................................................................................... 18 
1.1. Lysosomal Storage Disorders ............................................................................................ 19 
1.1.1. Pathobiology ............................................................................................................. 21 
1.1.2. Visceral manifestations ............................................................................................. 24 
1.1.3. Neuropathology ........................................................................................................ 25 
1.1.4. Therapies ................................................................................................................... 26 
1.2. Gaucher disease .................................................................................................................. 29 
1.2.1. Clinical classification ................................................................................................ 29 
1.2.2. Genetics and epidemiology ....................................................................................... 31 
1.2.3. Biochemistry and cellular pathology ........................................................................ 34 
1.2.4. Neuropathology ........................................................................................................ 38 
1.2.5. Therapies ................................................................................................................... 41 
1.2.6. Gaucher type II mouse models ................................................................................. 43 
1.3. Gene therapy ....................................................................................................................... 46 
1.3.1. Adeno-associated virus ............................................................................................. 48 
1.3.2. Adeno-associated virus as a gene delivery vector .................................................... 50 
1.3.3. Adeno-associated virus mediated gene delivery to the central nervous system ....... 54 
1.3.4. Gene therapy for lysosomal storage disorders .......................................................... 58 
1.4. Rationale .............................................................................................................................. 62 
2. Materials and methods ................................................................................... 64 
2.1. Primer sequences ................................................................................................................ 64 
2.2. Antibodies ............................................................................................................................ 64 
2.3. Cloning................................................................................................................................. 66 
2.3.1. Transformation of plasmid DNA .............................................................................. 66 
2.3.2. Amplification of plasmid DNA ................................................................................ 66 
2.3.3. Digest ........................................................................................................................ 66 
7 
2.3.4. Gel electrophoresis ................................................................................................... 67 
2.3.5. Extraction of DNA fragments from agarose gel ...................................................... 67 
2.3.6. Ligation of DNA fragments ..................................................................................... 68 
2.3.7. Sequencing ............................................................................................................... 68 
2.4. Tissue culture ..................................................................................................................... 68 
2.4.1. Cell lines ................................................................................................................... 68 
2.4.2. Cell transfection ....................................................................................................... 69 
2.5. AAV9 production ............................................................................................................... 69 
2.5.1. Seeding ..................................................................................................................... 70 
2.5.2. Transfection .............................................................................................................. 70 
2.5.3. Harvesting ................................................................................................................ 70 
2.5.4. Benzonase treatment ................................................................................................ 71 
2.5.5. Purification ............................................................................................................... 71 
2.5.6. Concentration ........................................................................................................... 72 
2.5.7. Titration .................................................................................................................... 72 
2.6. In Vivo animal studies ........................................................................................................ 74 
2.6.1. Maintenance of transgenic and wild-type mice ........................................................ 74 
2.6.2. Genotyping ............................................................................................................... 75 
2.6.3. Identification ............................................................................................................ 79 
2.6.4. Virus administration ................................................................................................. 79 
2.6.5. Behavioural assessment of mice .............................................................................. 79 
2.7. Collection and analysis of blood samples ......................................................................... 82 
2.7.1. Blood analysis .......................................................................................................... 82 
2.7.2. Dried blood spots collection ..................................................................................... 82 
2.7.3. Genotyping through GCase enzymatic assay on dried blood spot samples ............. 83 
2.8. Harvesting and tissue preparation ................................................................................... 85 
2.9. Histological analysis of tissues .......................................................................................... 85 
2.9.1. Cryosectioning of murine tissue samples ................................................................. 85 
2.9.2. Preparation of chrome-gelatine coated slides ........................................................... 86 
2.9.3. Immunohistochemical staining on free-floating tissue sections ............................... 86 
2.9.4. Immunofluorescent staining of tissue sections ......................................................... 87 
2.9.5. Nissl staining of brain sections ................................................................................. 87 
2.9.6. Hematoxylin and Eosin (H&E) staining .................................................................. 88 
2.9.7. Microscope imaging ................................................................................................. 88 
2.9.8. Staining quantification ............................................................................................. 89 
2.9.9. Neuronal counts in discrete brain regions using stereology ..................................... 89 
2.10. Protein analysis ................................................................................................................ 90 
2.10.1. Protein concentration measurements from tissue and transfected cell samples ..... 90 
8 
2.10.2. Glucocerebosidase enzymatic activity assay on frozen tissue ................................ 90 
2.10.3. Protein analysis using Western blot ........................................................................ 91 
2.10.4. Enzyme-linked immunosorbent assay (ELISA) ..................................................... 92 
2.11. Statistical analysis ............................................................................................................. 93 
3. Evaluation of intravenous AAV9 administration to neonatal and juvenile mice
 ............................................................................................................................... 94 
3.1. Introduction ........................................................................................................................ 94 
3.2. scAAV2/9.GUSB.GFP.bGHpA vector .............................................................................. 95 
3.3. Analysis of GFP expression in the brain following intravenous administration of the 
scAAV2/9.GUSB.GFP.bGHpA vector to neonatal and juvenile mice .................................. 96 
3.4. An evaluation of immune response following intravenous administration of 
scAAV2/9.GUSB.GFP.bGHpA ............................................................................................... 102 
3.5. Vector distribution in the visceral organs ...................................................................... 103 
3.6. Conclusions ....................................................................................................................... 105 
4. Intravenous AAV9-mediated gene therapy rescues a neonatal lethal mouse 
model of neuronopathic Gaucher disease ....................................................... 107 
4.1. Introduction ...................................................................................................................... 107 
4.2. scAAV2/9.GUSB.hGBA1.bGHpA gene therapy vector ................................................. 108 
4.3. Development of a blood spot assay for the identification of homozygous Gba1 deficient 
mice at day of birth .................................................................................................................. 108 
4.4. Increased life span of K14-lnl/lnl treated animals following neonatal intravenous 
administration of scAAV2/9.GUSB.hGBA1.bGHpA ............................................................ 110 
4.5. Assessment of neurological functions in intravenously Treated K14-lnl/lnl mice ...... 111 
4.6. Analysis of neuropathology in IV treated K14-lnl/lnl mice .......................................... 114 
4.6.1. Widespread overexpression of β-glucocerebrosidase following intravenous 
administration of scAAV2/9.GUSB.hGBA1.bGHpA to neonatal Gba1 knock-out mice. 114 
4.6.2. An assessment of lysosomes in the brain of IV treated K14-lnl/lnl mice ............... 116 
4.6.3. An assessment of astrogliosis in the brain of IV treated K14-lnl/lnl mice ............. 119 
4.6.4. An assessment of microglia activation in the brain of IV treated K14-lnl/lnl mice 122 
4.6.5. An analysis of neuronal loss and cortical thickness in IV treated K14-lnl/lnl mice125 
4.7. An amelioration of visceral pathology in treated K14-lnl/lnl mice .............................. 128 
4.7.1. Normalisation of spleen weight and reduction of macrophage activation in IV 
treated K14-lnl/lnl mice .................................................................................................... 129 
4.7.2. Systemic administration of scAAV2/9.GUSB.hGBA1.bGHpA ameliorates pathology 
in the liver of treated Gba1 knock-out mice ..................................................................... 131 
4.7.3. Amelioration of lung pathology resulting from intravenous administration of 
scAAV2/9.GUSB.hGBA1.bGHp ...................................................................................... 133 
4.7.4. Blood parameters in Gba1 knock-out mice treated following systemic injection of 
scAAV2/9.GUSB.hGBA1.bGHp ...................................................................................... 135 
4.7.5. Intravenous administration of scAAV2/9.GUSB.hGBA1.bGHp resulted in the 
increase of the β-glucocerebrosidase activity in some organs .......................................... 136 
9 
4.8. Long-term study ............................................................................................................... 138 
4.9. Conclusions ....................................................................................................................... 140 
5. AAV9-mediated expression targeted to neurons enhances therapeutic efficacy in 
the brain of a neuronopathic Gaucher disease mouse model ........................ 142 
5.1. Introduction ...................................................................................................................... 142 
5.2. Reporter gene study ......................................................................................................... 143 
5.2.1. ssAAV2/9.hSynI.eGFP.WPRE.hGHpA vector ..................................................... 143 
5.2.2. eGFP neuronal expression profile following intravenous administration of the 
ssAAV2/9.hSynI.eGFP.WPRE.hGHpA vector to neonatal mice .................................... 145 
5.2.3. Transduction of the visceral organs ....................................................................... 148 
5.3. ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA vector ........................................................... 149 
5.3.1. Cloning of the hGBA1 gene and in vitro testing .................................................... 150 
5.3.2. Codon optimisation of the GBA1 sequence ............................................................ 152 
5.3.3. ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA viral vector production ........................ 153 
5.3.4. Assessment of neuroinflammatory response .......................................................... 154 
5.4. Gene therapy in the mouse model for neuronopathic Gaucher disease ...................... 155 
5.4.1. Extension of lifespan and health monitoring .......................................................... 156 
5.4.2. Assessment of neurological manifestations ........................................................... 157 
5.4.3. Widespread overexpression of β-glucocerebrosidase in the brain of treated K14-
lnl/lnl mice ....................................................................................................................... 160 
5.4.4. Reduction of neuroinflammation in Gba1 knock-out mice following vector 
administration ................................................................................................................... 164 
5.4.5. Normalisation of microglia activation in treated K14-lnl/lnl mice ........................ 166 
5.4.6. Administration of the ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA vector prevented 
accumulation of lysosomes in the brain ........................................................................... 169 
5.4.7. Gene therapy prevents neuronal loss ...................................................................... 172 
5.4.8. Effects of gene therapy on the visceral pathology ................................................. 175 
5.5. Conclusions ....................................................................................................................... 178 
6. Discussion ....................................................................................................... 181 
6.1. Overview ........................................................................................................................... 181 
6.2. Intravenously administered AAV9 gene therapy can rescue an acute neonatal lethal 
mouse model of neurodegeneration ....................................................................................... 182 
6.3. Amelioration of neuropathology in the K14-lnl/lnl mouse model following intravenous 
AAV9-mediated gene therapy ................................................................................................ 183 
6.4. A single-stranded AAV9 vector that includes the synapsin promoter and the WPRE 
element is the preferred construct for treating type II neuronopathic Gaucher disease . 183 
6.5. Clinical precedent for intravenously administered AAV9 gene therapy for 
neurological diseases ............................................................................................................... 186 
6.6. Final considerations ......................................................................................................... 187 
6.7. Future perspective ........................................................................................................... 189 
10 
6.8. Conclusion ......................................................................................................................... 191 
Bibliography ...................................................................................................... 192 
11 
List of figures 
Figure 1 - Cellular mechanisms affected in lysosomal storage disorders. ...................... 23 
Figure 2 - Wide spectrum of phenotypes in Gaucher disease. ........................................ 30 
Figure 3 - GBA1 gene. ..................................................................................................... 32 
Figure 4 - β-glucocerebrosidase and glycosphingolipids metabolic pathway. ............... 36 
Figure 5 - Neuronopathic Gaucher disease mouse model. .............................................. 45 
Figure 6 - Generation of recombinant AAV vectors. ...................................................... 52 
Figure 7 - Cross-correction events following viral transfection. .................................... 59 
Figure 8 - K14-lnl/lnl mouse model. ............................................................................... 78 
Figure 9 - Tail suspension test. ....................................................................................... 81 
Figure 10 - Schematic of the scAAV2/9.GUSB.GFP.bGHpA final expression cassette.
 ......................................................................................................................................... 96 
Figure 11 - Immunoperoxidase detection for GFP protein in brain sections from mice 
administered with 4 x 1011 gc scAAV2/9.GUSB.GFP.bGHpA following intravenous 
injection into neonatal administered and juvenile administered mice. ........................... 97 
Figure 12 - Quantification of GFP immunostaining. ...................................................... 98 
Figure 13 - Distribution of GFP-positive cells in different brain regions. .................... 100 
Figure 14 - GFP transduction in neonatal and juvenile administered brains following 
intravenous injection of scAAV2/9.GUSB.GFP.bGHpA. ........................................... 102 
Figure 15 - Immune response in brains from mice administered with 
scAAV2/9.GUSB.GFP.bGHpA. .................................................................................. 103 
Figure 16 - GFP ELISA assay on visceral organ samples from neonatal and juvenile 
administered mice injected with scAAV2/9.GUSB.GFP.bGHpA. .............................. 104 
Figure 17 - Schematic of the scAAV2/9.GUSB.hGBA1.bGHpA expression cassette. 108 
Figure 18 - Identification of knock-out mice at day of birth......................................... 109 
Figure 19 - Increase in life span and weight analysis of K14-lnl/lnl treated mice........ 111 
Figure 20 - Behavioural analysis of IV treated mice. ................................................... 113 
Figure 21 - β-glucocerebrosidase expression following vector administration. ........... 116 
Figure 22 - Anti-LAMP1 lysosomal staining................................................................ 119 
Figure 23 - Astrocyte activation in K14-ln/lnl treated mice. ........................................ 122 
Figure 24 - Amelioration of microglia activation in IV treated mice. .......................... 125 
12 
Figure 25 - Nissl staining and stereology analysis. ....................................................... 127 
Figure 26 - Amelioration of spleen pathology following systemic administration of the 
scAAv2/9.GUSB.hGBA1.bGHpA vector. .................................................................... 129 
Figure 27 - Correction of the liver pathology in IV treated K14-lnl/lnl mice. ............. 132 
Figure 28 - Histological analysis of lung tissue from IV treated K14-lnl/lnl mice. ..... 134 
Figure 29 - Blood analysis. ........................................................................................... 135 
Figure 30 - Enzymatic activity in different visceral organs. ......................................... 137 
Figure 31 - Effects of the intravenous administration of gene therapy in K14-lnl/lnl in a 
long-term study. ............................................................................................................ 139 
Figure 32 - ssAAV2/9.hSynI.eGFP.WPRE.hGHpA vector. ........................................ 144 
Figure 33 - Titration of ssAAV2/9.hSynI.eGFP.WPRE.hGHpA. ................................ 145 
Figure 34 - Widespread neuronal expression following intravenous administration of 
ssAAV2/9.hSynI.eGFP.WPRE.hGHpA. ...................................................................... 146 
Figure 35 - Confocal microscopy imaging demonstrated neuronal-specific tropism of 
the vector. ...................................................................................................................... 148 
Figure 36 - Transduction of visceral organs following administration of the 
ssAAV2/9.hSynI.eGFP.WPRE.hGHpA vector. ........................................................... 149 
Figure 37 - Cloning and in vitro testing of the pAAV.hSynI.eGFP.WPRE.hGHpA 
plasmid. ......................................................................................................................... 151 
Figure 38 - Codon optimisation of the GBA1 gene. ...................................................... 153 
Figure 39 - ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA virus production....................... 154 
Figure 40 - Analysis of neuroinflammation following administration of the vector to 
wild-type mice............................................................................................................... 155 
Figure 41 - Prolonged lifespan of treated K14-lnl/lnl animals. .................................... 156 
Figure 42 - Behavioural assessment of treated mice. .................................................... 160 
Figure 43 - Overexpression of β-glucocerebrosidase in treated brains. ........................ 163 
Figure 44 - Reduction of astrocytosis in treated mice. ................................................. 166 
Figure 45 - Reduction of microglia activation in treated K14-lnl/lnl mice. ................. 169 
Figure 46 - Normalisation of lysosome accumulation levels following gene therapy 
administration................................................................................................................ 172 
Figure 47 - Analysis of neurodegeneration following gene therapy. ............................ 174 
Figure 48 - Analysis of visceral pathology following gene therapy administration. .... 177 
13 
List of tables 
Table 1 - Summary of the most common lysosomal storage disorders. ......................... 21 
Table 2 - Cellular tropism of AAV 1-9 serotypes. .......................................................... 50 
Table 3 - Summary of preclinical studies on intravenous administration of AAV9 
vectors targeting the central nervous system. ................................................................. 57 
Table 4 - Summary of clinical trials for lysosomal storage disorders............................. 61 
Table 5 – Primers. ........................................................................................................... 64 
Table 6 - List of antibodies used in the study. ................................................................ 65 
Table 7 - Coordinates from bregma. ............................................................................... 89 
14 
Abbreviations 
3D    Three-dimensional 
AAV    Adeno-associated virus 
BSA    Bovine serum albumin 
CA1/CA2    Cornus ammonis region 1 and 2  
CMV    Cytomegalovirus 
CBE    Conduritol B epoxide  
CD68    Cluster of Differentiation 68 
cDNA    Complementary DNA  
CENT2   Central lobule 2 
CLN    Neuronal ceroid-lipofuscinosis 
CNS    Central nervous system 
dH2O    Distilled water 
DNA    Deoxyribonucleic acid 
ER    Endoplasmic reticulum 
15 
FGF-2    Fibroblast growth factor 2 
GAGs    Glycosaminoglycans 
GalCer    Galactosylceramide  
gc    Genome copies 
GCase    β-glucocerebrosidase 
GFAP     Glial fibrillary acidic protein 
GFP    Green fluorescent protein 
Gi     Gigantocellular nuclei 
GlcCer    Glucosylceramide 
GM     Monosialotetrahexosylganglioside 
GUSB    β-glucuronidase 
H&E     Hematoxylin and Eosin 
IC     Intracranial 
ICV     Intracerebroventricular 
IT     Intrathecal 
ITR    Inverted terminal repeat 
16 
IV     Intravenous 
kb    Kilo base 
KO     Knock-out 
LAMP1   Lysosome-associated membrane protein 1 
LIMP-2    Lysosome integral membrane protein 2  
loxP    Locus of X(cross)-over in P1  
M6P     Mannose-6-phosphate  
MHC I    Major histocompatibility complexes class I 
MPSs     Mucopolysaccharidoses 
mRNA    Messenger RNA 
NPC     Niemann-Pick disease type C 
ns     Non-significant 
P     Postnatal day 
PEI     Polyethylenimine 
PFA     Paraformaldehyde  
rAAV     Recombinant AAV 
17 
RNA     Ribonucleic acid 
S1BF     Somato-barrel field region 1 
scAAV    Self-complementary AAv 
SD     Standard deviation 
SERCA   Sarco/endoplasmic reticulum ATPase   
ssAAV   Single-stranded AAV 
ssDNA    Single-stranded DNA 
TNF- α    Tumor necrosis factor alpha 
UPR    Unfolded protein response 
UV     Ultraviolet 
vg     Viral genome 
vp     Viral particle 
VPM/VPL    Ventral post medial/ventral post lateral thalamic nuclei 
WPRE    Woodchuck post-transcriptional regulatory element 
WT     Wild-type 
18 
1. Introduction 
Gaucher disease is the most common lysosomal storage disorder (Lal and Sidransky, 
2017). The disease is caused by mutations in the GBA1 gene, which encodes for the 
lysosomal enzyme β-glucocerebrosidase, resulting in the accumulation of storage 
material in macrophages within visceral organs and in some cases the brain of affected 
patients. The spectrum of clinical manifestations is broad and there can be a lack of 
direct correlation between genotype and phenotype. However, Gaucher disease has 
historically been broadly classified into three distinct types according to the absence or 
presence and severity of central nervous system impairment.  While there is a 
commercially available treatment that efficiently ameliorates the systemic 
manifestations, the neurological manifestations of the disease still remain incurable.  
Extraordinary advances in the gene therapy field shed a light on the potential use of 
adeno-associated viruses as a therapeutic tool for the treatment of genetic diseases and 
in particular lysosomal storage disorders. Gaucher disease represents a feasible 
candidate for viral gene therapy applications. Taking into consideration the successful 
results of many preclinical studies on gene delivery to the central nervous system, gene 
therapy may be a promising clinical therapeutic option for the untreatable neuropathic 
forms of Gaucher disease. 
The aim of this introductory chapter is to provide the reader with an overview of the 
main molecular and pathological features that characterise many lysosomal storage 
disorders, particularly Gaucher disease. Some of the current therapeutic options will be 
explored. Viral gene therapy and specifically gene delivery to the central nervous 
system will be examined. This chapter will conclude with a brief discussion of the 
rationale of the outlined research project. 
 
 
19 
1.1. Lysosomal Storage Disorders  
Lysosomal storage disorders are monogenic metabolic diseases caused by the 
accumulation of biological materials in the late endosome/lysosome system (Platt, 
2014). These include more than 60 different diseases, and even though they are referred 
to as rare their estimated combined frequency at birth is 1:7,500 (Cox and Cachon-
Gonzalez, 2012). Traditionally, lysosomal storage diseases have been classified 
according to the substrate that accumulates in the cells (Table 1). However, these 
diseases are mainly caused by mutations in the genes encoding enzymatic hydrolases 
involved in the metabolism of macromolecules, so that the same metabolic pathway can 
be affected in different pathologies. Therefore, although caused by different genetic 
defects, distinctive disorders could be characterised by the accumulation of the same 
biological material (Prinetti et al., 2011). Moreover, the identification of novel defects 
in lysosomal enzymes and integral proteins involved in trafficking broadened the 
traditional classification of lysosomal storage disorders (Boustany, 2013). 
In some ethnic groups, especially isolated communities and enclosed geographical 
areas, the incidence of lysosomal storage diseases or carrier frequency is drastically 
higher (Boustany, 2007). The known genetic defects involved in lysosomal storage 
diseases are numerous and even though lysosomal disorders are monogenic diseases, 
several diverse mutations have been identified in the same affected gene in different 
patients. The effects of distinctive mutations on the same gene are broad and can 
influence severity and onset of the disease. In fact, different mutations can lead to 
complete disruption of the enzymatic residual activity or only partially reduce it. The 
proximity of the mutation to the catalytic site of the enzyme, the distribution of stored 
substrate in specific tissues and the cell turnover rate are some of the factors that can 
influence the severity of the pathology. Taking these variations into consideration, it is 
clear that genetic analysis is not always enough to predict the symptoms, onset and 
progression of the disease, as the spectrum of the clinical manifestations is broad and 
there may not always be a direct genotype-phenotype correlation (Futerman and van 
Meer, 2004). 
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CLASS  DEFECTIVE ENZYME OR PROTEIN 
Sphingolipidoses   
Fabry disease α-Galactosidase A 
Farber lipogranulomatosis Ceramidase 
Gaucher disease type I β-Glucosidase 
Gaucher disease types II and III Saposin-C activator 
Niemann–Pick disease types A and B Sphingomyelinase 
GM1-gangliosidosis: infantile, 
juvenile and adult variants 
β-Galactosidase 
GM2-gangliosidosis (Sandhoff): 
infantile and juvenile 
β-Hexosaminidase A and B 
GM2-gangliosidosis (Tay–Sachs): 
infantile, juvenile and adult variants 
β-Hexosaminidase A 
GM2-gangliosidosis (GM2-activator 
deficiency) 
GM2-activator protein 
GM3-gangliosidosis GM3 synthase 
Metachromatic leukodystrophy (late 
infantile, juvenile and adult) 
Arylsulphatase A 
Sphingolipid-activator deficiency Sphingolipid activator 
Mucopolysaccharidoses   
MPS I (Scheie, Hurler–Scheie and 
Hurler disease) 
α-Iduronidase 
MPS II (Hunter) Iduronidase-2-sulphatase 
MPS IIIA (Sanfilippo A) Heparan N-sulphatase (sulphamidase) 
MPS IIIB (Sanfilippo B) N-acetyl-α-glucosaminidase 
MPS IIIC (Sanfilippo C) Acetyl-CoA; α-glucosamide N-acetyltransferase 
MPS IIID (Sanfilippo D) N-acetylglucosamine-6-sulphatase 
MPS IVA (Morquio syndrome A) N-acetylgalactosamine-6-sulphate sulphatase 
MPS IVB (Morquio syndrome B) β-Galactosidase 
MPS VI (Maroteaux–Lamy) N-acetylgalactosamine-4-sulphatase (arylsulphatase B) 
MPS VII (Sly disease) β-Glucuronidase 
MPS IX Hyaluronidase 
Glycogen storage disease   
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Pompe (glycogen storage disease 
type II) 
 
 
 
α-Glucosidase 
Oligosaccharidoses   
α-Mannosidosis α-Mannosidase 
β-Mannosidosis β-Mannosidase 
Fucosidosis α-Fucosidase 
Aspartylglucosaminuria Aspartylglucosaminidase 
Schindler disease α-N-acetylgalactosaminidase 
Sialidosis α-Neuraminidase 
Galactosialidosis Lysosomal protective protein 
Mucolipidosis II (I-cell disease); 
mucolipidosis III 
Urine diphosphate-N-acetylglucosamine; lysosomal 
enzyme N-acetylglucosaminyl-1-phosphotransferase 
Integral membrane protein 
disorders 
  
Cystinosis Cystinosin 
Danon disease Lysosome-associated membrane protein 2 
Action myoclonus–renal failure 
syndrome 
Lysosome membrane protein 2 
Salla disease Sialin 
Niemann–Pick disease type C1 NPC-1 , NPC-2 
Mucolipidosis IV Mucolipin 
Additional disease types   
Multiple sulphatase deficiency Sulphatase-modifying factor 2 
Niemann–Pick disease type C2 NPC-2 
Wolman disease (infantile); 
cholesteryl ester storage disease 
Lysosomal acid lipase 
Galactosialidosis Cathepsin A 
Table 1 - Summary of the most common lysosomal storage disorders. 
Classification of main lysosomal storage diseases and correspondent defective enzymes. 
1.1.1. Pathobiology 
The pathophysiology of lysosomal storage disorders is complex and still not fully 
understood. This is because the lysosomal compartment is involved in numerous 
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cellular mechanisms and several biological processes contribute to the propagation of 
pathology (Figure 1). 
The endosome/lysosome system is a tightly connected cellular compartment and it is 
responsible for the degradation and recycling of extracellular substrates. Moreover, 
cellular components, such as protein aggregates, damaged cytosolic organelles and 
intracellular pathogens can be targeted for degradation in lysosomes through the 
formation of autophagosomes and consequent fusion and release of the damaged 
cellular material into the lysosomal compartment (Levine and Klionsky, 2004). 
Autophagy is a tightly controlled cellular mechanism; therefore it is not surprising that 
this process is dysregulated in many lysosomal storage disorders. Indications of the 
involvement of impaired autophagy in lysosomal storage disorders have been found in 
several animal models of Neuronal Ceroid Lipofuscinoses (Koike et al., 2005), Pompe 
disease (Fukuda et al., 2006) and Niemann-Pick type C (Ko et al., 2005). 
Some of the macromolecules that accumulate in lysosomal storage disorders are 
involved in various signal transduction pathways, such as glycosaminoglycans (GAGs) 
in mucopolysaccharidoses, heparan sulphate in Hurler disease or galactosylceramide in 
Krabbe disease (Huizing et al., 2008). Metabolites produced from the degradation of 
GAGs have a similar structure to the bacterial endotoxin lipopolysaccharide. When this 
material accumulates it can activate the Toll like receptor 4 (TLR4), leading to the 
secretion of proinflammatory cytokines like TNF-α, and the proapoptotic signalling 
molecule ceramide (Simonaro et al., 2005). Ceramide synthesis is also upregulated in 
some ceroid lipofuscinosis, where the accumulation of CLN proteins activates the 
production of ceramide, contributing to the increased apoptosis (Haddad et al., 2012). 
Impairment of the fibroblast growth factor 2 signalling cascade due to the accumulation 
of heparan sulphate in neuronal precursor cells in Hurler syndrome promotes 
neurodegeneration and cell death (Pan et al., 2005). The aforementioned examples are 
only a few of the critical signal transduction pathways that can be impaired in lysosomal 
storage diseases, where dysfunctions in lipid rafts and trafficking result in cell death. 
However, the apoptotic pathway is not the only signalling mechanism that can be 
altered in lysosomal storage disorders. For instance, in Krabbe disease the accumulation 
of galactosylceramide’s derivative psychosine activates the T-cell associated gene 8 
(TDAG8) receptor, inhibiting physiological cytokinesis with consequent formation of 
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multinucleated ‘globoid’ cells (Esch et al., 2003). 
 
 
Figure 1 - Cellular mechanisms affected in lysosomal storage disorders. 
Schematic representation of the cellular functions of the lysosome. Many cellular compartments 
and organelles are disrupted in lysosomal storage diseases. Dysfunctions in the 
endosomal/lysosomal compartment lead to dysregulation of autophagy and cell death. Lipid raft 
and cellular signalling are also impaired. The endoplasmic reticulum (ER) and calcium 
homeostasis are affected.  
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Endoplasmic reticulum (ER) functionality is also impaired in some lysosomal storage 
disorders. In Gaucher disease the accumulation of glucosylceramide (GlcCer) within 
neurons causes supraphysiological release of calcium from the ER to the cytosol, 
inducing the activation of the calcium channel ryanodine receptor and consequent 
increased response of glutamate in affected neurons (Lloyd-Evans et al., 2003). On the 
contrary, in Sandhoff and Tay-Sach diseases the reuptake of calcium into the ER via the 
sarco/endoplasmic reticulum ATPase (SERCA) is inhibited (Pelled et al., 2003). The 
depletion of calcium within the endoplasmic reticulum affects the correct folding of 
proteins. It has been reported that a continued unfolded protein response (UPR) is 
induced by the accumulation of storage material in GM1-gangliosidosis, causing 
apoptosis through the caspase-12 pathway (Tessitore et al., 2004). As a result of 
alteration of calcium homeostasis neurotoxicity is promoted, ultimately leading to 
neuronal loss.  
1.1.2. Visceral manifestations 
Although the nature of the biologic material that accumulates in different lysosomal 
storage disorders varies, many of these pathologies share common clinical features. 
Typically, these disorders have multi-organ presentations. The onset of the phenotypes 
varies and even though lysosomal storage disorders are usually not congenital, in most 
acute cases the manifestations can be present at birth. In many diseases, like Gaucher, 
Niemann-Pick, MPSs, and other sphingolipidoses, one of the first pathological 
manifestations is hepatosplenomegaly, often already present at birth (Staretz-Chacham 
et al., 2009). Cardiomyopathies, including cardiomegaly, heart failure and deposition of 
glycogen in the heart valves are associated with many lysosomal storage disorders and 
can be present in newborns, like in infantile Pompe disease, or have a later onset as in 
several shpingolipidoses (Guertl et al., 2000). Severe respiratory manifestations have 
been described in Pompe disease patients, where muscular hypotonicity causes 
reduction in lung volume (Disease et al., 2006); as well as in NPC-2 (Morisot et al., 
2005) and Farber disease patients (Devi et al., 2006). Haematological and endocrine 
manifestations are also typical of lysosomal storage disorders: anaemia and 
thrombocytopenia are haematological features characteristic of Gaucher disease (Roth 
et al., 2005), while osteopenia and enlargement of endocrine glands are present in other 
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lysosomal storage disorders, especially in MPSs patients (Polgreen et al., 2008). As 
secondary manifestation of haematological disorders and organomegaly, many 
lysosomal storage disease patients, including MPS, GM1-gangliosidosis, NP-C, 
Gaucher and Farber disease, present with hydrops fetalis (Stone and Sidransky, 1999). 
Abnormal bone formation, joint contractures and swelling usually develop later in 
Gaucher, Farber, MPS and GM1-gangliosidosis patients, although bone disease has 
been occasionally described in neonates (Staretz-Chacham et al., 2009). Various 
cutaneous manifestations, such as ichtchyosis, skin lesions and an increase in body hair 
are typical of Gaucher (Sidransky et al., 1996), MPSs and Fabry disease (Boustany, 
2013). New born patients can also present dysmorphic features, as coarse facies, 
depressed or absent nasal septum and unusual facial appearances (Boustany, 2007). 
1.1.3. Neuropathology 
The central and peripheral nervous systems are affected in many forms of lysosomal 
storage diseases, causing a variety of symptoms, including neurocognitive impairment, 
movement disorders, seizures, optical manifestations and deafness, which usually lead 
to premature death (Walkley, 2009). Even though many lysosomal storage disorders 
share common neurological phenotypes, the pathological mechanisms underlying 
neurodegeneration can be various. Clearly, the accumulation of different substrates and 
their effects on neurons depend on the specific cell type, morphology and distribution: 
in fact, the storage can be widespread throughout the brain or affect just a restricted 
more vulnerable cell population. In Fabry disease deposits of primary substrate 
globotriaosylceramide have been found in a limited number of neurons in specific brain 
regions, such as the brain stem, hypothalamus, amygdala, and in the spinal cord 
(deVeber et al., 1992).  
It has been shown that the accumulation of sphingolipids, such as ceramide and 
glucosylceramide plays a significant role in the neuroinflammatory response in 
lysosomal storage diseases (Nixon, 2009). Whether primary neuronal damage triggers 
the activation of glial cells or neurodegeneration and neuronal death are caused by 
metabolic dysfunctions within microglia has not yet been clarified (Bosch and Kielian, 
2015). It is evident that chronic inflammation and neurodegeneration are tightly 
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correlated; however the neuropathology in lysosomal storage disorders is not triggered 
exclusively by primary storage in neurons. For instance, in α-mannosidosis brains are 
affected by primary accumulation of mannose-rich oligosaccharides, although 
secondary storage of GM2 and GM3-gangliosides specifically in cortical pyramidal 
neurons is thought to affect neuronal integrity and contribute to the formation of ectopic 
dendrites and axonal spheroids (Crawley and Walkley, 2007).  
Although severe neuropathology can be already present at birth, in most patients the 
onset of the first neurological symptoms may range from late infancy to adulthood in 
less acute chronic cases (Jardim et al., 2010). As for the visceral manifestations, 
neurological clinical expressions can vary accordingly to the severity of the mutations. 
The heterogeneity in symptoms and onset can lead to misdiagnosis or delayed 
diagnosis, in particular for subjects without family history. Therefore, the initial 
screening requires confirmation through biochemical and\or genetic analysis (Pastores 
and Maegawa, 2013). 
1.1.4. Therapies 
Enzyme replacement therapy is today’s standard approved treatment for many 
lysosomal storage disorders, including Gaucher disease type I, Fabry disease, Pompe 
disease and some MPSs (Desnick and Schuchman, 2012). In the early 1970s, it was 
already evident that replacing the specific missing or defective enzyme by systemically 
administering it to the body was sufficient to at least partially correct the intracellular 
enzymatic activity and consequently clear the stored material. Therefore, regular 
intravenous infusions of purified recombinant exogenous enzyme resulted in a feasible 
and effective therapeutic option, particularly successful in milder cases where patients 
present residual enzymatic activity. In the past two decades researchers have established 
new strategies to improve the enzyme formulation. The concept of cross-correction 
developed after the discovery that many lysosomal enzymes are targeted to the 
lysosomes via the mannose-6-phosphate (M6P) receptor pathway, and the same receptor 
is also present on the surface of the plasma membrane (Platt and Lachmann, 2009). 
According to this mechanism the addition of a M6P group to a recombinant enzyme 
allows the cellular uptake by nearby cells of administered or secreted enzyme and 
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facilitates its transport to the lysosomes. Thus, the necessity of correcting every cell is 
overcome and low levels of intracellular enzymatic activity can be sufficient to restore 
the metabolic defect. It is obvious that the cross-correction principle is limited to 
soluble enzymes and it is not suitable for disorders involving transmembrane proteins. 
Although enzyme replacement therapy is safe and usually well tolerated, it presents 
some disadvantages: patients are subjected to continuous and frequent infusions; the 
cost of repetitive administrations is significant; often combination therapies, like bone 
marrow transplantation are required; and more importantly the currently approved 
products do not show any efficacy in the treatment of central nervous system 
pathologies (Brady, 2006). In fact, the infused recombinant enzyme is not able to cross 
the blood-brain barrier, even when administered at high dose. Direct intracerebral or 
intrathecal administration can be a successful alternative. The U.S. Food and Drug 
Administration has recently approved a novel enzyme replacement therapy for late 
infantile CLN2 patients (Brineura©, (Administration, 2017)). The treatment is 
administered once every other week directly into the cerebrospinal fluid via a reservoir 
with a ventricular catheter. Although Brineura© has demonstrated to be efficacious in 
paediatric patients and has received Orphan Drug designation, the nature of the 
procedure is considered invasive and allows for further consideration of other treatment 
strategies. 
An alternative approach is to use a small molecule drug that reduces the synthesis of the 
accumulating pathogenic substrate. This is known as substrate reduction therapy. An 
approved substrate reduction therapy consists of the administration of the imino sugar 
N-butyldeoxynojirimycin (miglustat), a competitive inhibitor of ceramide 
glucosyltransferase that blocks the biosynthesis of glucosylceramide and 
glucosylceramide-derived glycosphingolipids (Platt et al., 1994). Although miglustat 
was first commercialised for Gaucher disease type I, it also has potential for treatment 
of other lysosomal storage disorders, such as Niemann-Pick type C, Fabry disease, and 
GM1 and GM2-gangliosidose, where secondary accumulation of glucosylceramide-
based glycosphingolipids occurs. Moreover, miglustat has shown the ability to cross the 
blood-brain barrier and therefore it can be used as a treatment for neurological 
manifestations (Jeyakumar et al., 2005). The main side effect of miglustat medication is 
the development of severe gastrointestinal symptoms and occasional peripheral 
neuropathy and tremor. 
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Most lysosomal storage disorders are associated with mutations in genes that influence 
protein conformation, folding and trafficking resulting in unstable and degradable 
enzymes. Pharmacological chaperones are molecules that, binding to the nascent 
polypeptides, promote protein stability and inhibit misfolding and protein aggregation 
(Parenti et al., 2015). Pharmacological chaperone therapy had first been proposed as a 
treatment for Fabry disease, where 1-deoxygalactonojirimycin (migalastat 
hydrochloride) binds to the active site of α-galactosidase A, increasing its activity 
(Young-Gqamana et al., 2013). More recently, Orphan Drug designation was granted to 
Arimoclomol© (Orphazyme AsP) as a potential treatment for Niemann-Pick type C 
patients. Arimoclomol© is a co-inducer of the heat-shock response that induces the 
expression of molecular chaperones like Hsp70, and activates natural cellular repair 
pathways (Parfitt et al., 2014). The treatment has already shown beneficial effects in 
pre-clinical studies on animal models of amyotrophic lateral sclerosis, spinal bulbar 
muscular atrophy and retinitis pigmentosa. The on-going phase 2 study (NCT02612129) 
is currently investigating the efficacy and safety of the drug on NP-C subjects. Since not 
all mutations will be responsive to potential chaperone therapy and the effects of the 
treatment may not always be sufficient, researchers are investigating the possibility of 
chaperone therapy in combination with other treatments. 
Bone marrow transplant for lysosomal storage diseases has been widely performed in 
the last two decades with the aim of engrafting donor cells of haemapoietic origin to 
correct enzyme deficiency in the host (Vellodi, 2014). Although this treatment results in 
amelioration of some disorders, such as Hurler disease, bone marrow transplant is not 
effective for acute neurodegenerative phenotypes. Although donor-derived cells can be 
found in the cerebrospinal fluid, the small percentage of corrected microglia cells is not 
always enough to provide robust enzyme expression and correct the most severe cases 
of neurodegeneration. 
To summarise, although there are some therapeutic options available to treat some 
specific types of lysosomal storage disorders, others remain only partially treatable or 
have no therapeutic strategies available at all. This is particularly so in those conditions 
that also affect the central nervous system.  Moreover, the significant financial cost 
associated to these therapies is a burden that the healthcare system will have to carry for 
the duration of the patients’ lives. 
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Viral gene therapy represents a suitable candidate for the treatment of lysosomal storage 
disorders and is a central theme in this thesis. Therefore, it will be further discussed in 
more detail as a promising potential therapeutic option. 
1.2. Gaucher disease 
Gaucher disease is the most common lysosomal storage disorder, with an approximate 
prevalence of 1:100,000 and annual incidence in the general population of 1:60,000  
(Belmatoug, 2012). The pathology was named after Philippe Gaucher in 1882, who first 
described the typical enlarged spleen cells in a 32-year-old woman. At that time, 
Gaucher incorrectly identified the pathology as splenetic cancer. It was only in 1965 
that the condition was defined as an autosomal recessive disease characterized by the 
inability of the defective lysosomal enzyme β-glucocerebrosidase to efficiently degrade 
its substrate glucosylceramide (Hruska et al., 2008). 
1.2.1. Clinical classification  
Classically, Gaucher disease has been broadly classified into three main forms based on 
the absence (type I) or presence and severity of neurological symptoms (type II and type 
III). However, the more realistic clinical assessment of patients has shown that Gaucher 
disease exhibits a continuum of phenotypes with the main distinction of presence or 
absence of neurological involvement (Sidransky, 2004) (Figure 2). Nevertheless, to aid 
in recognition, this text will refer to the traditional classification. 
Type I – Type I is the most frequent form of Gaucher disease and its manifestations do 
not involve central nervous system impairment. The physical presentation is 
characterised by a number of visceral symptoms. This includes severe splenomegaly: 
the size of the spleen can reach 1500-3000 cm3, compared to the average 50-200 cm3 in 
healthy adults (Stone et al., 2000a). Hypersplenism is accompanied by massive 
distention of the abdomen and consequent pancytopenia (Nagral, 2014). Anaemia, 
thrombocytopenia and leukopenia can be accompanied by coagulation defects. 
Although enlargement of the liver is common, it usually does not lead to empathic 
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failure. Bone disease is present in 70-100% of type I patients: individuals often develop 
bone crises, pathologic fractures, arthritis, osteonecrosis of the joints and collapse of the 
vertebrae (Pastores et al., 2000). Pulmonary involvement includes pulmonary 
hypertension and interstitial lung disease (Mistry et al., 2002). Renal and cardiac 
complications are less common. Gaucher disease type I has a broad range of onset: first 
symptoms can appear in early childhood and worsen with time, or they can manifest in 
adult patients (Mehta, 2006). 
 
Figure 2 - Wide spectrum of phenotypes in Gaucher disease. 
Although Gaucher disease has been classically classified in three distinct types (type I, II and 
III), it presents with a continuum of manifestations. The primary distinction is now based on the 
presence or absence of neurological symptoms (Sidransky, 2004). 
Type II – Type II is described as the acute neuronopathic form of Gaucher disease. The 
onset of the disease is in the neonatal period and death occurs by age two to four years 
(Goker-Alpan et al., 2003). However, some cases of perinatal-lethal Gaucher disease 
associated with hepatosplenomegaly, skin abnormalities and intrauterine death have 
been reported (Mignot et al., 2006). Gaucher disease type II presents the same visceral 
manifestation of type I, with significant hepatosplenomegaly and pulmonary 
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involvement. Patients develop ichthyosis, ranging from mild skin peeling to the “colloid 
baby” phenotype (Holleran et al., 2006). The earliest neurological symptoms are 
strabismus and horizontal gaze palsy (Harris et al., 1999), hypertonic posturing and 
retroflexion of the head (Pastores and Hughes, 2015). Soon after birth, patients manifest 
difficulties in swallowing, seizures and progressive epilepsy (Blom and Erikson, 1983). 
Death usually occurs following apnoea and laryngospasm as a consequence of extensive 
paralysis (Zimran, 2011). 
Type III – Type III is the chronic neuronopathic form of Gaucher disease. Individuals 
can manifest the first symptoms already in early infancy, however the progression of the 
disease is slow and lifespan can be prolonged to adulthood. The visceral pathology is 
extended and present at birth, while the neurological signs can appear before two years 
of age or manifest later in life (Goker-Alpan et al., 2003). In some cases of chronic 
neurologic Gaucher disease, dementia and ataxia can be observed in the latest stage of 
the pathology (Pastores and Hughes, 2015). The clinical course not always depends on 
age of onset and rate of progression. Furthermore, a subset of patients can manifest an 
intermediate phenotype between type II and III, characterised by a late onset and rapid 
progression of acute neurodegeneration (Goker-Alpan et al., 2003). 
1.2.2. Genetics and epidemiology 
The gene encoding β-glucocerebrosidase (GBA1; MIM# 606463) is located on 
chromosome 1 (1q21) (Barneveld et al., 1983). It consists of 11 exons and 10 introns 
spanning a total of 7.6kb (Hruska et al., 2008) A pseudogene (GBAP) that shares 96% 
of homology with the functional gene and has similar exonic organization is located 
16kb downstream (Horowitz et al., 1989). The GBA1 gene sequence is highly conserved 
among different species, in particular between human and different species of mammals 
(Chenna et al., 2003). On the contrary, the GBAP pseuodogene is only present in 
primates (Martinez-Arias et al., 2001). The cDNA sequence for GBA1 is 1.6kb long. 
The GBA1 gene is transcribed into different mRNAs, mainly deriving from alternative 
splicing events, alternative polyadenylation sites and transcription of the pseudogene 
(Graves et al., 1988). The levels of mRNA vary in different tissues, and they are not 
predictive of the enzymatic activity (Reiner and Horowitz, 1988). This is a reflection of 
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the dissimilarities in the ability to translate the mRNA into a mature protein in different 
cell populations (Xu et al., 1995). 
 
Figure 3 - GBA1 gene.  
A Exonic structure of the human GBA1 gene. The most common mutations described in 
Gaucher patients are indicated. B Proportion of patients carrying the most common mutations 
and predicted phenotype. Data are based on 1097 subjects in the Gaucher Registry (International 
Collaborative Gaucher Group, 1999) (Pastores and Hughes, 2015). 
Today, approximately 300 mutations in the GBA1 gene are known (Scholz and Jeon, 
2015) (Figure 3). The vast majority are missense mutations, but also nonsense 
mutations, small deletions and insertions, and splice junction mutations have been 
reported (Hruska et al., 2008). Different recombinant events between GBA1 and its 
pseudogene can also lead to pathological alterations (Eyal et al., 1990). Most of the 
missense pathological mutations found in patients are conserved in those mammalian 
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species that present high homology with the human gene sequence (Chenna et al., 
2003). The most common mutations1 were first described in 1988 by Tsuji and 
colleagues (Tsuji et al., 1988): N370S (c.1226A>G) and L444P (c.1448T>C) are the 
most prevalent mutated alleles found in Gaucher disease patients. The N370S 
substitution is the most common mutation within Jewish populations and is normally 
associated with Gaucher disease type I. L444P, F231I (c.754T>A), IVS2(+1) G>A and 
the 55bp deletion Δ55 (c.1263-1317del) are usually associated with the acute 
neuropathic form of Gaucher disease (Stone et al., 2000b). As already mentioned, the 
correlation between genotype and phenotype is not always direct, as the genetic state of 
the patients and the residual enzymatic activity do not always correspond to the severity 
of the pathology, resulting in the prediction of disease being challenging. Generally, 
individuals with at least one N307S allele do not develop neuropathology. In 
homozygous patients (N370S/N370S), the low residual enzyme activity is sufficient to 
prevent the central nervous system pathology, however, subjects present a wide range of 
systemic manifestations from asymptomatic adults to severe organomegaly and bone 
disease (Koprivica et al., 2000). Patients homozygous for the L444P and F231I 
mutations develop, in most of the cases, the chronic form of neuropathic Gaucher 
disease (Stone et al., 2000b). However, when either mutation is in combination with a 
null allele, patients are more likely to develop the acute type II phenotype. So far, more 
than 50 mutations have been described for Gaucher disease type II, generally including 
rare and recombinant alleles. Type III patients with mild neurological manifestation, in 
addition of the L444P allele, often carry the R463C (c.1504C>T) mutation; while the 
N188S (c.680A>G) and G377 (c.1246G>A) mutations in combination with a null or 
recombinant allele are more common in individuals with more severe epileptic 
phenotype (Koprivica et al., 2000). Patients carrying the D409H (c.1342G>C) mutation 
manifest a particular form cardiomyopathy consisting in calcification of the cardiac 
valves (Bohlega et al., 2000). However, when D409H is in cis with H255Q (c.882T>G) 
patients develop severe neuropathology. PCR-based detection techniques are not 
suitable to discriminate between the gene and the pseudogene, and may not identify 
recombinant alleles leading to misgenotyping. For this reason, today a combination of 
                                                 
1 Mutations discussed in the text are indicated with the traditional name of the allele. The cDNA 
nomenclature is reported in parentheses, as recommended at http://varnomen.hgvs.org, where nucleotide 
+1 (c.1) is the adenine of the first ATG initiation codon. 
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genome sequencing and genotyping at polymorphic repeat regions is successfully used 
to identify recombinant events and possible new GBA1 mutations 
Ethnic origin contributes to the distribution of pathological mutations between different 
populations. The N370S mutation generally occurs in European, American and Middle 
East populations, with greater frequency among Ashkenazi Jews, Spanish (46%) and 
Portuguese (63%), caused by a founder effect (Pastores and Hughes, 2015). In 
particular, in the Ashkenazi community Gaucher disease type I has a prevalence of 
almost 1:1,000 and the N370S mutation accounts for 70% of the pathogenic variants. 
The L444P allele is more common in North Sweden, Egypt and East Asia (Nagral, 
2014). The N370S and 84GG (c.84dupG) alleles are not present in Japanese and 
Chinese populations, while the L444P is more prevalent (41% and 54% respectively) 
(Wan et al., 2006) The mutation D409H prevails in Palestine (Jenin Arabs), Greece and 
Albania. 
1.2.3. Biochemistry and cellular pathology 
The lysosomal enzyme β-glucocerebrosidase (GCase) is responsible for the cleavage of 
the β-glucosidic linkage of the substrate glucosylceramide (GlcCer) (Grabowski et al., 
1990). The first crystal structure of the enzyme was solved in 2003 (Dvir et al., 2003) 
(Figure 4A). The enzyme has a molecular weight of 59kDa and is composed of three 
domains: domain I (residues 1-27, 383-414) is a three-stranded antiparallel β-sheet 
containing two disulphide bridges that are essential for the correct folding of the 
protein; domain II (residues 30-75, 431-497) is an independent immunoglobulin-like 
domain formed by two β-sheet structures; domain III (residues 76-381, 416-430) has a 
TIM barrel structure and contains the catalytic site. More recently the structure of one of 
the mutated form (N370S) of β-glucocerebrosidase was also obtained (Wei et al., 2011). 
The N370S mutation is located on the longest α-helix of the catalytic domain in the 
interface between domain II and III, where several other pathogenic mutations have 
been identified. The N370S mutant results in a correctly folded molecule; however the 
protein structure is less flexible and the enzyme does not efficiently bind the substrate, 
resulting in a reduction of its catalytic activity. The L444P mutation causes a 
conformational change in the hydrophobic core of the protein, altering the folding of 
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domain II and therefore the stability of the enzyme. β-glucocerebrosidase, unlike most 
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Figure 4 - β-glucocerebrosidase and glycosphingolipids metabolic pathway. 
A X-ray structure at 2.0 Å of the β-glucocerebrosidase enzyme (Dvir et al., 2003). Domain I is 
represented in magenta, domain II is in green and domain III is in blue. Some of the most 
common mutations discussed in the text are reported. N370S and L444P are highlighted with 
red circles. B Glycosphingolipids biochemical pathway associated with lysosomal storage 
disorders. The enzymes involved in the most common lysosomal storage disease are indicated 
by arrows. 
of the lysosomal enzymes, is transported via a mannose-6-phosphate independent 
pathway. In humans, the enzyme binds to the chaperone lysosomal integral membrane 
protein type 2 (LIMP-2), and the complex is then transported to the lysosomes in a 
M6P-independent trafficking pathway (Reczek et al., 2007). 
Glucosylceramide consists of a glucose molecule esterified to ceramide (C18, C22 or 
C24 sphingosine). This glucocerebroside is an important intermediate of the 
glycosphingolipid metabolic pathway (Figure 4B) and it is the basic biochemical 
structure from which most glycosphingolipids originate (Platt, 2014). Glucosylceramide 
derives from complex glycosphingolipids mainly resulting from the degradation of 
cellular membranes, in particular senescent blood cells (Sandhoff, 2013).  
β-glucocerebrosidase can also hydrolyse glucosylsphingosine, a deacylated form of 
glucosylceramide (Dekker et al., 2011). This second substrate is cleaved less efficiently 
than glucosylceramide. Nonetheless, it accumulates in the tissues of Gaucher patients, 
in particular within the brain of type II patients and contributes to the progression of the 
pathology. Indeed, glucosylsphingosine has detergent-like properties and damages the 
cell membrane; inhibits protein kinase C; interferes with signal transduction and cell 
differentiation processes; and promotes apoptosis (Spiegel and Merrill, 1996). 
Moreover, glucosylsphingosine is a non-competitive inhibitor of β-glucocerebrosidase, 
so that its accumulation leads to a negative feedback loop and exacerbates the storage of 
substrates (Schueler et al., 2003).  
Glucosylceramide accumulation also correlates with the levels of saposin C, since this 
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glycoprotein is a necessary activator for β-glucocerebrosidase (Tamargo et al., 2012). 
The proposed mechanism suggests that the saposin-enzyme complex is located in the 
proximity of the phospholipidic membrane, where saposin C can solubilise the 
membrane so that endogenous glucosylceramide is accessible for hydrolysis. In 
Gaucher disease, the interaction between saposin C and the N370S mutated form of the 
enzyme is reduced, contributing to the decrease in the enzymatic activity. Deficiency in 
saposin C can interfere with the normal β-glucocerebrosidase activity and lead to 
glucosylceramide accumulation. Few patients with mutations in the gene coding for 
saposin C have developed phenotypes similar to type I and type III Gaucher disease, 
despite their β-glucocerebrosidase activity being in the normal range. These findings 
confirm that deficiency in saposin C in association with mutations in the GBA1 gene 
can affect the β-glucocerebrosidase enzymatic activity and contribute to the severity of 
the pathology. 
Lysosomal accumulation of glucosylceramide is more prominent in those organs that 
present elevated levels of macrophage-lineage cells and cells with myeloid and 
lymphoid derivation (Grabowski, 2012) . Defects in the β-glucocerebrosidase enzyme 
result in the build-up of the substrate glucosylceramide in cells of liver, spleen, bone 
and blood. However, other organs like lungs, skin, heart, kidney and cells of the nervous 
system can be affected. With the development of organomegaly the accumulation 
process occurs at higher rate, further increasing the production of new antigen-
presenting cells, such as macrophages, dendritic cells, thymic T cells and osteoblasts 
(Mistry et al., 2010). These cells turn to an activated state and consequently release a 
series of cytokines and chemokines, contributing to inflammation and progression of the 
disease (Pandey et al., 2012). Activated macrophages become engorged with lysosomes 
containing the stored substrate. These swollen cells are the so-called ‘Gaucher cells’, a 
hallmark of disease progression (Bitton et al., 2004). Gaucher cells can reach 100μm in 
diameter and present morphological anomalies, such as small eccentric nuclei and 
abnormal cytoplasmic striations (Jmoudiak and Futerman, 2005). In addition, activated 
macrophages in inflammatory conditions produce high levels of chitotriosidase.  Serum 
levels of this enzyme are used as diagnostic biomarker in the screening and monitoring 
of Gaucher patients (Hollak et al., 1994). The mechanisms through which the 
accumulation of glucosylceramide leads to organomegaly are not fully elucidated 
(Grabowski, 2010) and even if the storage of the substrate is consistent, it does not fully 
38 
explain the massive enlargement of spleen and liver in Gaucher patients (Cox, 2001). 
Thus, dysfunctions in other metabolic pathways and the involvement of different 
organelles and cell types should be taken into consideration when investigating the 
causes of organomegaly in Gaucher disease. The involvement of other cell types in the 
storage of glucosylceramide is demonstrated by the fact that the knock out of the β-
glucocerebrosidase enzyme in macrophage-lineage cells only leads to a late 
development of visceral pathology in Gaucher mouse model, while the complete 
depletion of the enzyme in all tissues result in premature death (Xu et al., 2008). 
1.2.4. Neuropathology 
Neuronopathic forms of Gaucher disease are characterised by perivascular and 
parenchymal accumulation of Gaucher cells, with pronounced neuronal loss, neuronal 
atrophy and necrosis (Wong et al., 2004). In particular, the acute infantile form is 
characterised by a severe, widespread and rapid neurodegeneration. Neuronal loss is 
prominent in cortex, hippocampus, hypothalamus, nuclei of the midbrain, cerebellum 
and brain stem. Affected brains also show extensive astrogliosis, microglia activation 
and non-specific grey matter gliosis (Adachi et al., 1967). 
The most affected areas of the cortex are the calcarine cortical layer IV, cerebral cortex 
of the temporal and posterior parietal lobe, entorhinal cortex, cingulate gyrus, and 
occipital lobe of layer V (Wong et al., 2004).  Layer III is also affected but the 
neuropathology is less extensive. These regions are characterised by acute astrogliosis 
and neuronal loss. In type II patients, neurodegeneration is strictly confined within the 
layer IVb of the cortex. CA2, CA3 and CA4 hippocampal regions have acute pyramidal 
cell neuronal loss and severe astrogliosis (Wong et al., 2004). In these localised areas 
astrocytes have intricate glial fibrillary acidic protein (GFAP) positive filaments 
branching from the cell body (fibrillary astrogliosis) and also accumulate GFAP 
filaments in the soma (gemistocytic astrogliosis). There is no neuronal loss and increase 
in astrogliosis in CA1. Pryamidal neurons in CA2-4 hippocampal regions are rich in 
excitatory glutaminergic mossy fibres and work in concert with inhibitory GABA-ergic 
interneurons to maintain a finely controlled balance. Thus, minor disequilibrium in 
sensitivity caused by cytotoxic effects of accumulation glucosylceramide can lead to a 
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pathological hypersensitive state, resulting in diffuse seizures. 
Intense microglia activation is present in the reticular thalamic nucleus and in the 
ventral posterior nucleus, with extensive neuronal loss and Gaucher cell accumulation in 
the parenchyma (Wong et al., 2004). 
Pons, medulla, and dentate nuclei in the brain stem show neuronal loss and gliosis in 
proximity of foci of Gaucher cells. Neurons are swollen and contain floccular filaments 
(Conradi et al., 1984). 
Neuroinflammation is thought to further contribute to neuronal loss in severe cases of 
type II, which is mirrored in a murine model of neuronopathic Gaucher disease (Vitner 
et al., 2010). In particular, a chronic and sustained inflammatory state leads to cell 
death, contributing to neuropathology (Bosch and Kielian, 2015). Activated microglia in 
affected brains produce a series of cytokines and chemokines that recruit immune cells 
and activate surrounding cells. Reactive astrocytes are also involved in the 
pathogenesis, releasing chemokines and other cytotoxic molecules. In neuronopathic 
Gaucher disease brains it is possible to detect elevated levels of proinflammatory 
cytokines, like IL-1α, TNFα and reactive oxygen species (Vitner and Futerman, 2013). 
The accumulation of glucosylceramide in inflammatory cells impairs cell migration and 
antigen presentation, contributing to a persistent neuroinflammatory state. It is still not 
clear whether neuroinflammation is a triggering event or a response to 
neurodegeneration. However, it has been shown that neuroinflammation can be detected 
before neuronal loss in a mouse model of neuronopathic Gaucher disease (Farfel-Becker 
et al., 2011b). In this model, astrocytosis and microglia activation occur in those brain 
regions that are characterised by intense neuronal loss, possibly preceding the onset of 
neuronal death events. Enquist and colleagues created a Gaucher mouse model where 
microglia cells (of hematopoietic origin) express physiological levels of β-
glucocerebrosidase but neural and glial progenitor cells lack the enzyme (Enquist et al., 
2007).   The study proposes that when the glucosylceramide storage exceeds 
pathological levels in neurons, astrocytes and oligodendrocytes, a microglial 
proinflammatory response is activated, suggesting that neuronal loss is a cell-
autonomous reaction (Vitner et al., 2012). 
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More recently, a study from Vitner and colleagues on two different mouse models of 
neuronopathic Gaucher disease demonstrated that neuronal loss is not triggered by 
caspase-dependent apoptosis, but by a regulated cell death mechanism named 
necroptosis (Vitner et al., 2014). Necroptosis can be promoted by tumour necrosis 
factors, Toll-like receptors and various extracellular stimuli, which activate the receptor-
interacting kinases 1 and 3 (RIPK1 and RIPK3) signalling cascade, resulting in the 
disruption of the cell membrane and consequent cell death. The study showed that 
RIPK1 and 3 are upregulated in Gaucher disease, not only in the affected mice but also 
in the brain from a type II human patient. The involvement of the necroptotic 
mechanism in neuronal death was further corroborated in an additional mouse model of 
Krabbe disease. Since necroptosis is thought to be involved in several 
neurodegenerative diseases (Zhang et al., 2017), targeting the RIPK family could be a 
promising therapeutic strategy. However the currently known RIPK3 inhibitors are not 
suitable to treat neurodegenerative disorders, as they do not cross the blood-brain barrier 
or have an unfeasibly short half-life. 
Glucosylsphingosine, a second substrate for β-glucocerebrosidase, is an additional 
neurotoxic substance that promotes neuroapoptosis and is found in elevated levels in 
brains from type II and III patients (Nilsson and Svennerholm, 1982). It has been shown 
that the accumulation of glucosylsphingosine alters neuronal morphology, disrupting 
the plasma membrane and leads to neuronal death (Schueler et al., 2003). High levels of 
glucosylsphingosine appear during development and drastically increase throughout 
gestation in type II patients, confirming that the neurotoxic effect may already be 
present before birth (Orvisky et al., 2000).  
In recent years, many studies have demonstrated that mutations in the GBA1 gene are 
linked to parkinsonism (Neumann et al., 2009), and they are now considered an 
important risk factor for developing Parkinson’s disease (Sidransky and Lopez, 2012). 
Parkinson’s patients with mutations to the β-glucocerebrosidase enzyme present 
accumulation of glucosylceramide in the majority of Lewy bodies (Goker-Alpan et al., 
2010). It has been suggested that dysfunction in the lysosomal system might contribute 
to the build-up of α-synuclein, and this accumulation can inhibit β-glucocerebrosidase 
activity establishing a loop mechanism that regulates the link between synucleinopathy 
and Gaucher disease (Mazzulli et al., 2011). The accumulation of misfolded β-
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glucocerebrosidase proteins can either interfere with the clearance of α-synuclein or 
increase its aggregation. The exact mechanisms through which the mutated enzyme 
could affect α-synuclein aggregation are still not fully understood. Since various 
lysosomal storage disorders have been linked to Parkinson’s disease (Shachar et al., 
2011), it is plausible that this gain-of-function effect is not specific for β-
glucocerebrosidase only. A contrasting hypothesis based on a loss-of-function 
mechanism has been proposed (Futerman and Hardy, 2016). In fact, mice completely 
deficient for β-glucocerebrosidase do not produce the misfolded protein but can still 
develop α-synuclein aggregates. It is evident that, since most Gaucher patients do not 
develop parkinsonism, mutations in the GBA1 gene are not a separate risk element, but 
they rather augment more complex pathological modifiers like ageing and 
environmental factors. Different GBA1 mutations influence risk and onset of 
Parkinson’s disease: carriers of severe mutations, like L444P, have a higher risk to 
develop parkinsonism with earlier onset, compared to those carrying milder mutation, as 
N370S (Gan-Or et al., 2015). 
α-synuclein inclusions similar to Lewy bodies have been found in the cortex, 
hippocampus and brain stem of Gaucher patients that also develop milder parkinsonian 
symptoms (Goker-Alpan et al., 2008). These patients present profound neuronal loss 
and extended gliosis the in substantia nigra. The age of onset of Parkinson’s is typically 
earlier than in the sporadic patients and in carriers of a single mutated GBA1 allele. 
1.2.5. Therapies 
Currently, there are different treatment options available for the non-neurological 
Gaucher disease type I. Enzyme replacement therapy and substrate reduction therapy 
are administered in combination with other standard treatments for lysosomal storage 
disorders, such as splenectomy, transfusions, and analgesic treatments (Pastores and 
Hughes, 2015). 
Aglucerase was the first recombinant human enzyme successfully used in clinical trials 
and became available in 1991for the treatement of Gaucher disease (Barton et al., 1991). 
A few years later, more efficient molecules engineered from Chinese hamster ovary 
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cells (imiglucerase, Cerezyme®; Genzyme) and human fibrosarcoma cell line 
(velaglucerase alfa; Shire HGT) became the gold standard treatment for Gaucher 
disease (Deegan and Cox, 2012). Taliglucerase alfa (Elelyso®; Pfizer) is derived form a 
carrot cell line and is commercially available in the USA since 2012. These drugs show 
a significant dose-response effect, reducing the systemic manifestations in viscera, 
bones and blood of Gaucher patients, with mild and occasional adverse effects. 
Imiglucerase is administered via intravenous infusions every two weeks for the duration 
of the patient’s life. Due to the cost of production and the prolonged time of 
administration, enzyme replacement treatment is expensive, with an annual cost of 
approximately $300,000 per patient in USA (Sinha, 2014), up to £187,800 in UK 
(https://www.gaucher.org.uk). Although the cost-effectiveness balance abundantly 
exceeds the normal threshold, imiglucerase has been approved as an Orphan Drug 
(Belmatoug, 2012). 
The first molecule used for substrate reduction therapy in Gaucher disease was the 
imminosugar miglustat (Zavesca®) (Cox et al., 2000). The drug is administered orally 
three times a day. Substrate reduction therapy is effective in reducing the organomegaly 
and the chitotriosidase activity, and ameliorating the skeletal diseases. However, it does 
not have major effects on the hematopathology and its administration is accompanied 
by persistent gastrointestinal adverse effects. Although miglustat crosses the blood-
brain barrier, no beneficial effects on the neuropathology have been reported when 
administered to type III patients (Marshall et al., 2016). An alternative molecule used in 
substrate reduction therapy is eliglustat (Genzyme) (Lukina et al., 2010). The treatment 
demonstrates reversal of organomegaly, amelioration of anaemia and thrombocytopenia, 
and improvement in bone disease. However, since it does not cross the blood-brain 
barrier, eliglustat is not suitable for type II and type III patients. 
A more recent therapeutic strategy for treating the neuropathology of Gaucher patients 
relies on the use of pharmacological chaperones (Parenti et al., 2014). These small 
molecules help maintaining a mutated protein into a stable conformation and therefore 
prevent their degradation by the endoplasmic reticulum quality control system. Since 
pharmacological chaperones are thought to cross the blood-brain barrier, they could be 
suitable for the treatment of neuronopathic forms of Gaucher disease. A 2016 pilot 
study showed that the administration of high-dose ambroxol was well tolerated and 
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resulted in improvements in neuro-ophthalmologic parameters and seizure frequency in 
type III patients (Narita et al., 2016). 
1.2.6. Gaucher type II mouse models 
A number of mouse models have been generated to mimic the acute neuronopathic form 
of type II Gaucher diseases, the primary focus of this study. This has been achieved 
through genetic manipulation or chemical induction, and has helped shed light on the 
pathological pathways leading to neurodegeneration. 
K14-lnl/lnl model – A murine model of acute neuronopathic Gaucher disease was 
developed at Lund University by Prof. Karlsson’s group using Cre-lox technology 
(Enquist et al., 2007). In the first attempt to create a Gaucher type II mouse model, a 
loxP-neo-loxP cassette enclosing the neomycin gene was inserted into intron 8, causing 
abnormal splicing of the Gba1 mRNA (lnl allele). However, β-glucocerebrosidase-
deficient mice die at birth because of skin dehydration. In fact, glucosylceramide is one 
of the major component of the skin lipids, forming lamellar bodies in the stratum 
corneum of the epidermis, and plays an important role in maintaining the water 
permeability of the skin (Coderch et al., 2003). To prevent the mice from dying from 
skin phenotype, the Gba1 knock-out mice were bred with a K14-Cre strain, which 
expresses the enzyme Cre recombinase under control of the human keratine promoter 
K14 (  
Figure 5). Therefore, K14-lnl/lnl animals are knocked-out for Gba1 in all organs and 
tissues except epidermis, where they express the wild-type allele (wt). These mice 
present a minimal residual β-glucocerebrosidase activity, although the enzyme levels 
are severely reduced in brain (<10% of controls), spleen (<2%) and liver (<8%) 
compared to the wild-type levels. Heterozygote animals (K14-lnl/wt) do not show any 
pathological phenotype. 
This K14-lnl/lnl mouse model recapitulates the symptoms described for human Gaucher 
disease type II patients. The animals develop both the visceral disease and the acute 
neuropathology. The major disease’s visceral symptoms are enlarged spleen and liver, 
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thrombocytopenia and lungs impairments. The brain pathology is severe and manifests 
with intense neuronal loss affecting particularly cortex, hippocampus, thalamus and 
cerebellum, extended microglia activation, volume brain reduction and massive 
accumulation of glucosylceramide in enlarged vacuoles. After an asymptomatic period 
of about 10 days, mice start to develop the neurological symptoms, with tremor, 
seizures, motor dysfunction and clasping phenotype. The neurodegeneration progresses 
rapidly and the animals die of end-stage paralysis at 12-14 days of age. Unlike other 
models, in the K14-lnl/lnl mice both neurons and microglia are defective for Gba1. This 
results in high levels of activated microglia throughout the entire brain (Vardi et al., 
2016) and leads to severe neurodegeneration and premature death. 
This is the first genetically modified animal model that recapitulates the pathology of 
Gaucher type II and therefore provides a useful tool for studying the neuropathology 
progression, as well as the systemic diseases. The K14-lnl/lnl model has been 
previously used in a pre-clinical study on neonatal intracerebroventricular 
administration of recombinant  human β-glucocerebrosidase for the possible treatment 
of neuronopathic Gaucher patients (Cabrera-Salazar et al., 2012). The therapy doubled 
the life span of the treated animals and reduced the accumulation of substrate in the 
brain; however mice developed severe neurodegeneration and died at 23 days of age. 
The study demonstrated that the acute neuropathology of the K14-lnl/lnl mouse model, 
and Gaucher patients, requires a substantial and more sustained treatment. 
Nestin-flox/flox model – Enquist and colleagues developed a second mouse model in 
which neuronal and glial precursor cells are Gba1 deficient whereas microglia maintain 
normal enzymatic activity (Enquist et al., 2007). Nestin-Cre mice (Tronche et al., 1999), 
in which Cre recombinase is expressed in neuron and glia precursor cells in the central 
nervous system, were bred with the gbaflox/flox strain. Resulting Nestin-flox/flox mice 
develop the Gaucher neurological symptoms, although the pathology has later onset and 
slower progression, demonstrating that Gba1 deficiency in microglia is not a primary 
cause of neurodegeneration. The use of this model suggested that the restoration of 
enzyme levels in microglia following bone marrow transplantation has a minor effect on 
the fatal neurodegeneration and therefore will not be sufficient to cure the devastating 
neuropathology occurring in type II patients. The Nestin-flox/flox mice manifest first 
symptoms in 2-3 weeks and reach the end-stage of paralysis 7-10 days after. The 
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neuropathology is characterised by extensive and severe neuronal loss, astrocytosis and 
microglial activation, similarly to the K14-lnl/lnl mice. Because the Nestin-flox/flox 
mice survive longer than the K14-lnl/lnl ones, it was possible to monitor the progression 
of the neuropathology over time and in particular elucidate the correlations between 
neuroinflammation and neuronal loss (Farfel-Becker et al., 2011b). In the Nestin-
flox/flox mice neuroinflammation is detectable in the brain of pre-symptomatic animals 
and occurs in the same brain regions characterised by neuronal cell death.  
  
Figure 5 - Neuronopathic Gaucher disease mouse model. 
Schematic representation of the generation of the knock-out mouse model (Enquist et al., 2007). 
Intron 8 is interrupted by a neomycin cassette flanked by loxP sites. The Cre recombinase is 
under control of the K14 promoter and reverts the mutation in the epidermis cells, so that mice 
have the wild-type allele in the skin. All other tissues are knocked-out for the Gba1 gene. 
Neonate mice affected by skin dehydration die soon after birth, while K14-lnl/lnl mice express 
the wild-type Gba1 alleles in skin cells and die at 12-14 days because of severe 
neurodegeneration. 
CBE induced model – Conduritol-β-epoxide (CBE) is a glucocerebrosidase inhibitor. 
Daily intraperitoneal injections of CBE for 3 weeks result in drastic reduction (>90%) 
of enzymatic activity in the brain, liver and spleen (Stephens et al., 1978). The cessation 
of the administration reverts the disease progression in the viscera; however, early 
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depletion of β-glucocerebrosidase in the brain is not reversible. In fact, when neonatal 
mice receive high dose of CBE (8-9 daily injections) the neuropathology is not restored 
upon cessation of administration and animals die from severe neurodegeneration 7-12 
days after last injection (Xu et al., 2008). The use of this chemically induced model for 
the study of the neuropathology was questioned, due to the fact that the blood-brain 
barrier could prevent the complete penetration of CBE into the brain, especially when 
administered to older animals. It has been demonstrated that mice injected during the 
neonatal period develop a neuropathological pattern similar to the Nestin-flox/flox 
animals, in a dose-dependent fashion (Vardi et al., 2016). However later injections 
result in less severe neurodegeneration, showing that administration of CBE to older 
mice is less effective in penetrating the brain and suggesting that the central nervous 
system might be less sensitive to glucosylceramide accumulation in older animals.  
Furthermore, Vardi and colleagues demonstrated that astrogliosis and microglia 
activation precede neuronal loss. Nonetheless, the brain pathology caused by CBE 
administration is less severe than in the acute K14-lnl/lnl model. 
Models based on point mutations – Mice carrying the L444P/L444P and L444P/A456P 
mutations have been generated using insertion mutagenesis (Liu et al., 1998). The 
L444P/A456P (or RecNciI) mice show very reduced (>90%) glucosylceramide levels in 
brain and visceral organs, while the L444P/L444P animals present a 20% residual 
enzymatic activity. Both strains die soon after birth because of skin dehydration rather 
than neuropathology. 
1.3. Gene therapy 
Gene therapy can be defined as the introduction of genetic material to the cells of 
patients for therapeutic benefit (NIH, 2017). This includes the delivery of a functional 
version of a gene to compensate for an inherited defective disease-causing copy. In 
2012 alipogene tiparvovec (Glybera®; uniQure) was the first gene therapy product to be 
approved in the Western world for the treatment of lipoprotein lipase deficiency 
(Melchiorri et al., 2013).  Many successful clinical studies followed focusing not only 
on inherited genetic disorders, like factor IX deficiency in haemophilia B (Nathwani et 
al., 2014), but also on several types of cancer (Husain et al., 2015). Different strategies 
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have been employed, ranging from ex vivo gene therapy on hematopoietic stem cells, T-
cell immunotherapy, and in vivo gene delivery using viral vectors to the latest 
CRISPR/Cas9 gene editing system (Naldini, 2015). 
Despite the significant and rapid advancements, the gene therapy field still needs to 
address some major problematic issues. Although gene therapy is a promising technique 
for the treatment of genetic disorders, it has become clear over the years that delivering 
genes into the cell and to a specific cell population is a very challenging process 
(Naldini, 2015). The cells of the body are composed of numerous physical (e.g. cell 
membrane, nuclear envelope, cytoplasm, etc.) and biochemical (e.g. nucleases, acidic 
compartments, etc.) barriers. Therefore, an essential component of gene therapy is the 
development and availability of gene delivery technology that can efficiently transport 
genetic material into cells. Yet, once cells are corrected they must be able to persist in 
the organism long enough to sustain the therapeutic effect, providing robust and 
constant gene expression and avoiding immunological responses. The safety issue has 
been one of the main concerns over gene therapy technology. However, the increasing 
number of successful clinical trials in recent years is providing evidence that gene 
therapy can be an efficient and safe treatment option. The cost of these therapies 
remains a major challenge. Although the price of Glybera® at over €1 million ($1 
million) (Morrison, 2015) per patient seems to be excessive, one needs to take into 
consideration that the initial cost of pre-clinical studies and manufacturing conforming 
to the Good Manufacturing Practice (Administration, 2016) are extremely high. 
Nonetheless the production costs will be more likely to pay off in the long term as a 
single long-lasting administration could result cheaper than the dispensation of standard 
treatments for the time of a patient’s life. However, of note, uniQure who manufactures 
Glybera® have now terminated post-marketing studies which are required for 
prolonging the market approval from the European Medicine Agency. 
The most successful gene therapy clinical trials and applications are based on the use of 
viral vectors. Different virus families have been employed, according to their packaging 
size, cell tropism, integration properties and transduction efficiency. These viral vectors 
have been extensively engineered with the intent of replacing the genomic regions 
responsible for viral replication and toxicity with the transgene or therapeutic gene of 
interest. Thus, the virus retains the sequences that are necessary for packaging and 
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synthesis of structural proteins, yet removing pathogenic features. 
Hereafter, the attention will be focused on viral vectors as a therapeutic tool in the 
development of gene therapy approaches for lysosomal storage disorders, in particular 
on the potential use of adeno-associated viruses for the treatment of neuronopathic 
Gaucher disease. 
1.3.1. Adeno-associated virus 
Adeno-associated viruses (AAV) belong to the family Parvoviridae, specifically the 
Dependovirus genus, as they are not able to replicate autonomously (Siegl et al., 1985). 
A successful replicative cycle of an adeno-associated virus requires the presence of a 
lytic helper virus (adenovirus or herpesvirus) that provides those genes necessary for 
replication and productive infection of the cell. When the helper virus is not present the 
AAV particle remains latent. Adeno-associated viruses are small (20-26nm in diameter), 
non-enveloped, and contain a linear single-stranded DNA genome (ssAAV) (Berns and 
Giraud, 1996). Although most of the adult population is seropositive, adeno-associated 
viruses are not pathogenic in humans or any other species (Daya and Berns, 2008). 
Several serotypes are known in nature: because the capsid serotype determines the 
tissue specificity of the virus, the capsid proteins can be engineered in order to alter the 
cellular tropism and create more efficient pseudotypes. All these characteristics, 
together with the ability to produce high titre of the vector, make adeno-associated 
viruses an excellent candidate as a gene therapy vector. 
The most studied adeno-associated virus serotype is AAV2 (Srivastava et al., 1983). 
The AAV2 genome is linear single-stranded DNA of 4.7kb in size. Both sense and 
antisense strands are packaged into the capsid with the same frequency. The genome is 
organised into two open reading frames, flanked by two inverted terminal repeats 
(ITRs) of 145bp each. These form a hairpin structure and play a fundamental role in the 
replication. These sequences are also the origins of replication for the synthesis of the 
second strand of DNA. The two open reading frames encode for the genes rep and cap. 
rep is expressed from two promoters in four different transcripts: Rep78, Rep68, Rep52 
and Rep40. Rep proteins are involved in DNA replication, binding to the ITR hairpins, 
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regulating AAV gene expression and in virion assembly (Pereira et al., 1997). cap 
encodes three capsid proteins (VP1, VP2 and VP3). The gene is transcribed in two 
mRNAs: the unspliced transcript produces the biggest protein VP1 (87kDa), while the 
second transcript is spliced and originates VP2 (72kDa) and VP3 (62kDa). 60 capsid 
proteins combine and arrange in an icosahedral capsid outer shell, in a 1:1:10 molar 
ratio of VP1, VP2 and VP3 respectively (Daya and Berns, 2008). 
AAV2 alone is not able to replicate and it is maintained in a lysogenic state. When the 
virus is latent its gene expression is repressed, and it can either exist in the episomal 
state, or stably integrate in the human chromosome 19q13.4 upstream of the 
transcription starting site of the myosin binding subunit 85 gene (MBS85) with a 
frequency of 0.1% (Kotin et al., 1990). If the helper virus is present, it will provide all 
those elements necessary for the replication, like DNA polymerase and helicase, and 
allows the release of the AAV2 particles from the infected cell (Daya and Berns, 2008). 
Adeno-associated virus binds to the heparan-sulphate proteoglycan receptors on the cell 
surface and through the interaction with a series of co-receptors, like integrins and 
growth factor receptors, is internalised through the endocytic pathway (Summerford and 
Samulski, 1998). Once internalised, the viral particle escapes the late endosomal 
vesicles probably through the interaction of the phospholipase A2 motif present at the 
N-terminus of the VP1 protein (Girod et al., 2002). The mechanism through which the 
particle is then translocated into the nucleus is still unclear. In the nucleus the capsid 
proteins are disassembled, the single-stranded DNA is released, the complementary 
strand is synthesised and transcription of the viral genome begins.  
So far, 12 natural serotypes in both human and non-human primates have been 
described in literature (Schmidt et al., 2008, Saraiva et al., 2016). Despite the high 
homology in the capsid amino acid sequences (50-90%) (Lisowski et al., 2014), 
different serotypes have distinct cellular tropism (Table 2). Neutralising anti capsid 
antibodies are widespread in the human population (AAV2: 72%, AAV1: 67%, AAV9: 
47%, AAV4: 46%, AAV5: 40% and AAV8: 38%) (Boutin et al., 2010). In addition to 
neutralising antibodies resulting from natural exposition to the virus, the capsid epitopes 
can be cross-presented on major histocompatibility complexes class I (MHC I) after 
cellular transduction, triggering an adaptive immune reaction. 
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TISSUE TROPISM SEROTYPE 
CNS AAV1, AAV2, AAV4, AAV5, AAV8, AAV9 
Liver AAV7, AAV8, AAV9 
Heart AAV1, AAV8, AAV9 
Lung AAV4, AAV5, AAV6, AVV9 
Kidney AAV2, AAV9 
Pancreas AAV8 
Skeletal muscle AAV1, AAV6, AAV7, AAV8, AAV9 
Photoreceptors AAV2, AAV5, AAV8 
Table 2 - Cellular tropism of AAV 1-9 serotypes. 
The table summarises the cellular tropism of the main natural occurring AAV serotypes (Naso 
et al., 2017). 
1.3.2. Adeno-associated virus as a gene delivery vector 
The lack of pathogenicity, the ability to infect both dividing and non-diving cells, broad 
tropism and a variety of naturally occurring serotypes available has meant that 
development of gene delivery vectors based on adeno-associated virus has been the 
focus of much research in the gene therapy community. However, some obstacles like 
the small packaging capacity, tissue tropism and the host immune response needed to be 
circumnavigated in order to produce efficient vectors for the clinical use. In recent 
years, significant advances in adeno-associated virus engineering have been achieved, 
resulting in the design and production of more effective adeno-associated vectors 
(Snyder et al., 2011). 
51 
Recombinant vectors (rAAV) are generally based on the well characterised AAV2 
genome and have been manipulated, so that the reading frames of rep and cap can be 
substituted with the expression cassette of interest.  The inverted terminal repeat 
sequences contain the cis-acting elements necessary during replication and packaging, 
while the genes required for replication and assembly are provided in trans (Figure 6). 
The resulting vectors remain as extrachromosomal elements. (Daya and Berns, 2008). 
The efficiency of gene expression is limited among other factors by the synthesis of the 
complementary DNA strand after the translocation to the nucleus (Ferrari et al., 1996). 
The generation of self-complementary vectors (scAAV) can circumvent this (McCarty, 
2008). These vectors can reanneal into a double-stranded DNA molecule and therefore 
bypass the rate-limiting process. However, the improvement in efficiency comes at the 
price of reduced packaging capacity: the size of the expression cassette is in fact halved 
(2.4kb), although the packaging capacity of scAAVs can be stretched up to 3.3kb 
without affecting transduction efficiency (Wu et al., 2007). 
As an alternative to the use of self-complementary vectors, the transgene expression of 
ssAAV can be improved by the presence of enhancer sequences, like the woodchuck 
hepatitis virus regulatory element (WPRE).  When the WPRE element is provided in cis 
with the transgene in recombinant vectors, the efficacy of gene expression is increased 
(Loeb et al., 1999). Gene expression mediated by a scAAV9 vector lacking WPRE and 
a ssAAV9 with the WPRE sequence has previously been compared (Mattar et al., 
2015). The study revealed that following systemic administration to foetal and neonatal 
mice, transgene expression was higher in those animals injected with the single-
stranded version of the vector carrying the WPRE sequence, compared to the WPRE-
less scAAV counterpart. 
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Figure 6 - Generation of recombinant AAV vectors. 
Cells are co-transfected with three plasmids: the expression plasmid contains the transgene 
expression cassette, the helper plasmid carries the adenoviral sequences responsible for viral 
replication, and the RC plasmid contains the rep and cap genes for replication and capsid 
assembly (Saraiva et al., 2016). 
Although adeno-associated viruses show a broad tissue tropism, some cell types are not 
efficiently transduced by naturally available serotypes. Therefore, different capsid 
engineering approaches have been developed in order to create libraries of novel viral 
particles (Kotterman and Schaffer, 2014). The capsid genes can be modified through the 
insertion of point mutations and casual peptide sequences, or form random chimeras of 
cap open reading frames following DNA shuffling. These novel engineered variants are 
then screened in in vitro and in vivo systems and finally selected for the desired 
characteristics.  
Despite the significant progress in the development of novel adeno-associated vectors, 
host immune response remains one of the most challenging aspects of using AAV in 
therapeutic gene delivery. Previous exposure of the virus triggers the humoral immune 
response accompanied by the harbouring of neutralising antibodies against the capsid 
proteins (Halbert et al., 2006). The immune reaction against adeno-associated virus is 
thought to be T-cell dependent and is associated with the loss of viral gene expression. 
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This phenomenon was first observed in the phase I/II clinical trial for the treatment of 
haemophilia B, where cell-mediated immunity against the AAV vector caused gradual 
decline in Factor IX gene expression and induced transaminitis in liver of treated 
patients (Manno et al., 2006). The absence of pre-existing antibodies is therefore a strict 
criterion for inclusion of patients participating in AAV-based gene therapy clinical 
trials. 
Although adeno-associated viruses are defined as non-integrating vectors, an increased 
risk of insertional mutagenesis has first been reported in a preclinical study on 
carcinoma hepatocytes in mouse (Donsante et al., 2007). These findings were confirmed 
by several following studies, which in addition highlighted the correlation between 
hepatocarcinoma and administration of the vector during the neonatal period (Chandler 
et al., 2015). Interestingly, recent studies have reported that similar integration events of 
the wild-type AAV2 genome have been observed in human patients with hepatocellular 
carcinoma (Nault et al., 2015). Therefore, although clinical trials using recombinant 
adeno-associated viral vectors have not shown any major safety complications, the 
possibility of the development of genotoxicity following AAV administration in clinical 
application should be taken in serious consideration (Chandler et al., 2017). 
Despite the existing limitations, AAV-based gene therapy is one of the most promising 
gene transfer technology platforms, as demonstrated by the increasing number of 
preclinical studies and clinical trials in recent years (Naldini, 2015). The gene therapy 
clinical trial for the treatment of haemophilia B is perhaps one of the best example 
examples of a successful AAV-mediated gene therapy study (Nathwani et al., 2011, 
Nathwani et al., 2014).  A previous separate study attempted gene therapy for severe 
haemophilia B by delivering an adeno-associated viral vector carrying the Factor IX 
therapeutic gene through intramuscular injections first to a canine model and 
consequently to human patients (Manno et al., 2003). However, levels of factor IX in 
the serum did not increase in treated patients. Nathwani and colleagues used a different 
approach with the intravenous administration of a rAAV2/8 vector carrying the 
therapeutic gene through the hepatic artery. Patients that had received the treatment 
achieved long-term expression of the defective factor IX, reaching 3%-11% of 
physiological levels. This was enough to drastically reduce the clinical manifestations 
from severe to a milder form of haemophilia. 
54 
1.3.3. Adeno-associated virus mediated gene delivery to the central 
nervous system 
Targeting the central nervous system can be challenging, because of the unique features 
that characterise the brain. Firstly, the skull represents a physical barrier in its own right, 
encapsulating the brain. Then the blood-brain barrier plays an essential role in 
protecting the brain and limiting the access to the CNS. Recombinant adeno-associated 
viral vectors are currently considered a valuable gene delivery system for combining 
efficient and widespread central nervous system transduction. The ability to transduce 
post-mitotic cells leads to stable and persisted gene expression, for at least 15 years in 
non-human primates (Sehara et al., 2017) and 10 years in the human brain (Leone et al., 
2012). Different AAV serotypes have been used to efficiently transduce the central 
nervous system in several animal models (Bradbury et al., 2015, Davidson et al., 2000, 
Watakabe et al., 2015). Moreover, some serotypes (AAV1, 8 and 9) have shown the 
ability to transduce brain regions distal from the injection site, through both anterograde 
and retrograde axonal transport (Castle et al., 2014). Overall, CNS transduction 
following AAV-mediated gene delivery results in widespread and highly efficient 
expression in many brain regions, like cortex, hippocampus, thalamus, striatum and 
cerebellum (Cearley and Wolfe, 2006). Due to their characteristics adeno-associated 
viruses are suitable vectors for gene therapy of neurological disorders. Several studies 
have demonstrated that AAV9-based virus is the preferred vector for CNS gene 
delivery, due to its extraordinary ability to cross the blood-brain barrier compared to 
other serotypes in different species like mice, rats and cats (Dayton et al., 2012, Foust et 
al., 2009, Duque et al., 2009). These studies demonstrated how the use of adeno-
associated viral vectors, particularly AAV9, to target neurons in the central nervous 
system is not limited to intracranial topical administration but can be extended to other 
less invasive delivery routes, such as systemic injections. 
Focal gene delivery is successfully achieved with stereotactic intracranial injections (IC) 
of the vector into the brain parenchyma. Target-site gene expression is suitable for the 
treatment of those diseases in which only a circumscribed area of the brain is affected, 
like the substantia nigra in Parkinson’s disease (Bartus et al., 2014). However, this route 
of administration is less likely to be effective in those neurological conditions where the 
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neuropathology is substantial and larger areas of the brain are affected. In order to 
achieve the widespread transduction required to treat sufficiently large areas of the 
brain, multiple parenchymal injection sites might be necessary to achieve therapeutic 
effects (Worgall et al., 2008, Tardieu et al., 2014). Yet this procedure is highly invasive 
and can lead to serious complications. 
A less invasive administration route is the injection into the cerebrospinal fluid through 
intracerebroventricular (ICV) or intrathecal (IT) infusions.  Extensive gene expression 
has been achieved when an adeno-associated viral vector is injected into the ventricles 
of the brain or via intrathecal administration through the spine: the transduction spreads 
throughout the brain due to the continual movement of the cerebrospinal fluid (Liu et 
al., 2005). The vector distributes to both hemispheres allowing a more global delivery to 
both grey and white matter, transducing not only neurons but also other surrounding cell 
types. Interestingly, more efficient penetration of the vector has been reported when 
injecting neonatal animals compared to adults (Passini et al., 2003). This phenomenon is 
thought to be due to the incomplete maturation of ependymal cells that line the luminal 
surface of the ventricles in new-born mice, allowing the virus to diffuse from the 
ventricle to the brain parenchyma.  
While the intraparenchymal and intraventricular administrations of gene delivery 
vectors hold great promise for treating a range of neurological diseases, they are 
invasive techniques that require significant neurosurgical skills and discomfort to the 
patient. The ideal administration route would be to deliver the vector directly into the 
bloodstream of the patient via intravenous infusion, which is minimally invasive and 
uses the brain vasculature, to allow for maximal spread of the vector throughout the 
brain. Historically, intravenous drug administration for the treatment of the central 
nervous system has been challenging, due to the selective properties of the blood-brain 
barrier (Zhang et al., 2011). However, it has now been shown that AAV9 vectors can 
efficiently cross the blood-brain barrier through an active transport mechanism and 
effectively deliver genes to cells throughout the brain and spinal cord (Manfredsson et 
al., 2009). Intravenous administration of AAV9 leads to a differential transduction 
pattern depending on the age of administration (Foust et al., 2009). Injections into 
neonatal mice result in neuron specific targeting, while the administration into adult 
animals is followed by predominant transduction of astrocytes. It has been hypothesised 
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that once the virus escapes the vases of the blood-brain barrier it preferentially 
transduces astrocytes in the proximity of the capillary endothelial cells; although the 
precise molecular mechanism is still under investigation. Moreover, neurons are more 
abundant in number than glia in neonatal brains. Similar results have been achieved in a 
neonatal rat model, where the administration of a single-stranded AAV9 vector resulted 
in efficient transduction of motor neurons, dorsal root ganglion and Purkinje neurons 
(Wang et al., 2010). Consistent outcomes have been reported in neonatal and adult non-
human primates injected with AAV9 (Dayton et al., 2012). A summary of the most 
relevant studies comparing different times of injections in several animal models is 
described in Table 3 (Saraiva et al., 2016). These findings clearly bring to light the 
potential use of intravenously administered gene therapy for the treatment of paediatric 
neurological disorders. While intravenous administration of AAV9 leads to efficient 
transduction of the brain, other organs of the body will also receive a significant dose of 
vector. Different studies have demonstrated that a wide variety of visceral organs and 
tissues are also transduced by AAV9 leading to significant gene delivery and expression 
in foetal and neonatal mice (Rahim et al., 2011) and non-human primates (Mattar et al., 
2013). Hence, systemic gene delivery is potentially highly advantageous in treating 
those neurological diseases that also have additional significant visceral components 
like many lysosomal storage diseases. On the downside, the elevated vector dose that is 
needed to achieve effective transduction in the central nervous system following 
systemic administration raises the problem of developing more efficient vectors. In 
addition, the intravenous administration route could be more challenging for disorders 
caused by defects of integral proteins, where cross-correction mechanism is not 
applicable and the largest number of neurons must be transduced.
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Table 3 - Summary of preclinical studies on intravenous administration of AAV9 vectors targeting the central nervous system. 
The table summarises the most relevant studies comparing different times of administration in rodent, feline and non-human primate animal models (Saraiva et al., 
2016). Abbreviations: CBA: chicken-β-actin promoter; CMV: cytomegalovirus promoter; GFP: green fluorescent protein; P: postnatal day; vg: viral genome. 
ANIMAL MODEL STUDY TIME OF 
INJECTION
VIRUS TITER ASSESMENT 
POST-INJECTION
OUTCOME
Neonatal rodents
Mouse Foust et al., 2009 P1 scAAV9.CBA.GFP 4 x 10^11 vg/animal 10-21 days
Neuronal expression in striatum, cingulate gyrus, anterior commissure, 
internal capsule, corpus callosum, hippocampus, dentate gyrus, midbrain, 
cerebellum.
Mouse Rahim et al., 2011 P1 ss and scAAV2/9.CMV.GFP 4 x 10^11 vg/animal 1 month Neuronal expression in CNS (bain, spinal cord, retina) and PNS 
(myenteric plexus and innervating nerves).
Mouse Miyake at al., 2011 P1, P5, P14 ssAAV1, 8, 9, 10. CAG.GFP 1.5 x 10^11-12 vg/animal 1 month
Expression in neurons and/or astrocytes in cortex, cerebellum olfactory 
bulbs, brain stem, spinal cord. Transduction efficiency decreases over 
time.
Rat Wang et al., 2010 P1 ssAAV9.CAG.GFP 2 x 10^12 vg/animal 1-3 months
Neuronal expression in cortex, olfactory nuclei, cingulate cortex, lateral 
septum, striatum, hippocampus, thalamus, midbrain, cerebellum, brain 
stem, spinal cord.
Adult rodents
Mouse Foust et al., 2009 10 weeks scAAV9.CBA.GFP 4 x 10^11-12 vg/animal 2-7 weeks Astrocytic transduction.
Mouse Duque et al., 2009 6 weeks scAAV9.CMV.GFP 3 x 10^11 - 2 x 10^12 vg/animal 2-4 weeks Motor neurons and glia in spinal cord.
Mouse Gray et al., 2011 8-12 weeks scAAV9.CBA.GFP 2.5 x 10^10 - 1.6 x 10^12 vg/animal 4 weeks Astrocytic expression in cortex; neuronal expression in hippocampus, 
striatum, spinal cord. Dose-dependent transgene expression.
Felines
Cat Duque et al., 2009 P2 scAAV9.CMV.GFP 1.5 x 10^12 vg/animal 15 days High transduction efficiency im cervical and lumbar motor neurons.
Cat Duque et al., 2009 7 weeks scAAV9.CMV.GFP 1.2 x 10^12 vg/animal 15 days Lower motor neurons.
Non-human primates 
Cynomolgus macaque Foust et al., 2010 P1 scAAV9.CBA.GFP 1 x 10^14 vg/kg 21 days Extensive motor neuron transduction.
Cynomolgus macaque Bevan et al., 2011 P1-P90 scAAV9.CBA.GFP 1-3 x 10^14 vg/kg 21-24 days Cortex, thalamus, putamen, hippocampus.
Cynomolgus macaque Bevan et al., 2011 3 years scAAV9.CBA.GFP 2.7 x 10^13 vg/kg 21-24 days Predominantly astrocytes and microglia. Cortex, thalamus, putamen, 
hippocampus, cranial nerves.
Rehsus macaque Gray et al., 2011 3-4 years scAAV9.CBA.GFP 1 x 10^13 vg/kg 4 weeks Neuronal and glial transduction in cortex, hippocampus, cerebelum, 
spinal cord. 
Rehsus macaque Dehay et al., 2012 P1 scAAV9.CMV.GFP 10^12 - 10^15 vg/kg 2 months Neuronal expression in layer II/III/IV, striatum, globus pallidus, 
thalamus, substantia nigra, hippocmpus, cerebellum.
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The promising results of AAV-mediated gene delivery to the central nervous system 
opened the way to clinical application of gene therapy for neurological disorders. An 
AAV9 vector has been used to target motor neurons in a clinical trial for spinal 
muscular atrophy type I (NCT02122952). This phase I study involves an intravenous 
delivery of the AAV9 carrying the therapeutic SMN gene to affected infants. While this 
study is on-going, preliminary results have shown remarkable improvement in neck 
strength, breathing, swallowing abilities and sitting (Mendell, 2016b). AAV2 vectors 
are used in phase I/II current studies for the treatment of neurodegenerative disorders 
like Alzheimer’s disease (NCT00876863) and Parkinson’s disease (NCT01973543), in 
which the virus has been stereotactically injected into the brain parenchyma into the 
basal forebrain and striatum, respectively. Due to its cellular tropism, AAV2 has been 
extensively used in phase I/II trials for the treatment of eye disorders, like neurovascular 
age-related macular degeneration (NTC01024998) and Tübingen choroideremia 
(NCT02671539). Efficacy phase III studies are on going for Leber congenital amaurosis 
(NCT00999609) and Leber’s hereditary optic neuropathy (NCT02652767). 
1.3.4. Gene therapy for lysosomal storage disorders 
Lysosomal storage disorders possess optimal characteristics that render these 
pathologies an appropriate target for viral gene therapy (Rastall and Amalfitano, 2015). 
The pathological mechanisms underlying most lysosomal storage diseases are well 
established, and because of their monogenic nature the administration of a vector 
carrying a single therapeutic gene could reverse the genetic defects. Moreover, it has 
been shown that reaching wild-type enzyme levels might not always be necessary, since 
a modest increase in the enzymatic activity can restore the pathology in milder cases. 
Averagely, patients with a mild form of lysosomal disease with adult onset exhibit a 
higher residual enzymatic activity (<10% of wild-type), compared to the infantile acute 
cases (<1%). Thus, even reduced transfection efficiency leading to a moderate increase 
in the defective enzyme levels could have significant beneficial effects. These results 
can be further improved taking in account the already mentioned cross-correction 
mechanism, according to which a functional soluble enzyme can be taken up from other 
neighbouring untransfected cells and trafficked to the lysosomes (Figure 7). The same 
approach is exploited by enzyme replacement therapy approaches, where the circulating 
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enzyme can reach distal organs through the bloodstream. However, a gene therapy 
based administration of the enzyme can strategically target individual cell populations, 
so that a specific organ becomes a factory for the production and release of the 
therapeutic protein. This concept has been demonstrated in liver-targeted gene therapy 
studies, in which the use of an adeno-associated virus vector carrying a specific liver 
promoter resulted in amelioration of systemic manifestations in MPS IIIA (Sorrentino et 
al., 2013), Fabry disease (Ziegler et al., 2007) and Pompe disease animal models 
(Franco et al., 2005). Finally, the availability of many animal models allows the 
development of preclinical studies, providing significant advances on pathogenesis and 
therapeutic effects of the treatment. 
 
Figure 7 - Cross-correction events following viral transfection. 
Once the vector successfully transfects the target cell, the transgene is translated and the 
functional protein is produced. The soluble therapeutic enzyme is either translocated to the 
lysosomes, or secreted. The surrounding cells can up-take the secreted molecule via the 
mannose-6-phosphate receptors or alternative M6P-independent pathways and translocate the 
enzyme to the lysosomal compartment. 
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The increased number of gene therapy clinical trials has highlighted the potential 
benefits of the use of adeno-associated virus as a gene delivery system in the treatment 
of lysosomal storage disorders. Some of the phase I and II on going and completed trials 
(https://clinicaltrials.gov, http://www.isrctn.com) on lysosomal storage diseases are 
reported in Table 4. The ability of adeno-associated viral vectors to successfully 
transduce neurons has provided significant evidence to justify the use of AAVs as 
therapeutic option for lysosomal storage disorders with neurological manifestations. 
Indeed more than 50% of lysosomal storage disorders present neurological involvement 
(Futerman and van Meer, 2004) and currently there are no treatments for many of these 
diseases. Therefore, it is not surprising that most of the clinical studies focused on gene 
delivery to the central nervous system. 
Several gene therapy based strategies for the treatment of Gaucher disease have been 
attempted in preclinical studies. Initial experiments on the feasibility of gene therapy for 
Gaucher disease were performed on in vitro systems, using retroviral vectors to express 
the GBA1 gene in cultured bone marrow cells derived from patients (Fink et al., 1990).  
A decade later, the advent of adeno-associated virus technology lead to the development 
of in vivo strategies, where the intravenous administration of a recombinant AAV vector 
carrying the GBA1 gene under control of the human elongation factor 1-alpha promoter 
to wild-type mice resulted in sustained expression of β-glucocerebrosidase for weeks 
after injection (Hong et al., 2004). More recently, gene therapy has been applied to a 
mouse model of Gaucher disease type I using an AAV8 vector expressing the human 
GBA1 gene under control of a hepatocyte-specific promoter (McEachern et al., 2006). 
The treatment was administered to juvenile (4 weeks old) and adult mice (6 months old) 
carrying the D409V mutation, in which the visceral pathology was already established. 
These mice presented Gaucher cells accumulation with high levels of glucosylceramide 
in the liver, spleen, lungs and bone marrow. The treatment successfully rescued the β-
glucocerebrosidase deficiency to therapeutic levels and cleared the accumulation of 
substrate in liver and spleen, with only minimal effects on the lung pathology. Rescue 
of the established phenotype in old type I mice was also achieved through ex vivo 
transfection of bone marrow cells and consequent transplantation (Enquist et al., 2006, 
Dahl et al., 2015, Enquist et al., 2009). This ex vivo approach was previously employed 
in a first clinical attempt utilising early retroviral vectors; however the transduction 
efficiency of hematopoietic stem cells was not sufficient to trigger a therapeutic affect 
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on treated patients (Cox, 2010). 
DISEASE  STUDY ID  PHASE VECTOR ROUTE OF 
ADMINISTRATION 
Batten         
  NCT00151216 I AAV2.Cuh.CLN2 Intracerebral 
 
NCT01414985 I/II  AAVrh.10CU.CLN2 Intracerebral 
 NCT02725580 I/II scAVV9.CB.CLN6 Intrathecal 
Metachromatic 
leukodystrophy 
        
 
NCT01801709  I/II AAVrh.10cu.ARSA Intracerebral 
MPS IIIA         
  NCT02716246  I/II scAAV9.U1a.hSGSH Intravenous 
 
NCT02053064 I/II AAVrh10.hSGSH, 
SUMF1 
Intracerebral 
MPS IIIB         
  ISRCTN19853672 I/II AAV5.NAGLU Intracerebral 
Pompe         
  NCT02240407 I rAAV9.DES.hGAA Intramuscular  
Table 4 - Summary of clinical trials for lysosomal storage disorders. 
The table reports some of the on going clinical trials for lysosomal storage diseases. The vector 
used and the route of administration are also described. 
These reports, regardless of their successful results, targeted only the visceral pathology 
while the therapeutic intervention on the neuropathology of type II and III was not 
addressed.  The present study describes the attempt to treat both the neurological and 
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visceral manifestations of neuronopathic Gaucher disease, intravenously administering 
two different AAV9 vectors carrying the therapeutic copy of the human GBA1 gene to a 
type II mouse model. 
1.4. Rationale 
There is currently no effective clinical treatment for the lethal neurological 
manifestations of the neurodegenerative forms of Gaucher disease. Ideally, a treatment 
would primarily address the lethal neurological involvement, but also the visceral 
manifestations. The ability of AAV9 to cross the blood-brain barrier following 
intravenous administration provides a potential systemic therapy that could achieve this 
ideal therapeutic result.  
The aim of this project is to evaluate the efficacy of the intravenous administration of 
gene therapy for the treatment of neuronopathic Gaucher disease using adeno-associated 
viral vectors. The overarching hypothesis of the study is demonstrating that systemic 
delivery of gene therapy will result in increase in lifespan, amelioration of 
neuropathology and improvement of visceral pathology in a neuronopathic Gaucher 
disease mouse model. In order to achieve these objectives, two suitable gene delivery 
vectors were produced and administered to neonatal knock-out mice, following 
evaluation of their transduction efficiency. 
The first part of the current study provided evidence of efficient systemic transduction 
of the brain and the viscera following intravenous administration of the 
scAAV2/9.GUSB.GFP.bGHpA vector in a reporter gene analysis. 
The second part aimed to treat the acute K14-lnl/lnl mouse model of type II Gaucher 
disease with a single intravenous administration of the therapeutic 
scAAV2/9.GUSB.hGBA1.bGHpA vector to neonatal animals. Survival, body weight, 
splenomegaly and a series of behavioural motor function parameters were assessed in 
treated animals. The β-glucocerebrosidase enzymatic activity was measured in different 
organs and a blood analysis was performed. Finally, post-mortem neuropathology and 
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histopathology analysis provided indication of amelioration of the pathology in the 
brain and viscera. Intracerebroventricular treated mice were used as age-matched 
controls in the analysis of the visceral pathology. 
The third part focused on the use of an alternative single-stranded vector, in which the 
GBA1 expression is driven by a strong neuronal promoter 
(ssAAV2/9.hSyn1.hGBA1.WPRE.hGHpA), as an attempt to increase the therapeutic 
efficacy in the central nervous system yet maintaining a beneficial systemic effect 
following intravenous administration. A preliminary reporter gene study demonstrated 
the widespread transgene expression, not only in the brain but also in some of the 
visceral organs. The viral vector carrying the human GBA1 gene was administered 
intravenously to neonatal K14-lnl/lnl mice and the pathological parameters were 
assessed.
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2. Materials and methods 
2.1. Primer sequences 
Primer sequences were designed using the MacVector v15.0 software (MacVector Inc., 
Apex NC, USA) and purchased from Sigma-Aldrich (St. Louis MI, USA). 
The sequences of the primers used in this study are shown in Table 5. 
PRIMER NAME SEQUENCE 
GCex8-2 5'-GTACGTTCATGGCATTGCTGTTCACT-3' 
METex8-2 5'-ATTCCAGCTGTCCCTCGTCTCC-3' 
NEO-AO2  5'-AAGACAGAATAAAACGCACGGGTGTTGG-3' 
Cre 134_f 5'-AATGCTTCTGTCCGTTTGCCGGTC-3' 
Cre 365_r 5'-GATCCGTCGCATGACCAGTGAAAC-3' 
GBA_BspEI_f 5’-CACATCCGGAGCCACCATGGAGTTTTCAA-3’ 
GBA_EcoRI_r 5'-CAATGAATTCTCACTGGCGACGC-3’ 
Seq-1 5’-CTGCCTCAGTCTGCGGTG-3’ 
Table 5 – Primers. 
Names and sequences (5’-3’) of the primers used in the study (Sigma-Aldrich). 
2.2. Antibodies 
A description of the antibodies used in the study is presented in Table 6. 
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ANTIBODY HOST DILUTION USED  
Primary antibodies     
Anti eGFP (ab290, Abcam, Cambridge, UK) Rabbit 1:1,000 
Anti C-terminal Gcase (G4171, Sigma-Aldrich)  Rabbit 1:1,000 
Anti CD68 (MCA1957, AbD Serotech, Kidlington, 
UK) 
Rat 1:2,000 
Anti GFAP (MAB3402, Millipore, Burlington MA, 
USA) 
Mouse 1:1,000 
Anti LAMP1 (ab24170, Abcam) Rabbit 1:2,000 
Anti Calbindin (CB38, Swant, Marly, Switzerland) Rabbit 1:10,000 
Anti NeuN (MAB377, Millipore) Rabbit 1:500 
Secondary antibodies     
Biotinylated anti mouse IgG (BA-9200, Vector Lb Inc., 
Burlingame CA, USA) 
Goat 1:1,000 
Biotinylated anti rabbit IgG (BA-1000, Vector Lb Inc.) Goat 1:1,000 
Biotinylated anti rat IgG (BA-9400, Vector Lb Inc.) Goat 1:1,000 
Fluorescence secondary antibody     
Alexa Fluor 488 (A11008, Life Technology, Carlsbad 
CA, USA) 
Goat 1:200 
Alexa Fluor 568 (A11034, Life Technology) Goat 1:200 
Table 6 - List of antibodies used in the study. 
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2.3. Cloning 
2.3.1. Transformation of plasmid DNA 
Plasmid DNA was amplified into E. coli bacterial cells (SURE competent cells, Agilent 
Technologies, Santa Clara CA, USA) following manufacturer’s protocol. The 
transformed culture was grown on lysogenic broth agar (Fisher Scientific, 
Loughborough, UK) plates containing 100μg/ml of ampicillin antibiotic (Sigma-
Aldrich) at 37°C overnight. Positive colonies were used to inoculate 5ml of lysogenic 
broth as starter cultures (Sigma-Aldrich) with 100μg/ml of ampicillin at 37°C overnight 
and constant shaking at 225rpm. 
2.3.2. Amplification of plasmid DNA 
Plasmid DNA was purified using the QIAprep Spin Miniprep kit (QIAGEN, Hilden, 
Germany) according to manufacturer’s instructions. The DNA was eluted into 50μl of 
dH2O and the concentration was determined by spectrophotometry (NanoDrop 1000, 
Thermo Scientific, Waltham MA, USA). Absorbance of the sample was measured at 
260nm, and the ratio of absorbance at 260nm and 280nm (~1.8) was used to assess the 
purity of the DNA sample. 
For large-scale plasmid DNA preparations, 500μl of bacterial culture was incubated 
with 500ml of lysogenic broth with 100μg/ml of ampicillin at 37°C overnight and 
constant shaking at 225rpm. The plasmid DNA was purified using the Plasmid Maxi kit 
(QIAGEN) according manufacturer’s instructions. The plasmid was resuspended in 
500μl of dH2O and the concentration was assessed (NanoDrop 1000, Thermo 
Scientific). 
2.3.3. Digest 
DNA sequences were analysed with the MacVector v15.0 software (MacVector Inc.) 
and the appropriate restriction cut sites were selected. 1μg of DNA was digested with 
67 
the defined restriction enzymes (New England Biolab, Ipswich MA, USA) according to 
manufacturer’s specifications. 
The reaction mix was assembled as following: 
1μg DNA 
2.5μl 10X Restriction buffer (New England Biolab)  
1u (unit) Restriction enzyme  
dH2O to final volume of 25μl 
2.3.4. Gel electrophoresis 
50X Tris Acetate-EDTA TAE buffer: 242g Trizma (Sigma-Aldrich), 57.1ml Glacial 
acetic acid (Fisher Scientific), 100ml 0.5M Ethylenediaminetetraacetic acid EDTA 
(Sigma-Aldrich), dH2O to total volume of 1l. 
1X Orange G loading buffer (Sigma-Aldrich) was added to the samples and DNA 
fragments were separated on an agarose gel (1% agarose in 1X TAE buffer for optimal 
resolution of 500-10,000 bp DNA; Invitrogen, Carlsbad CA, USA) with 1:10,000 
Safeview nucleic acid stain (Applied Biological Materials, Richmond, Canada) in 1X 
TAE buffer for DNA visualisation. 1Kb plus molecular weight marker (Invitrogen) was 
used to determine the DNA sample size. Gels were run at 110V (PowerPac Basic, 
Biorad, Hercules CA, USA) for a minimum of 30 minutes depending on the expected 
band size. The results were visualised using a UV transilluminator and images were 
captured with the attached CCD digital camera (InGenius, Syngene, Cambridge, UK). 
2.3.5. Extraction of DNA fragments from agarose gel 
DNA fragment of interest were excised from the agarose gel under limited exposure of 
UV light and processed using the QIAquick Gel Extraction kit (QIAGEN) following the 
manufacturer’s instructions. The purified plasmid DNA was eluted in dH2O to a final 
volume of 30μl. 
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2.3.6. Ligation of DNA fragments 
The molar ratios of 1:1 or 1:2 of vector:insert DNA were used when cloning a DNA 
fragment into a plasmid vector. 
The ligation reaction was assembled as followed: 
100ng Vector DNA 
100-200ng Insert DNA 
1μl 10X Ligase buffer (Promega, Madison WI, USA) 
1u (unit) T4 DNA Ligase (Promega)  
dH2O to final volume of 10μl 
The reaction was incubated at 4°C overnight. 
2.3.7. Sequencing 
Automated Sanger sequencing (Table 5 ‘Seq-1’) of the plasmids was outsourced to 
SourceBioscience (www.lifesciences.sourcebioscience.com, UK). The resulting 
sequences were aligned to the original consensus and analysed with the MacVector 
v15.0 software. 
2.4. Tissue culture 
2.4.1. Cell lines 
HEK-293T cells were used for in vitro testing of gene expression from the plasmids. 
HEK-293T AAV pro cells (Clonetech, Mountain View CA, USA) were used for virus 
production. Cells were grown in Dulbecco’s Modified Eagle Medium DMEM 
GlutaMax™ (ThermoFisher Scientific) in standard conditions of 37°C and 5% CO2. 
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When specified, 10% heat-inactivated Fetal Bovine Serum FBS (Gibco, ThermoFisher 
Scientific) (56°C for 30 minutes) and/or 1% Pen/Strep antibiotic (Gibco) were added to 
standard DMEM GlutaMax™. Cells were passaged with trypsin (trypsin-EDTA 0.05%, 
Gibco) when 70% confluent, with a standard ratio of 1:10 every 48 hours. 
2.4.2. Cell transfection 
HEK-293T cells were grown in DMEM GlutaMax™ (ThermoFisher Scientific) with 
10% FBS (Gibco) and 1% antibiotics (Pen/Strep Penicillin 5,000 unit/ml, Streptomycin 
5,000 μg/ml, Gibco). 250,000 cells/well were seeded onto 6-well plates and transfected 
24 hours later. The transfection mix per sample was the following: 500μl of Opti-MEM 
(Gibco), 2μg of DNA plasmid and 2.5μl of polyethylenimine PEI (Polyscience, Niles 
IL, USA). The solution was vortexed and left at room temperature for 20 minutes to 
allow the formation of DNA-PEI complexes. The transfection mix was then added to 
the cells. 48 hours post-transfection the cells were harvested. Cells and supernatant were 
processed separately. The medium was transferred into microcentrifuge tubes and 
centrifuged at 12,000 x g at 4°C for 5 minutes. The supernatant was placed into fresh 
tubes and kept at -20°C for future use. The cells were washed with 400μl of phosphate 
buffered saline PBS (Gibco). 250μl of ice-cold RIPA Lysis buffer (ThermoFisher 
Scientific) supplemented with 1X of protease inhibitor cocktail (ThermoFisher 
Scientific) were added. The plate was kept on ice for 5 minutes. The cells were then 
scraped and transferred to centrifuge tubes. The samples were centrifuged at 14,000 x g 
at 4°C for 15 minutes. The supernatant was transferred into fresh tubes and stored at -
20°C for future use. 
2.5. AAV9 production 
1X Lysis Buffer: 140mM NaCl (Sigma-Aldrich), 5mM KCl (Sigma-Aldrich), 0.7mM 
K2HPO4 (Sigma-Aldrich), 3.5mM MgCl2 (Sigma-Aldrich), 25mM Trizma. pH 7.5. The 
solution was filter sterilized and autoclaved. 
PBS-MK: 1X PBS 2.5mM KCl, 1mM MgCl2. The final solution was filter sterilized 
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(0.22μm filter, Millipore). 
5X TD buffer: 5X PBS (Sigma-Aldrich), 5mM MgCl2, 12.5 mM KCl. 
2.5.1. Seeding 
A 10 layer cell factory (Corning, NY, USA) was seeded with 5x108 HEK-293T AAV 
pro cells in 1 litre of DMEM GlutaMax™ (ThermoFisher Scientific) with 10% FBS 
(Gibco) and 1% Pen/Strep (Gibco), ensuring equal distribution of the media in each 
layer of the cell factory. Cells were incubated at 37°C in 5% CO2 for 24 hours. 
2.5.2. Transfection 
The transfection mixes were prepared as following: the transgene plasmid, the 
packaging plasmid pDG9, and the helper plasmid pHGTI were added to 50ml of 
DMEM GlutaMax™ (ThermoFisher Scientific) in a 1:1:3 proportion; 2.8ml of PEI 
(Polyscience) were added to 50ml of DMEM GlutaMax™ to a final ratio of 5 PEI : 1 
DNA. Both solutions were well mixed and incubated at room temperature for 15 
minutes. The transfection solutions were added to 1l of DMEM GlutaMax™ with 10% 
FBS and 1% Pen/Strep and mixed thoroughly. The media was removed from the cell 
factory and replaced with the transfection mix ensuring that the solution was distributed 
evenly across the cell factory. Cells were incubated at 37°C in 5% CO2 for 72 hours. 
2.5.3. Harvesting 
The media was poured out from the cell factory and collected into 250ml centrifuge 
tubes. The solution was centrifuged at 1,800 x g for 10 minutes. Afterwards, the 
supernatant was collected in a clean bottle and the cellular pellet was kept for 
subsequent use. 
The cell factory was washed with 500ml of PBS. The solution was poured into the 
250ml tubes containing the previously collected cell pellet. Cells were centrifuged at 
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1,800 x g for 10 minute. The supernatant was then discarded and 50ml of medium was 
added to each tube. 500ml of PBS with 50ml of Trypsin-EDTA X10 (Gibco) were 
added to the cell factory. The cell factory was gently shaken to help the cells detach and 
was incubated at 37°C for 15 minutes. The solution was collected in the 250ml tubes 
containing the medium and centrifuged at 1,800 x g for 5 minutes. The cell factory was 
washed one final time with 500ml of PBS. The solution was poured into the same tubes 
and centrifuged at 1,800 x g for 5 minutes. The final cell pellets were thoroughly 
resuspended in 25ml of 1X Lysis Buffer. 
2.5.4. Benzonase treatment 
The cell lysate obtained from the previous step was frozen at -80°C and then thawed at 
37°C in a water bath. When defrosted, the solution was vortexed for 10 minutes. The 
process was repeated 3 times. 31.3g of (NH4)2SO4 (Sigma-Aldrich) per 100ml were 
added to the previously collected supernatant. The solution was shaken until dissolved, 
incubated on ice for 30 minutes and centrifuged at 8,300 x g for 30 minutes. The pellet 
was then resuspended in 25ml of 1X Lysis Buffer. 
1mM MgCl2 was added to the lysing mix of both the cell pellet and the supernatant. 
5000 units of Benzonase (Sigma-Aldrich) were added respectively to the cell pellet and 
the supernatant. The solutions were mixed thoroughly, incubated at 37°C for 1 hour and 
centrifuged at 4,200 x g at 4°C for 30 minutes. The supernatants were transferred and 
combined into the same tube and stored at -80°C for the following purification. 
2.5.5. Purification 
Iodixanol gradients buffers were prepared as followed: 
15% Iodixanol: 7.5ml Optipep (Sigma-Aldrich), 6ml 5M NaCl, 6ml 5X TD buffer, 
10.5ml dH2O. 
25% Iodixanol: 8.33ml Optipep, 4ml 5X TD buffer, 7.7ml dH2O, 50μl Phenol Red 
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(Sigma-Aldrich). 
40% Iodixanol: 10.2ml Optipep, 3ml 5X TD buffer, 1.8ml dH2O. 
60% Iodixanol: 15ml Optipep, 37.5μl Phenol Red. 
The gradient was prepared in ultracentrifuge tubes (Beckman Coulter, Brea CA USA) 
carefully overlaying 1.55ml of 60% Iodixanol, 1.55ml of 40% Iodixanol, 1.88ml of 25% 
Iodixanol, 2.8ml of 15% Iodixanol, and 5ml of lysate. The tubes were placed into 
SW40-Ti swing-out buckets, balanced to within 0.001g and centrifuged at 200,000 x g 
(Beckman Coulter; acceleration fast, deceleration slow) at 18°C for 3 hours. 
When the centrifugation was completed, the ultracentrifuge tubes were carefully 
extracted from the buckets. Using a 5ml syringe with a 19G11/2 needle (BD 
Microlance) the 1ml layer below the 60-40% interface containing the virus was 
aspirated. The extract was diluted in PBS-MK to a total volume of 50ml, filter sterilised 
(EMD Millipore™ Steritop™ sterile vacuum bottle-top filter 0.22μm, Fisher Scientific) 
and stored at 4°C. 
2.5.6. Concentration 
A sterile concentrator (Vivaspin 20, 100KDa cut off, Sartorius Stedim Biotech, 
Göttingen, Germany) was washed with 5ml of PBS-MK, and equilibrated with 
additional 10ml of PBS-MK. The column was centrifuged at 2,000 x g for 5 minutes. 
The solution was discarded from the collector bucket and residual PBS in the 
concentrator was aspirated. 20ml of sample was added to the column and centrifuged at 
2,000 x g to bring the volume down to 1ml. The process was repeated adding the rest of 
the sample to the concentrator. The column was filled one last time with PBS-MK and 
concentrated to a final volume of 500μl. The virus was aliquoted and stored at -80°C. 
2.5.7. Titration 
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6X Loading buffer: 0.8g sodium dodecyl sulfate SDS (Sigma-Aldrich), 5ml Trizma pH 
6.8, 5ml glycerol (Sigma-Aldrich), 4mg bromophenol blue (Sigma-Aldrich). Add 5% 
beta-mercaptoethanol (Sigma-Aldrich) before use. 
5X Tris-glycine running buffer: 15.1g Trizma, 94g glycine (Sigma-Aldrich), 50ml SDS 
10% in 1l dH2O. 
Gel fix solution: 50ml methanol, 7ml acetic acid, 43ml dH2O. 
Gel wash solution: 10ml methanol, 7ml acetic acid, 83ml dH2O. 
50X Alkaline running buffer: 2.5M NaOH (Sigma-Aldrich), 50mM EDTA (Sigma-
Aldrich). 
4X Alkaline loading buffer: 20% glycerol, 4X alkaline running buffer, 1.2% SDS, 1mg 
xylene cyanol. 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis SDS-PAGE (viral 
protein quantification) - The virus samples and bovine serum albumin BSA (Sigma-
Aldrich) standards of known concentration (250ng, 500ng, 750ng, 1000ng) were diluted 
in 3μl of 6X Loading buffer and heated at 95°C for 5 minutes. The samples were loaded 
on a NuPAGE Bis-Tris 4-12% polyacrylamide gel (Life Technologies) and the 
electrophoresis was run at 120V for 2 hours (PowerPac Bio-Rad, Hemel Hampstead, 
UK). The gel was then incubated twice in gel fix solution for 30 minutes and stained 
with Sypro Ruby (Invitrogen) overnight. The gel was washed in gel wash solution for 3 
minutes, and rinsed in dH2O before imaging with UV transilluminator (InGenius, 
Syngene). Quantification of the bands was performed (ImageJ, USA) and VP3 protein 
concentration (ng/ml) was calculated. 
Alkaline gel electrophoresis (viral genome quantification) - A 0.8% alkaline agarose 
gel was prepared in 980ml of dH2O and 20ml of 50X alkaline running buffer. 25μl of 
virus sample was diluted in 8.5μl of 4X alkaline loading buffer, cooled down to 4°C and 
loaded into the gel. The electrophoresis was performed at 20V at 4°C overnight. The 
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next day, the gel was washed in 0.1M Trizma pH 8.0 for 1 hour and stained with 4X 
GelRed (Biotium, Fremont CA, USA) in 0.1M NaCl for 2 hours. Afterwards, the gel 
was rinsed with water and imaged with a UV transilluminator (InGenius, Syngene). The 
band quantification of samples and HyperLadder 1kb standard (Bioline Reagents, 
London, UK) was performed and the genomic concentration (ng/ml) of the AAV 
sample was calculated. 
2.6. In Vivo animal studies 
2.6.1. Maintenance of transgenic and wild-type mice 
K14-Cre gbalnl/lnl knock-out mice (K14-lnl/lnl) were used as a model of acute 
neuronopatic Gaucher Disease (Enquist et al., 2007) (Figure 8A). Heterozygote mice 
(K14-lnl/wt) were mated to generate knock-out, heterozygotes and wild-type (K14-
wt/wt) animals which were used as controls. 
Wild-type CD1 strain mice were used in the scAAV2/9.GUSB.GFP.bGHpA gene 
reporter study and in the ssAAV2/9.hSynI.hGBA1.WPRE.hHGpA vector toxicity study. 
Animals were maintained in the Biological Services Unit at UCL Bloomsbury Campus, 
London, UK on a 12h light/dark cycle, with free access to water and food. Animals 
were group-housed into individually ventilated cages (IVCs) with appropriate litter and 
nesting material, and environmental enrichment elements. No more than two females 
aged from 6 to 15 weeks per stud male were weekly timed mated. 
All listed procedures were conducted under Dr. Waddington’s project licence (PPL N 
70/8030) and have been approved by the UK Home Office for the conduct of regulated 
procedures under license (Animal Scientific Procedures Act, 1986), and by the ethical 
review committees of University College London. The Animal Research Reporting of 
In Vivo Experiments (ARRIVE) guidelines were followed. 
Mice were weighed weekly and were sacrificed if a loss of more than 15% of the total 
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body mass was observed as a comprehensive humane endpoint. The animals were 
routinely monitored and culled if the humane endpoint was reached (mouse presents 
with paralysis, spasticity, neck hypertension or unconsciousness for more than 4 hours). 
2.6.2. Genotyping 
DNA extraction from earclips 
DNA Extraction Solution 1, pH 12: 1g NaOH, 74.4mg EDTA in 1l of dH2O. 
DNA Extraction Solution 2, pH 5: 40mM Trizma-HCl. 
Tissue samples (2-3mm ear clips) were placed in microcentrifuge tubes. 75μl of DNA 
Extraction Solution 1 was added to each tube and mixed making sure that tissue is 
submerged. Samples were incubated at 95°C for 10-30 minutes. Once the solutions 
cooled to room temperature, 75μl of DNA Extraction Solution 2 was added. Samples 
were stored at -20°C if not used immediately. 
DNA extraction from liver samples 
Liver samples were extracted from culled mice, being careful to avoid any contact or 
contamination from the skin. DNeasy Blood & Tissue Kit (QIAGEN) was used to 
extract DNA from liver tissues as per manufacturer’s protocol. 
Polymerase Chain Reaction (PCR) 
DNA extracted from liver tissues was used for PCR genotyping (Figure 8B) to confirm 
the phenotyping results obtained from the dried blood spot assay. 
Uninjected mice were earclipped at 21 days of age and genotyped through PCR. 
The reaction mix was assembled as follows: 
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2μl Buffer 10X (Promega) 
2μl 10mM dNTPs (VWR, Lutterworth, UK) 
1μl each 50μM primers (GCex8-2, METex8-2, NEO-AO2) 
0.1μl Pfu DNA polymerase (Promega) 
4μl DNA 
dH2O to final volume of 20μl 
The cycle conditions were set up as follows: 
Initial denaturation 94°C for 5 min 
Denaturation 94°C for 30 sec 
Annealing 61°C for 30 sec 
Extension 72°C for 5 min 
Final extension 72°C for 8 min 
(35 cycles of denaturation, annealing and extension) 
Uninjected animals were also screened for Cre recombinase expression within the skin. 
The reaction mix was assembled as follows: 
2μl Buffer 10X (Invitrogen) 
2μl 10mM dNTPs (VWR) 
0.6μl 50mM MgCl2 (Invitrogen) 
1μl each 50μM primers (Cre 134_f, Cre 365_r) 
0.1μl Taq DNA polymerase (Invitrogen) 
4μl DNA 
dH2O to final volume of 20μl 
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The cycle conditions were the following: 
Initial denaturation 94°C for 4 min 
Denaturation 94°C for 30 sec 
Annealing 60°C for 30 sec 
Extension 72°C for 1 min 
Final extension 72°C for 7 min 
(35 cycles of denaturation, annealing and extension) 
DNA amplicates were run on an agarose gel via electrophoresis and the results were 
visualised with a UV transilluminator (InGenius, Syngene). 
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Figure 8 - K14-lnl/lnl mouse model. 
A Schematic representation of the genetics of the K14-lnl/lnl mouse. The Gba1 gene is 
disrupted by a neomycin cassette (NeoR), flanked by two loxP sites. The Cre recombinase is 
expressed in keratinocytes, so that mice carry a wild-type allele in the skin. The primers used for 
genotyping and the length of the fragments are reported. B Example of genotyping gel of a 
heterozygote mouse (K14-lnl/wt) expressing the Cre recombinase in the skin, and a knock-out 
mouse (K14-lnl/lnl). 
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2.6.3. Identification 
Animals were identified through permanent paw tattooing performed at day of birth 
(Castelhano-Carlos et al., 2010). 2μl of tattoo ink (Harvard Apparatus, Holliston MA, 
USA. Dilution 1:3 in PBS) were injected subcutaneously into pups’ palms using a 33-
gauge needle (Hamilton, Cole-Parmer, London, UK). The needle was slowly removed 
from the paw 2-3 seconds after the injection and the excess of ink was removed. A 4-
feet numbering system was used to identify different animals when house-grouped. 
2.6.4. Virus administration 
Injections were performed by Dr. Waddington, UCL Institute for Women’s Health, UK. 
At postnatal day 0-1 pups were anesthetised on ice for 30-60 seconds and intravenous 
injections were performed via the superficial temporal vein with 40μl of vector using a 
33-gauge needle (Hamilton) (Gombash Lampe et al., 2014). Once the needle was slowly 
removed, gentle pressure was applied to the injection site. When the pup fully recovered 
it was returned to the dam. 
The bilateral intracerebroventricular injections were directed to the anterior horn of the 
lateral ventricle. The injection site was identified at 2/5 of the distance from the lambda 
suture to each eye (Kim et al., 2014). P0-1 mice were anesthetised on ice for 30-60 
seconds. The needle was inserted perpendicularly at the injection site to a depth of 3mm 
and 5μl of vector was slowly administered. Following a brief pause to allow vector 
distribution, the contralateral ventricle was injected with the same volume of vector. 
The pup was allowed to recover and placed back into the cage. 
Adult mice (P30) were injected into the lateral tail vein using a 33-gauge needle 
(Hamilton) (Walter et al., 1996). Animals were administered with 40μl of vector. 
2.6.5. Behavioural assessment of mice 
Animals were moved to the test room 20 minutes before the assessment. All tests were 
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filmed and results recorded. 
Rotarod test - Mice were trained for three days before performing the tests. The rotarod 
(Panlab LE8200, Cornella, Spain) was set with a start speed of 4 rpm and 20 rpm/min 
acceleration (Deacon, 2013). The animal was placed on the rotating rod. After having 
ensured that the animal was able to grip the rod and walk forward, the acceleration 
started. When a mouse fell off the time and speed was noted, up to four times per 
experiment. If the mouse fell within the first 5 seconds due to poor placing, the 
experiments would not be recorded. The speed of the rotarod and the time of each fall 
were recorded. 
Open field test - The mouse was placed in the centre of a square transparent Plexiglas 
chamber measuring 27cm x 27cm and allowed to freely explore the chamber (Bailey, 
2009). Animals were filmed from the top of the chamber. The duration of each session 
was 4 minutes. The analysis of the tests was carried out using ANY-maze Behaviour 
Tracking Software v. 4.99 (Stoelting, Dublin, Ireland), assessing distance, average 
speed, mobility and immobility time of each animal. 
Tail suspension test - The mouse was suspended by the end of its tail approximately 
20cm from the bench, ensuring that the animal cannot grasp its tail (Can et al., 2012). 
The test was recorded for 1 minute with a camera facing towards the abdomen of the 
mouse. Limb clasping phenotype was assessed. Wild-type mice extend out all limbs, 
while mice with motor deficiency would clasp their limbs towards the abdomen when 
suspended by the tail (Figure 9). The clasping phenotype was scored as following: 
• All limbs extended out from the body all the time = 0 
• Hind limbs are extended out most of the time; one hind limb is retracted in a 
clasping position less than 50% of the time = 1 
• Both hind limbs are partially retracted for more than 50% of the time = 2 
• Both hind limbs exhibit a clear clasping phenotype touching the abdomen for 
more than 50% of the time = 3 
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Righting reflex test - The mouse was placed in a supine position on a flat surface and 
rapidly released (Brooks and Dunnett, 2009). The ability of the mouse to right itself 
(four paws on the ground) was assessed. Wild-type healthy animals show fast latency to 
return to prone position (< 1 second, score=1), while animals with impairments in motor 
coordination functions exhibit slow latency to right their selves (>10 seconds, score=0) 
or completely fail the test. The time each mouse spent to return in supine position was 
recorded. 
 
Figure 9 - Tail suspension test. 
A Wild-type mouse extends out all limbs when suspended by the tail. B Affected mouse 
showing the clasping phenotype. 
Foot fault test - The mouse was placed on a metal mesh surface (mesh gap size 1.3cm) 
elevated 20cm from the bench. The animal was allowed to cross the device and the run 
was recorded over one minute. The number of total steps for fore limbs and hind limbs 
was counted (Shelton et al., 2008). The number of paw misplacements was also 
recorded. 
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Footprint pattern test - The paws of the mouse were painted with different coloured 
non-toxic dyes (fore paws: blue; hind paws: red). The animal was then allowed to walk 
along a corridor, leaving a trail of footprints on a paper sheet. The stride length and base 
width were measured (Brooks and Dunnett, 2009). 
2.7. Collection and analysis of blood samples 
2.7.1. Blood analysis 
Large volume samples of up to 1ml were collected through ventricular cardiac puncture 
at terminal stages of the study while animals were in terminal anaesthesia. 
Samples were stored in tubes with EDTA at 4°C and analysed on the same day. Blood 
samples were processed through fluorescence-activated cell sorting (FACS) by Central 
Diagnostic Service at the Queen’s Vet School Hospital, Cambridge, UK. 
2.7.2. Dried blood spots collection 
Blood samples were taken from the temporal vein of P0 mice. The vein was punctured 
with a 25g needle (BD Microlance) and a drop of blood was collected with a pipette. A 
maximum of 10% of the total blood volume was collected. Gentle pressure was applied 
to the sampling site in order to stop the bleeding. The pup was allowed to recover and 
consequently placed back into the home cage. 
10μl of blood was blotted on filter paper (Whatman 903 paper, CDC 5‐spot card, 
100/pk, GE Healthcare, USA). If not immediately processed, the samples were placed in 
plastic bags with a dessicant sachet and kept at -20°C, or at -80°C for longer periods. 
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2.7.3. Genotyping through GCase enzymatic assay on dried blood spot 
samples 
All stock solutions were stored protected from light, and placed in bags with dessicant 
sachets. 
0.2M Citrate Buffer: 46.5ml of 0.15M citric acid (Sigma-Aldrich), 53.5ml of 0.3M 
Na3PO4 (Sigma-Aldrich). 
GAUCHER EXTRACTION BUFFER: Triton X-100 was made by adding 5ml of Triton 
X-100 to 45ml of 0.2M Citrate Buffer.  5ml of 10% Triton X-100 (Sigma-Aldrich) were 
added to the bottle containing 1g of sodium taurodeoxycholate (Sigma-Aldrich) and the 
solution was transferred to a cylinder. 5ml of 10% Triton X-100 were added again to 
wash the bottle and transferred to the cylinder two more times. 0.2M Citrate Buffer was 
added up to 100ml ad the pH was adjusted to 5.2. The solution was aliquoted and 
stored at 4°C. 
GAUCHER SUBSTRATE BUFFER (4-MUβGlu): 2.3ml of DMSO (Sigma-Aldrich) were 
added to 778.11mg of 4-methylumbelliferyl-β-D-glucopyranoside (Sigma-Aldrich). The 
solution was mixed and aliquots were stored at -20°C. 
GAUCHER WORKING SOLUTION (GWS): 75μl of 4-MUβGlu were dissolved in 
5.925ml of dH2O. The solution was prepared fresh on the day. 
CBE SOLUTION: 5mg of 0.26M Conduritol B epoxide (Sigma-Aldrich) were dissolved 
in 120.5μl of DMSO. The solution was aliquoted and stored at -20°C. 
GAUCHER INHIBITING SOLUTION (GIS): 5.6μl of CBE solution were added to 3ml 
of GWS. The solution was prepared fresh on the day. 
GAUCHER STOP SOLUTION: 0.5M EDTA pH 11.3-12. The solution was filtered using 
0.22μm filter. 
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GAUCHER STANDARD SOLUTION (6μM 4-MU): 0.011g of 4-methylumbelliferone 
(Sigma-Aldrich) was dissolved in 10ml of methanol. 1μl of the solution was then diluted 
in 99μl of dH2O. 
Since all mice carried the wild-type allele in the skin, it was not possible to genotype 
neonatal animals using the standard DNA extraction from ear or tail clips. Therefore, 
knock-out mice were identified through detection of β-glucosicerebrosidase enzymatic 
activity in blood samples. This assay allowed the identification of Gba1 knock-out 
animals; however, it was not suitable to differentiate with certainty between 
heterozygote and wild-type mice. 
A 6mm disk was punched from the centre of a blood spot directly into a 1.5ml tube and 
400μl of Gaucher extraction buffer were added. When the punch was not completely in 
contact with the buffer, the tube was quickly vortexed allowing the liquid to entirely 
cover the paper. The tube was mixed for 1 hour at 4°C. The paper disk was removed 
and the tube was centrifuged for 30 minutes at RT at 10,000 x g. The sample was 
returned immediately onto ice and the supernatant was moved to a fresh tube. 40μl of 
sample were incubated with 80μl of Gaucher working solution in 96-well black bottom 
plates (Corning, USA). Each sample was tested in duplicate. Columns 11 and 12 were 
left empty for following use. The plate was sealed and incubated at 37°C for a minimum 
of 6 hours to a maximum of 24 hours. After the incubation period, the adhesive film 
was removed from the plate. 100μl of dH2O were added to all wells in column 11. 100μl 
of the Gaucher standard solution (6μM 4-MU) were added to wells A11. The following 
serial dilutions of the Gaucher standard solution were created transferring 100μl of the 
solution from each well to the following one, starting from wells A11 to B11, from B11 
to C11, from C11 to D11 and so on: 0.3125nM (A11), 0.1563nM (B11), 0.0781nM 
(C11), 0.039nM (D11), 0.098nM (E11), 0.0049nM (F11), 0.000nM (G11). Well G11 
contained only 100μl of dH2O. The serial dilutions described above were repeated for 
column 12, starting from well A12. 100μl of the Gaucher Stop Solution were added in 
each well. Fluorescence was red from the top of the plate using the following 
parameters: excitation wavelength: 360nm; emission wavelength: 450nm (FluoStar 
Optima Plate Reader, BMG Labtech, Aylesbury, UK). 
85 
2.8. Harvesting and tissue preparation  
Mice were euthanised by transcardial perfusion using PBS while under terminal 
isofluorane anaestehsia and organs were subsequently harvested. 
One hemisphere of the brain was fixed in 4% PFA (Sigma-Aldrich) for 48 hours, 
transferred to a cryopreserving solution of 30% sucrose (w/v) (Sigma-Aldrich) in PBS 
and stored at 4°C. The other hemisphere was frozen and stored at -20°C. 
Visceral organs were cut in two parts and placed in separate tubes. One half was 
preserved in 4% PFA at 4°C for 48 hours, then moved to 30% sucrose in PBS and 
stored at 4°C; the parts intended for enzymatic assay and protein extraction were frozen 
and stored at -20°C. 
2.9. Histological analysis of tissues 
2.9.1. Cryosectioning of murine tissue samples 
1X Tris Buffered Saline TBS: 6.04g Trizma, 8.5g NaCl, 3.2ml 1M HCl (Sigma-Aldrich), 
dH2O to final volume of 1l. 
TBS with anti-freeze (TBSAF): 350ml of TBSA (1X TBS, 0.05% sodium azide (VWR)), 
150ml of ethylene glycol (VWR), 30%  sucrose solution. 
Fixed organs were embedded with specimen matrix (Thermo Scientific), frozen and cut 
at 40μm in thickness at constant temperature of -20°C with a Cryostat Leica CM3050 
(Leica Biosystems, Milton Keynes, UK). Coronal brain sections were sliced starting 
from the front of the olfactory bulbs to the cerebellum and brain stem. Slices were 
stored at 4°C in TBSAF in 96-well plates. 
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2.9.2. Preparation of chrome-gelatine coated slides 
2.5g of gelatin (VWR) and 0.25g of chromium (III) potassium sulphate 12-hydrate 
(VWR) were dissolved in 500ml of dH2O preheated to 45°C. The slides (75 x 25 x 1.2 
mm, VWR) were immersed in the gelatine solution for a few seconds and left to dry at 
56°C overnight. The process was repeated on the next day. 
2.9.3. Immunohistochemical staining on free-floating tissue sections 
TBS with Triton X-100 (TBS-T): 1X TBS, 0.3% Triton X-100. 
A series of representative sections was collected in six-well plates and washed three 
times with 3ml of TBS with 5 minutes between each wash on a rocking table. 
Endogenous peroxidase activity was blocked with 1% H2O2 in 1X TBS for 30-60 
minutes under constant gentle agitation. Slices were rinsed three times in 1X TBS and 
the non-specific binding was blocked in 15% normal serum (Sigma-Aldrich) in 1X 
TBS-T for 30 minutes on a rocking table. Sections were washed three times with 1X 
TBS and the primary antibody diluted with 10% normal serum in TBS-T was added. 
The plate was incubated at 4°C overnight on a rocking table. The following day, slices 
were washed three times with 1X TBS and incubated for 2 hours at room temperature 
with the secondary antibody diluted with 10% normal serum in TBS-T. Afterwards, 
sections were rinsed three times in 1X TBS and incubated for 2 hours with 1:1000 
avidine-biotin reagent (Vectastain Elite ABC kit, Vector Labs, UK). Sections were then 
washed three times in 1X TBS and immunoreaction was detected by adding 0.45μm 
filtered 0.05% 3,3’-diaminobenzidine tetrahydrochloride (Sigma-Aldrich) and 0.001% 
H2O2 in 1X TBS (one DAB tablet in 20ml of TBS). The plate was covered with foil and 
kept under agitation for a few minutes. The reaction was stopped by adding ice-cold 1X 
TBS. After three washes in 1X TBS, sections were mounted on chrome-gelatine coated 
slides and left to air-dry overnight. Slides were dehydrated in 100% ethanol, cleared in 
Histo-clear (National Diagnostic, Atlanta GA, USA) for 30 minutes and cover slipped 
with DPX mountant (Fisher Scientific). 
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2.9.4. Immunofluorescent staining of tissue sections 
DAPI working solution: 1mg/ml (aq) 4′,6-diamidino-2-phenylindole (DAPI, Sigma-
Aldrich) diluted 1:1,000 in 1X TBS. 
Sections were initially stained as described in Section 2.9.3. Following incubation with 
secondary antibodies with Alexa Fluor conjugates, the sections were washed three times 
in 1X TBS and incubated with DAPI working solution for 5 minutes protected from 
light. 
Sections were rinsed three times in 1X TBS and mounted on chrome-gelatine coated 
slides. When the sections were dried, the slides were coverslipped with Fluoromount G 
(SouthernBiotech, Birmingham AL, USA) and kept at 4°C protected from light. 
2.9.5. Nissl staining of brain sections 
0.05% Cresyl Violet Working Solution: 0.5ml of 10% (aq) acetic acid per 100ml of 
0.5% (aq) cresyl fast violet (VWR). 
Brain sections were mounted on chrome-gelatine coated slides and air-dried overnight. 
Slides were stained in 0.05% Cresyl Violet Working Solution at 60°C for 30-45 
minutes. Slides were then rinsed twice in fresh dH2O and dehydrated in IMS and Histo-
clear as follows: 
- 70% IMS, 5 min - 80% IMS, 2 min - 90% IMS, 2 min - 95% IMS, 2 min - 100% IMS, 2 min - 100% IMS, 2 min - 50% Histo-clear in  IMS, 2 min - 100% Histo-clear, 2 min 
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When the background staining disappeared, the slides were incubated in fresh Histo-
clear for 30 minutes and consequently coverslipped with DPX mountant medium. 
2.9.6. Hematoxylin and Eosin (H&E) staining 
0.5% Eosin: 1.5g of Eosin (Sigma-Aldrich) in 300ml of 95% ethanol. 
Tissue sections were mounted on chrome-gelatine coated slides and air dried overnight. 
The sections were stained protected from light with filtered 0.1% Mayer Hematoxylin 
(Sigma-Aldrich) for 10 minutes. The slides were rinsed in dH2O for 5 minutes and 
consequently dipped 12 times in 0.5% Eosin solution. The sections were quickly 
washed in dH2O and subsequently dehydrated for 30 seconds in rising concentrations of 
ethanol (50%, 70%, 95%, 100%). The slides were finally incubated in Histo-clear for 30 
minutes and coverslipped with DPX mountant medium. 
2.9.7. Microscope imaging 
Light bright-field images were taken with a Nikon DS-Fi1 camera (Nikon, Tokyo, 
Japan) attached to a Nikon Eclipse E600 microscope. Representative images of the full 
brain section were taken with a 1X. Higher magnification pictures of discrete areas of 
the sections were taken with 10X/0.25 and 40X/0.65 objectives (CFI Achromat, Nikon). 
Specific brain regions were identified according to the Paxinos and Franklin’s Mouse 
Brain Atlas (Paxinos, 2012). Antero-posterior coordinates from bregma for each region 
are reported in Table 7.  
Immunofluorescent stained sections were analysed with Zeiss LSM 710 laser scanning 
confocal microscope (Carl Zeiss AG, Oberkochen, Germany). 
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BRAIN REGION BREGMA (mm) 
Prefrontal cortex From +3 to +2 
Lateral ventricles From +1 to 0  
Cortex From -1 to -2 
Hippocampus From -1.5 to -2 
Thalamus From -1.5 to -2 
Midbrain From -2.5 to -3 
Cerebellum From -5.5 to -6.5 
Brain stem From -5.5 to -6.5 
Table 7 - Coordinates from bregma.  
Brain regions analysed in the study and relative antero-posterior coordinates from bregma are 
reported. 
2.9.8. Staining quantification 
The region of interest on a section was first identified at low magnification. The 
objective was then changed to 40X and the optimal focus and light intensity were 
adjusted. 10 consecutive non-overlapped images per distinct area were taken. The light 
intensity was kept constant throughout the imaging process of each region of all brains 
and visceral organs stained against the same antibody. 
The evaluation of the immunoreactivity of stained sections was performed using the 
Image-Pro Premier analysis system (Media Cybernetics, Rockville MD, USA). The 
minimum threshold value of stained pixel intensity was assigned. All the images of 
sections stained with the same antibody were processed simultaneously. The extent of 
staining, defined as level of intensity above the assigned threshold for each stained 
pixel, and expressed as percentage of the total area of the image was measured. Results 
were presented as the percentage of average value of immunoreactivity of 10 
consecutive images for each distinct region. 
2.9.9. Neuronal counts in discrete brain regions using stereology 
Neuron counting and cortical thickness measurements were estimated with Stereo 
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Investigator software (MBF Bioscience, Williston VE, USA) on Nissl stained sections 
with a Nikon Optihot light microscope (Nikon) attached to a Q-Imagin camera (MBF 
2000R-CLR-12, Bioscience). The user was blinded to the experimental slides being 
analysed by another person covering the slide labels with tape. 
Neurons were counted with the Optical Fractionator probe using the 40X objective. The 
grid size and the counting frame used for analysing different brain regions were the 
following: S1BF 150 x 150 μm, 50 x 50 μm; VPM/VPL 175 x 175 μm, 50 x 50 μm; Gi 
100 x 100 μm, 50 x 50 μm. Cells were counted using a 100X objective. Efficient 
sampling was estimated by a coefficient of error between 0.05 and 0.1 (Gundersen et al., 
1999). 3 to 4 sections for each brain were analysed and the average values of cell 
counting were used in the calculations. 
The mean thickness of the S1BF cortical region was estimated by using the Cavalieri 
vertical sections principle (Baddeley et al., 1986). The length of 10 parallel consecutive 
lines intersecting perpendicularly the cerebral cortex, traced from the somatosensory 
barrel cortical layer 1 to the corpus callosum, was measured. 3 sections of the midbrain 
region per each brain were analysed and the average values were reported. 
2.10. Protein analysis 
2.10.1. Protein concentration measurements from tissue and 
transfected cell samples 
The total protein concentration of tissue homogenates and transfected cell extracts was 
estimated using the Pierce BCA Protein Assay Kit (Thermo Scientific) accordingly to 
the manufacturer’s instructions. 
2.10.2. Glucocerebosidase enzymatic activity assay on frozen tissue 
1M Glycine buffer: 7.5g glycine, 5.8g NaCl in 100ml dH2O. Add 5.6ml of solution to 
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4.4ml of 1M NaOH solution. pH 10.4. 
Frozen tissue samples were homogenised with dH2O on ice. The total protein 
concentration was measured. 
The same reagents described for the dried blood spot assay (Section 2.7.3) were used. A 
96-well plate was divided into rows of 4 wells per each sample. 3μl of sample and 30μl 
of 4.8mM 4-MUβGlu in Gaucher Extraction Buffer were added in duplicate into the 
first and second wells of each row. The plate was incubated at 37°C for 2 hours. 1ml of 
1M Glycine buffer pH 10.4 was added to wells 1 and 2 to stop the reaction. For each 
sample a standard and a standard blank were set up as following: 200μl of 1nM 4-
methylumbelliferone, 950μl of 1M Glycine buffer and 15μl of sample were added to 
well 3; 200μl of dH2O, 950μl of 1M Glycine buffer and 15μl of sample were added to 
the last well. Fluorescence was read (FluoStar Optima Plate Reader. Excitation 
wavelength: 360nm; emission wavelength: 450nm; fluorescent top reading; gain: 750). 
The enzymatic activity (nmol/hr/μg) was calculated using the following equations. 
For each sample: 
Standard – Standard blank = fluorescence of 1nmol of 4-methylumbelliferone 
𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑠𝑎𝑚𝑝𝑙𝑒
𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
∗
60(minutes)
120(minutes)
∗
1000(μl)
15(μl)
∗
1(μ𝑔)
𝑠𝑎𝑚𝑝𝑙𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (μ𝑔μ𝑙 )
 
2.10.3. Protein analysis using Western blot 
1X SDS Running buffer: 50ml 20X NuPAGEMES (Invitrogen, USA), 950ml dH2O. On 
the day, add 250μl of anti-oxidant (Invitrogen) per 100ml of buffer. 
TBS-Tween: 1X TBS, 0.1% Tween (Sigma-Aldrich). 
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Transfected cells were processed as described in Section 2.4.2. Protein concentrations 
from cell samples were normalised to 1μg/μl. 1X LDS Sample buffer (Life 
Technologies) and 1X Reducing agent (Life Technologies) were added to each sample. 
The samples were boiled at 95°C for 5 minutes to denaturate the proteins. 20-40μg of 
protein sample and 10μl of molecular weight marker (RPN800E, GE Healthcare) were 
loaded into NuPAGE Bis-Tris 4-12% polyacrylamide gel (Novex, Life Technologies) 
with 1X SDS Running buffer. The gel was run at 90V for 2 hours (PowerPac, Bio-Rad). 
PDVF membrane (Millipore) was incubated in methanol for 1-2 minutes. Afterwards, 
the membrane and the gel were equilibrated in ice-cold Transfer buffer for 5 minutes. A 
sandwich of filter paper/PVDF membrane/gel/filter paper wetted in Transfer buffer was 
placed into the transfer apparatus (Trans-Blot SD, Bio-Rad). The transfer was 
performed at 400mA for 1 hour. The membrane was washed in TBS-Tween buffer and 
blocked in 5% BSA in TBS-Tween at 4°C for 1 hour with agitation. The membrane was 
then incubated with the primary antibody diluted in TBS-Tween with 3% BSA at 4°C 
overnight with agitation. The membrane was then washed 3 times in TBS-Tween buffer 
while agitating, 5 minutes per wash. The membrane was incubated with the secondary 
HRP-conjugated antibody (Abcam) diluted in TBS-Tween with 3% BSA at room 
temperature for 1 hour with agitation, and finally washed 3 times in TBS-Tween. 
The membrane was developed using SuperSignal West Pico kit (Thermo Fisher) 
accordingly to manufacturer’s instructions. The imaging of the membrane was 
performed with GeneGnome Imager (Syngene). 
2.10.4. Enzyme-linked immunosorbent assay (ELISA) 
The ELISA test was carried out by Dr. Buckley, UCL Institute for Women’s Health, 
London, UK in order to obtain a quantitative measurement of GFP protein in the 
visceral organs for mice injected with the scAAV2/9.GUSB.GFP.bGHpA vector. 
A 96-well plate was incubated with the primary anti GFP antibody (ab1218, Abcam) 
diluted 1:10,000 in bicarbonate buffer overnight at 4°C. The wells were washed three 
times with a Tween20-PBS solution (1:2,000) and incubated with a blocking solution 
(1% BSA in PBS) at 37°C for 1 hour. Tissues were homogenised in lysis buffer and 
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protein concentration was measured. 100μl/well of sample and serial dilutions of the 
standards (1μg/ml GFP in wash buffer) were added. The plate was then incubated at 
37°C for 1 hour. After three washes, 1:5,000 secondary polyclonal antibody (ab6658, 
Abcam) in blocking solution was added. The plate was incubated at 37°C for an 
additional hour. The samples were washed and a streptavidin-HRP substrate solution 
(1:20,000 in blocking solution) was added. The plate was incubated at 37°C for 1 hour. 
100μl/well of tetramethylbenzidine were added and the plate was incubated at room 
temperature for 10 minutes. 100μl/well of 2.5 H2SO4 were added and the fluorescence 
was immediately read at 450nm (FluoStar Optima Plate Reader). 
2.11. Statistical analysis 
The statistical analysis was performed with GraphPad Prism Software (v. 6.0e). Data 
are presented as average values (mean) + standard deviation (SD). t-test, one-way 
ANOVA and two-way ANOVA tests were performed where appropriate. The survival 
data were analysed with Kaplan-Meier estimate. Tukey’s and Mantel-Cox’s honest 
significance ad-hoc tests were used for multiple comparison analysis. Non-statistical 
significance (ns) was assumed for p > 0.05.
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3. Evaluation of intravenous AAV9 
administration to neonatal and 
juvenile mice 
The current study provides pre-clinical evidence on the beneficial effects of AAV-based 
gene therapy as a possible treatment for Gaucher disease. The results of this work are 
articulated in three major sections: (i) the preliminary gene reporter analysis confirms 
the widespread transduction following intravenous administration to neonatal wild-type 
mice; (ii) the administration of an AAV vector carrying the functional therapeutic gene 
rescues the lethal neurodegeneration of an acute Gaucher type II mouse model (Enquist 
et al., 2007); (iii) the administration of a novel vector with strong neuronal tropism 
results in recovery of the neuropathology in the mouse model. 
3.1. Introduction 
Previous studies have shown that the intravenous administration of an AAV9 vector to 
neonatal mice leads to efficient widespread transduction of neurons, while the 
administration to adult animals result in a more predominant astrocytic transduction 
(Foust et al., 2009). Efficient neuronal transduction is necessary to ameliorate the severe 
neuropathology that characterises Gaucher disease type II. The acute neurodegeneration 
is already present in the early neonatal period (Goker-Alpan et al., 2003), therefore an 
early intervention is necessary to prevent further development of neurological 
impairment. Although Foust and colleagues already demonstrated that the intravascular 
administration of a scAAV9 vector to neonatal mice results in neuronal transduction, 
there are no previous data on the use of the β-glucuronidase promoter employed in this 
study. This chapter will examine the importance of therapeutic intervention in early 
developmental stages to achieve an efficient and widespread neuronal transduction using 
an AAV9 vector configuration and promoter that would be suitable as part of a 
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preclinical study. 
In this preliminary reporter gene study, a scAAV2/9 vector carrying the green 
fluorescent protein (GFP) gene was administered intravenously to wild-type mice at two 
different time points and brain transduction was assessed. The transgene expression was 
under control of the ubiquitous β-glucuronidase (GUSB) promoter. Although GUSB has 
been used in other preclinical studies (Husain et al., 2009), relatively little is known on 
whether it can mediate gene expression in neural cells following systemic 
administration. The present study aimed to confirm that central nervous system 
transduction was achievable following intravenous administration of the vector into 
neonatal mice and any potential advantages this has over administration into older 
juvenile mice. The immune response against the virus or transgene expression in the 
central nervous system was also evaluated. In order to evaluate the efficiency of the 
vector to transduce different cell types, the distribution of the transgene expression in the 
viscera was assessed. 
3.2. scAAV2/9.GUSB.GFP.bGHpA vector 
The construct was kindly provided by Dr. Seng H. Cheng (Sanofi Genzyme). The green 
fluorescent protein gene was cloned into a shuttle plasmid containing the inverted 
terminal repeat (ITR) sequences derived from a scAAV2 vector and the β-glucuronidase 
(GUSB) promoter, followed by a short bovine growth hormone poly-adenylation signal 
(bGHpA). The recombinant scAAV2/9.GUSB.GFP.bGHpA vector (Figure 10) was 
generated by standard triple plasmid transfection. The titre of the supplied viral stock 
was 1x1013 gc/ml. 
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Figure 10 - Schematic of the scAAV2/9.GUSB.GFP.bGHpA final expression cassette. 
The reporter gene GFP was cloned into the scAAV2/9 vector backbone downstream the β-
glucuronidase promoter (GUSB). The viral inverted terminal repeats (ITRs) are derived from a 
scAAV2 vector. 
3.3. Analysis of GFP expression in the brain following 
intravenous administration of the 
scAAV2/9.GUSB.GFP.bGHpA vector to neonatal and juvenile 
mice 
Wild-type outbred CD1 mice were intravenously injected via the superficial temporal 
vein at the day of birth (from now referred to as ‘neonatal administered’) with 4 x 1011 
gc of scAAV2/9.GUSB.GFP.bGHpA in a total volume of 40μl (n=5).  Young adult 
mice (referred to as ‘juvenile administered’) were injected at 30 days of age (n=4). 
Uninjected CD1 mice were used as controls (n=3). The animals were sacrificed one 
month after virus administration and the brains were harvested, sectioned and examined 
for GFP expression using immunoperoxidase staining. 
The brains from neonatally injected mice showed widespread rostro-caudal transduction 
in both hemispheres, including the pre-frontal cortex, hippocampus, thalamus, midbrain, 
cerebellum and brain stem (Figure 11). In comparison the transgene expression in 
brains from juvenile administered mice was limited to fewer areas and staining for GFP 
was less intense. Highly efficient transduction was detected in distinct regions of the 
brain stem, however the GFP expression in the anterior part of the brain was reduced 
compared to the neonatal administered mice. Some scattered GFP positive cells could 
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be detected in the midbrain. 
 
Figure 11 - Immunoperoxidase detection for GFP protein in brain sections from mice 
administered with 4 x 1011 gc scAAV2/9.GUSB.GFP.bGHpA following intravenous 
injection into neonatal administered and juvenile administered mice. 
When injected into neonates, the scAAV2/9.GUSB.GFP.bGHpA vector efficiently 
transduced the cortex, hippocampus, thalamus, hypothalamus, cerebellum and brain 
stem. The brains from mice injected at P30 (juvenile administered) showed reduced 
transduction limited to fewer areas of the brain stem. Uninjected mice were used as 
control (Scale bar: 1mm). 
Quantification of the immunoreactivity (Figure 12) was performed using thresholding 
image analysis to estimate the transgene expression in five discrete brain regions, 
including: somato-barrel field cortex (S1BF), cornu annuli 1 and 2 of the hippocampus 
(CA1/CA2), ventral post-medial and post-lateral nuclei of the thalamus (VPM/VPL), 
central lobule 2 of the cerebellum (CENT2) and the gigantocellular region of the brain 
stem (Gi). Statistical analysis confirmed that the GFP expression in neonatal 
administered brains was elevated in all regions compared to uninjected controls. 
Although the staining for GFP was predominantly more intense in the brain of neonatal 
administered mice compared to the juvenile administered ones, GFP expression was 
significantly higher in the hippocampus (p<0.0001) and in the cerebellum (p=0.003) of 
98 
neonatal administered mice compared to juvenile administered mice. 
 
Figure 12 - Quantification of GFP immunostaining. 
Analysis of immunostaining of uninjected controls (n=3), neonatal administered (n=5) and 
juvenile administered (n=4) brains. The average immunoreactivity of each brain region has been 
reported. The areas taken into consideration were: cortex (S1BF), hippocampus (CA1/CA2), 
thalamus (VPM/VPL), cerebellum (CENT2), and brain stem (Gi). Brains from neonatal 
administered mice showed elevated and widespread GFP expression. Significant difference in 
immunoreactivity was observed in the juvenile administered brains compared to uninjected 
controls (Data presented as average + SD. Statistical analysis: two-wayANOVA, Tukey’s 
multiple comparisons test; * p<0.05, ** p<0.01, *** p<0.0001, **** p<0.0001). 
Using light microscopy, a semi-quantitative analysis of GFP expression in more 
detailed regions of the brain was carried out (Figure 13). Overall, higher levels of GFP 
expression were visible in the brains from mice that received intravenous neonatal 
administration of scAAV2/9.GUSB.GFP.bGHpA compared to those that received 
injections at P30. 
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Figure 13 - Distribution of GFP-positive cells in different brain regions. 
The colour indicates the density of GFP positive cells. The absence of transduced cells is 
represented by a white square, while the highest GFP expression is represented by a dark 
square. Neonatal injections of scAAV2/9.GUSB.GFP.bGHpA resulted in higher and 
widespread transduction compared to juvenile administered brains. 
Higher magnification light microscopy pictures showed in detail the differences in 
transgene expression between neonatal and juvenile administered mice within discrete 
regions of the brain (Figure 14). From the images it was possible to appreciate that the 
expression in the neonatal administered mice appeared to be predominantly in cells of 
neuronal morphology, whereas in the juvenile administered brains transduced cells 
appeared to be a more heterogeneous population of astrocytes and neurons. In 
particular, within the cortex, the hippocampus and partially in the thalamus of juvenile 
administered brains the tropism of the vector is mainly astrocytic.
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Figure 14 - GFP transduction in neonatal and juvenile administered brains following 
intravenous injection of scAAV2/9.GUSB.GFP.bGHpA. 
Brain sections from mice administered neonatally showed widespread transduction in the 
cortical region cortical S1BF, hippocampal CA1/CA2, thalamic nuclei VPM/VPL, cerebellar 
lobi and brain stem. The later administration of the vector to juvenile mice resulted in moderate 
GFP expression (Scale bars: low magnification 100μm; high magnification 60μm). 
3.4. An evaluation of immune response following intravenous 
administration of scAAV2/9.GUSB.GFP.bGHpA 
In order to assess if the systemic administration of the scAAV2/9.GUSB.GFP.bGHpA 
vector harbored an immune response in the brains of injected mice, 
immunohistochemistry was performed on tissue sections using antibodies against the 
macrophage/microglial protein cluster of differentiation 68 (CD68). This lipoprotein is 
usually found in the cytoplasmic granules of macrophage-lineage cells and can be 
utilised as a useful marker for detecting microglia associated with brain injury and 
neuroinflammation (Graeber et al., 1990). Untreated K14-lnl/lnl mice were used as 
positive control for microglia activation. The quantification of the immunoreactivity 
(Figure 15) confirmed that the administration of the vector did not cause immune 
response in the brain of injected mice. In fact here was no indication of increased 
microglial staining in brains from mice that received neonatal and juvenile 
administration of scAAV2/9.GUSB.GFP.bGHpA when brain sections were examined 
by light microscopy (Figure 15A). Quantification by threshold image analysis 
confirmed that there was no significant difference between controls uninjected mice and 
any of the AAV9 administered animals (Figure 15B). 
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Figure 15 - Immune response in brains from mice administered with 
scAAV2/9.GUSB.GFP.bGHpA. 
A Brain sections were assessed for microglia activation. Brains from mice administered 
neonatally (n=5) and as juveniles (n=4) did not showed staining for the microglia marker CD68 
following administration of the vector. Untreated K14-lnl/lnl mice were used as positive 
controls. B Quantification of the staining for CD68 confirmed that the administration of the 
vector did not cause microglia activation in the brains of injected mice (Data presented as 
average + SD. Statistical analysis: one-wayANOVA, Tukey’s multiple comparisons test; *** 
p≤0.001). 
3.5. Vector distribution in the visceral organs 
The aim of this study is to gain an insight into systemic gene delivery of a scAAV2/9 
vector expressing GFP under control of the GUSB promoter in neonatal mice. 
Intravenous administration of the vector would also mean that systemic delivery may 
also be possible. This would be advantageous for the treatment of the Gaucher disease 
type II mouse model since, although the primary cause of death is neurodegeneration, 
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the mice also suffer from symptoms in the visceral organs (Enquist et al., 2007). 
Therefore the distribution of viral transduction in visceral organs following the injection 
was analysed. GFP expression in different tissues was evaluated by ELISA analysis 
(Figure 16). Overall, GFP detection was robust in mice injected at day of birth. In 
particular, the analysis of the lungs revealed a highly significant increase (p=0.0005) in 
GFP levels in the mice administered neonatally when compared to the mice 
administered as juveniles. High levels of GFP protein were identified in the liver of both 
neonatal administered mice and mice administered as juveniles. The presence of GFP 
protein in the liver of control animals can be attributed to the high background signal of 
the assay. 
 
Figure 16 - GFP ELISA assay on visceral organ samples from neonatal and juvenile 
administered mice injected with scAAV2/9.GUSB.GFP.bGHpA. 
Levels of GFP protein in the liver, lung and heart of treated mice neonatal administered (n=5), 
juvenile administered (n=4) and controls (n=3) were determined by ELISA assay. High levels of 
GFP protein were detected in the organs harvested from the neonatal administered mice (Data 
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presented as average + SD. Statistical analysis: one-way ANOVA, Tukey’s multiple 
comparisons test; ** p≤0.01, *** p≤0.001). 
3.6. Conclusions 
The aim of the preliminary reporter gene study was to evaluate the feasibility of an 
adeno-associated viral vector to efficiently transduce the central nervous system and the 
viscera following a single systemic administration. The result of the study confirmed 
that a scAAV2/9 vector carrying the GUSB promoter is able to efficiently transduce 
cells of both the viscera and central nervous system following a single intravenous 
administration in neonatal mice. 
The scAAV2/9.GUSB.GFP.bGHpA vector was injected into neonatal and young adult 
wild-type mice and the efficiency of gene delivery was assessed one month after 
administration. The early administration of the vector led to a more extensive central 
nervous system transduction in neonatal administered mice compared to juvenile 
administered animals. The analysis of some areas (cortex, hippocampus, thalamus, 
cerebellum and brain stem) revealed that the scAAV2/9.GUSB.GFP.bGHpA vector 
seems to preferentially transduce cells with neuronal morphology following neonatal 
administration, whereas its cellular tropism appears more astrocytic in juvenile 
administered brains. These results confirmed the possible use of an AAV9-based vector 
for effective gene delivery to the central nervous system using a transgene that is driven 
by the GUSB promoter. In particular, the ability of the virus to transduce preferentially 
neuronal cells when administered at early age (Foust et al., 2009) confirmed that an 
early intervention can be beneficial for the treatment of the severe neurodegeneration, as 
characterised by acute neuronopathic Gaucher disease. 
In order to establish whether the administration of the vector provoked an immune 
response in the brain of treated mice, the levels of microglia activation were analysed. 
No increase in CD68-positive cells was detected in brains of treated mice, confirming 
that adeno-associated viruses are non-pathogenic and the administration to animals that 
have not previously been exposed to the virus does not harbour immune response. 
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Finally, the distribution of the vector in the viscera was evaluated. The GFP ELISA 
analysis revealed that the transgene is efficiently expressed in the liver, heart and lungs 
of treated mice. The early administration to neonatal mice resulted in elevated levels of 
GFP protein in the heart and in the lungs, compared to the juvenile administered 
animals. The GFP expression levels in the liver of neonatal administered mice were 
similar in both groups. Adeno-associated virus serotype 9 is known to transduce the 
liver, lung and heart well (Grimm and Kay, 2003); however in the context of the 
ubiquitous β-glucuronidase promoter its tropism required confirmation. 
Overall, the reporter gene study showed that the administration of the 
scAAV2/9.GUSB.GFP.bGHpA vector resulted in widespread transduction of the brain 
and the visceral organs of wild-type mice when injected intravenously to neonatal 
animals. This study validated the use this vector configuration and switching the GFP 
marker gene for the therapeutic human GBA1 gene for extensive neonatal gene delivery 
to a Gaucher type II mouse model.
107 
4. Intravenous AAV9-mediated 
gene therapy rescues a neonatal 
lethal mouse model of 
neuronopathic Gaucher disease 
4.1. Introduction  
The reporter gene study confirmed that the self-complementary AAV2/9 vector was 
able to transduce neurons in the brain and a variety of visceral organs. Therefore, a 
vector with the same configuration of the scAAV2/9.GUSB.GFP.bGHpA carrying the 
human GBA1 gene was provided, in order to conduct a gene therapy rescue study on the 
acute lethal mouse model of Gaucher disease type II. The K14-lnl/lnl knock-out mouse 
is deficient in Gba1 and develops severe neurodegeneration and visceral pathology, 
resulting in premature death at two weeks of age (Enquist et al., 2007). Hence this 
mouse strain is a valuable model for studying the effects of gene therapy on both the 
neuropathology and the systemic diseases. 
In this study an AAV9 vector carrying the functional GBA1 gene was intravenously 
administered to neonatal K14-lnl/lnl mice and the effect on lifespan, amelioration of the 
neuropathology and the therapeutic outcome on the viscera were assessed. The health of 
the mice was constantly monitored and a series of behavioral tests were performed in 
order to evaluate changes in the neurological symptoms of treated animals. The 
neuropathology was extensively studied performing a wide range of 
immunohistochemical and stereological analysis. The visceral organs were examined 
for the presence of Gaucher cells, and the β-glucocerebrosidase enzymatic activity was 
measured. Finally, a long-term study was conducted to assess any extension in lifespan. 
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4.2. scAAV2/9.GUSB.hGBA1.bGHpA gene therapy vector 
The scAAV2/9.GUSB.hGBA1.bGHpA vector (Figure 17) was produced by Dr. Seng H. 
Cheng (Sanofi Genzyme). The virus maintains the same configuration as the 
scAAV2/9.GUSB.GFP.bGHpA vector used in the reporter gene study (Chapter 3). The 
human β-glucocerebrosidase gene (hGBA1) was cloned into the AAV9 construct, 
downstream of the GUSB promoter and followed by the bHGpA poly-adenylation 
signal sequence. The human and murine GBA1 gene sequences are 86% homologous 
(O'Neill et al., 1989) and all the amino acids essential for the correct enzymatic activity 
of the protein are conserved between mouse and man. Taking into account any potential 
future perspective of clinical application, the human sequence was chosen. The 
expression cassette was flanked by two ITRs driving from a scAAV vector. The titre of 
the supplied viral vector was 1x1013 gc/ml. 
 
Figure 17 - Schematic of the scAAV2/9.GUSB.hGBA1.bGHpA expression cassette.  
The human hGBA1 gene was cloned into the scAAV2/9.GUSB backbone. 
4.3. Development of a blood spot assay for the identification of 
homozygous Gba1 deficient mice at day of birth 
Mouse models of neuronopathic Gaucher disease in which the Gba1 activity is 
completely deficient die shortly after birth due to dehydration and loss of fluid through 
the skin. The mouse model used in this study is genetically engineered so that the Gba1 
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gene is knocked-out in all the tissues apart from the skin using Cre-lox technology. As a 
consequence, the affected mouse dies from neurological symptoms associated to 
Gaucher disease rather than dehydration (Enquist et al., 2007). However, because the 
Gba1 gene is reconstituted in the skin, the conventional genotyping from ear or tail 
clipping is not suitable to determine the genotype of the animals. An alternative, 
accurate and rapid method was required to identify homozygous Gba1 knockout mice at 
birth. In collaboration with Prof. Simon Heales and Mr. Derek Burke (UCL Institute of 
Child Health, London, UK) an alternative phenotyping strategy based on GCase enzyme 
activity was developed. The enzymatic assay was based on dried blood spots and 
allowed the detection of β-glucocerebrosidase activity in the samples, enabling the 
recognition of Gba1 deficient mice on the day of birth. Blood spots were collected from 
mice at birth and a fluorescence-based assay for GCase activity was conducted using a 
synthetic version of the beta-galactoside substrate that is cleaved by the enzyme. 
Minimal enzymatic activity indicated that the animal was homozygote (K14-lnl/lnl) for 
the Gba1 mutation (Figure 18A).  The results were confirmed by PCR on DNA 
extracted from liver samples (Figure 18B), demonstrating that the blood spot assay was 
a reliable alternative method to genotype the animals at day of birth. 
 
Figure 18 - Identification of knock-out mice at day of birth. 
A The graph shows the GCase enzymatic activity in blood samples from newborn mice from a 
K14-lnl/wt x K14-lnl/wt breeding pair. 5 (red) out of 19 mice showed reduced levels of 
enzymatic activity in the blood samples (samples 8, 9, 11, 14 and 16). The remaining littermates 
(grey) were either wild-type (K14-wt/wt) or heterozygotes (K14-lnl/wt) for the Gba1 mutation. 
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B Confirmation of the genotyping by PCR. L: ladder; lane 1: sample 1 (K14-lnl/wt); lanes 2-6: 
samples 8, 9, 11, 14, 16 (K14-lnl/lnl). 
4.4. Increased life span of K14-lnl/lnl treated animals 
following neonatal intravenous administration of 
scAAV2/9.GUSB.hGBA1.bGHpA 
The blood spot assay allowed the phenotyping of Gba1 knock-out mice on the day of 
birth. Eleven K14-lnl/lnl mice were identified, of which five animals were intravenously 
injected at P0 into the temporal vein with 4 x 1011 gc of 
scAAV2/9.GUSB.hGBA1.bGHpA in a total volume of 40μl (IV treated K14-lnl/lnl); 
three were administered with 1 x 1011 gc of the same vector via bilateral 
intracerebroventricular injection (ICV treated K14-lnl/lnl); three remained untreated and 
were used as controls (Untreated K14-lnl/lnl), together with three wild-type littermates 
(K14-wt/wt). 
The animals were continually monitored for neurological symptoms and sacrificed if the 
humane end point (greater than 15% body weight loss; severe and prolonged paralysis 
or unconsciousness) stipulated on the UK Home Office Project Licence was reached. 
Consistent with the study from Enquist and colleagues, untreated Gba1 knock-out mice 
started developing observable and progressive neurological symptoms at 10 days after 
birth and by 12-14 days of age they had seizures, tremor, motor dysfunction and 
paralysis, and required sacrificing in accordance with the humane end point. Both the 
IV and the ICV treated mice survived beyond the critical point of 14 days (Figure 
19A). Since the animals did not show any abnormal behaviour or develop any evident 
pathological symptoms, the treated mice and the wild-type controls were sacrificed at 
55 days of age in order to conduct a short-term analysis. This promising result 
demonstrated that the treated K14-lnl/lnl mice were rescued from premature death 
associated with neurodegeneration and a single administration of the 
scAAV2/9.GUB.hGBA1.bGHpA vector resulted in approximately a 4-fold increase in 
the life span of the animals. 
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Treated animals were weighted regularly in order to keep track of any significant loss of 
body weight. IV and ICV treated K14-lnl/lnl mice did not show any significant 
difference in their body weight at any of the time points compared to the wild-type 
controls (Figure 19B). 
 
Figure 19 - Increase in life span and weight analysis of K14-lnl/lnl treated mice. 
A Kaplan-Meier survival curve. IV treated K14-lnl/lnl (n=5) and ICV treated K14-lnl/lnl (n=3) 
survived the critical time point of 14 days after birth. All untreated knock-out mice (n=3) died 
before two weeks of age. Treated animals and wild-type (K14-lnl/lnl) controls were sacrificed at 
55 days of age. Life span of treated animals was significantly extended following viral vector 
administration (Statistical analysis: log rank (Mantel-Cox) test; p<0.001). B Body weight of IV 
and ICV treated animals and wild-type controls. No significant differences were observed 
between treated animals and wild-type controls (Data presented as average + SD. Statistical 
analysis: two-wayANOVA, Tukey’s multiple comparisons test; ns p>0.05). 
4.5. Assessment of neurological functions in intravenously 
Treated K14-lnl/lnl mice 
Treated K14-lnl/lnl, untreated K14-lnl/lnl and wild-type K14-wt/wt animals were 
assessed for motor coordination impairment at P10. At this time point, the untreated 
mice started to exhibit neurological phenotype. The onset of neurological manifestations 
was confirmed by the results of the righting reflex test (Figure 20A). Untreated K14-
112 
lnl/lnl mice were not able to return to prone position when placed on their back. In 
comparison IV treated K14-lnl/lnl mice showed a fast latency to right themselves, with 
no significant difference from wild-type controls (p>0.9999). Since untreated K14-lnl/lnl 
mice did not survive two weeks of age, conducting further behavioural analysis on this 
cohort of the experiment was not feasible as the animals were too young for more 
complex tests. 
The rotarod test was conducted to assess the motor coordination of the IV treated K14-
lnl/lnl mice compared to age-matched wild-type animals (Figure 20B). At 50 days of 
age IV treated mice did not show any significant difference in motor co-ordination 
compared to the wild-type littermates. Although locomotor function was not impaired in 
the injected mice, the IV treated K14-lnl/lnl animals showed a moderate hind limb 
clasping phenotype (Figure 20C). Four animals did retract both limbs for more than 
50% of the test time, while only one adopted the clasping position for less than 50% of 
the time (average score: 1.8). Wild-type mice did not display pronounced clasping 
phenotype (average score: 0.3). 
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Figure 20 - Behavioural analysis of IV treated mice. 
A Righting reflex test. IV treated K14-lnl/lnl mice, wild-type controls and untreated K14-lnl/lnl 
animals were tested for motor coordination at P10. Untreated animals failed the test, showing 
slow latency to right themselves (score=0), while treated K14-lnl/lnl mice exhibited the same 
phenotype as healthy wild-type controls (score=1) (Statistical analysis: one-wayANOVA, 
Holm-Sidak’s multiple comparisons test; ns p>0.9999, **** p<0.0001).  B Rotarod test at P50. 
The speed of the first four falls was reported. Treated mice did not show any behavioral 
difference compared to the controls when placed on the rotarod (Data presented as average + 
SD. Statistical analysis: unpaired t-test, Welch’s correction; ns p>0.05). C Tail suspension test 
at P50. IV treated K14-lnl/lnl animals displayed moderate clasping phenotype compared to 
wild-type littermates (Statistical analysis: unpaired t-test, Welch’s correction; * p<0.01). 
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4.6. Analysis of neuropathology in IV treated K14-lnl/lnl mice 
In order to further study the effects of intravenously administered gene therapy on the 
rescued K14-lnl/lnl mice, a wide range of immunoperoxidase based experiments were 
performed on brain sections to assess the following parameters: the expression of the 
human GCase protein, astrogliosis, microglial cell activation and the presence of 
enlarged lysosomes. A quantitative evaluation of the staining was performed in the 
regions of the brain known to be most affected in neuronopathic Gaucher disease. 
Finally, a stereological analysis determined the effects of the treatment on the 
neurodegeneration by counting the number of neurons within a region and any atrophy 
by measuring cortical thickness. 
4.6.1. Widespread overexpression of β-glucocerebrosidase following 
intravenous administration of scAAV2/9.GUSB.hGBA1.bGHpA to 
neonatal Gba1 knock-out mice 
Immunostaining of brains from K14-wt/wt controls, age-matched IV treated K14-lnl/lnl 
and untreated knock-out mice at their end-stage at P14 showed that the administration 
of the vector resulted in a strong and widespread expression of the GCase protein 
(Figure 21A). In particular, the cortical region S1BF (p=0.0006), the cerebellar lobe 
CENT2 (p=0.02) and the brain stem (p=0.014) showed a significant increase in GBA1 
expression compared to end-stage knockouts and age-matched wild-type mice (Figure 
21B). Although no statistical difference between the IV treated mice and the age-
matched wild-types groups was measured in the hippocampus (CA1/CA2) and the 
thalamic region VPM/VPL, GBA1 expression was more elevated in treated brains 
compared to untreated K14-lnl/lnl mice. Unexpectedly, GCase-positive cells were 
detected at low levels in the tissue of untreated K14-lnl/lnl mice, particularly in the 
thalamic region. However, high magnification light microscopy revealed that the 
background of the immunoperoxidase signal was elevated, as most of GCase-positive 
elements were blood vessels and not discrete neural cells.
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Figure 21 - β-glucocerebrosidase expression following vector administration. 
A Brains from wild-type controls, IV treated knock-out mice and untreated knock-outs were 
stained for GCase. Intravenous administration of the scAAv2/9.GUSB.GBA1.bGHpA vector 
resulted in widespread overexpression of β-glucocerebrosidase in treated brains of knockout 
K14-lnl/lnl mice (Scale bars: low magnification 100μm; high magnification 60μm). B S1BF 
cortex; CA1/CA2 hippocampus; VPL/VPM thalamus, CENT2 cerebellum; Gi brain stem. 
Cortex, cerebellum and brain stem of IV treated K14-lnl/lnl mice showed a significant increase 
in GCase-positive cells compared to both the wild-type animals and the untreated controls (Data 
presented as average + SD. Statistical analysis: two-way ANOVA, Tukey’s multiple 
comparisons test; * p≤0.05, *** p≤0.001). 
4.6.2. An assessment of lysosomes in the brain of IV treated K14-lnl/lnl 
mice 
The lysosome-associated membrane glycoprotein 1 (LAMP1) was used as a marker to 
detect enlarged lysosome resulting from the build-up of glucosylceramide in the brain 
(Figure 22A). Tissue from the untreated end-stage K14-lnl/lnl mice showed extensive 
staining throughout the brain, as most of the brain regions were affected by lysosomal 
accumulation.  The IV treated K14-lnl/lnl mice showed a heterogeneous pattern of 
LAMP1 staining intensities in various regions of the brain. While some areas, like 
cortex, thalamus and cerebellum, expressed high levels of LAMP1 marker, other 
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regions in the hippocampus and brain stem showed consistent reduction in the staining 
intensity, indicative of normal cellular lysosomal content comparable to wild-type 
levels. The quantification of the immunoreactivity (Figure 22B) confirmed a significant 
decrease (p=0.0013) in LAMP1 staining in the gigantocellular nuclei region in the brain 
stem of IV treated K14-lnl/lnl mice compared to untreated Gba1 knock-out animals and 
was comparable to that of age-matched wild-type mice. However, in the somato-barrel 
field cortical region LAMP1 expression was significantly increased in IV treated K14-
lnl/lnl (p=0.02) and the lysosomal protein levels in the treated brains were comparable 
to the untreated end-stage knock-out mice. Other than the cortex, there was no 
statistically significant difference between wild-type animals and IV treated knock-out 
mice.
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Figure 22 - Anti-LAMP1 lysosomal staining. 
A Representative images of brain sections stained for the lysosomal marker LAMP1. Diffuse 
lysosomal staining was detected in the untreated knock-out brains. The IV treated K14-lnl/lnl 
samples showed elevated levels of LAMP1 in the cortical regions. However, the rest of the 
brain was less affected by lysosomal accumulation (Scale bars: low magnification 100μm; high 
magnification 60μm). B S1BF cortex; CA1/CA2 hippocampus; VPL/VPM thalamus, CENT2 
cerebellum; Gi brain stem. Untreated end-stage knock-out mice showed a significant increase in 
the lysosomal marker in the brain stem (Gi) compared to age-matched wild-type controls and 
treated mice. In the cortical region S1BF the immunoreactivity of IV treated K14-lnl/lnl was 
significantly higher than the wild-type controls (Data presented as average + SD. Statistical 
analysis: two-wayANOVA, Tukey’s multiple comparisons test; * p≤0.05, ** p≤0.01). 
4.6.3. An assessment of astrogliosis in the brain of IV treated K14-
lnl/lnl mice  
The glial fibrillary acidic protein GFAP was used to detect activated astrocytes as a 
readout of neuroinflammation. As previously reported, the K14-lnl/lnl mice developed 
acute astrogliosis with activated GFAP positive cells observed throughout the whole 
brain (Enquist et al., 2007). Brains from IV treated K14-lnl/lnl mice showed diffuse 
glial cell activation in the cortex, hippocampus, thalamus and cerebellum when 
compared to the wild-type animals (Figure 23A). The Gi region of the brain stem did 
not develop severe astrogliosis in the treated mice, although it was still possible to 
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identify a few diffuse positive cells. However, quantification of the staining and 
statistical analysis (Figure 23B) did not reveal significant differences in GFAP staining 
intensity in hippocampus, thalamus and brain stem of IV treated Gba1 knock-out mice, 
untreated K14-lnl/lnl and wild-type controls. A significant increase in astrogliosis 
marker was present in the somato-barrel field cortex (p=0.03) and cerebellar lobe 
(p=0.02) of treated mice when compared to K14-wt/wt animals.
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Figure 23 - Astrocyte activation in K14-ln/lnl treated mice. 
A Immunoperoxidase staining for the astrocytic marker GFAP. IV treated mice developed 
widespread neuroinflammation compared to age-matched wild-type controls. Activated 
astrocytes were diffuse in the untreated brains (Scale bars: low magnification 100μm; high 
magnification 60μm). B S1BF cortex; CA1/CA2 hippocampus; VPL/VPM thalamus, CENT2 
cerebellum; Gi brain stem. Quantification of the immunoreactivity. IV treated K14-lnln/lnl mice 
showed an increase in GFAP-positive cells in the cortex (S1BF) and cerebellum (CENT2) 
compared to the wild-type controls. Activated astrocytes were not detected in the brain stem 
(Gi) of IV treated brains (Data presented as average + SD. Statistical analysis: two-
wayANOVA, Tukey’s multiple comparisons test; * p≤0.05). 
4.6.4. An assessment of microglia activation in the brain of IV treated 
K14-lnl/lnl mice 
K14-lnl/lnl mice developed extensive microglia activation. Staining for the microglial 
CD68 marker showed intense proliferation of microglial cells, in the cortex, 
hippocampus, thalamus, cerebellum and brain stem of untreated mice (Figure 24A). 
However, brain tissue from IV treated K14-lnl/lnl mice revealed a general amelioration 
of microglial activation, with a heterogeneous staining pattern throughout the brain. As 
for the neuroinflammatory marker GFAP, intense CD68 expression was present in the 
cortical regions of treated brains. Scattered CD68-positive cells were found in the 
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midbrain and cerebellum, while the brain stem showed the most dramatic amelioration 
in CD68 staining for microglia when compared to the end-stage untreated mice. An 
elevated accumulation of activated microglia was found in the CA2 layer of the 
hippocampus of IV treated brains. Quantification of immunoreactivity (Figure 24B) 
confirmed that there was no statistical difference between treated mice and wild-type 
controls in the CA1/CA2 layers of the hippocampus, the thalamic nuclei, the central 
lobule 2 of the cerebellum and the brain stem. However, the increase in CD68-positive 
cells in the somato-barrel cortical field in IV treated K14-lnl/lnl mice were significantly 
higher than both the physiological levels in the wild-type controls (p<0.0001) and in the 
affected K14-lnl/lnl mice (p=0.0005). 
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Figure 24 - Amelioration of microglia activation in IV treated mice. 
A Representative brain sections stained for the microglial marker CD68. IV treated K14-lnl/lnl 
mice showed intense CD68 staining in the cortex, while the presence of CD68-positive cells 
was reduced in the hippocampus, thalamus and cerebellum compared to untreated end-stage 
K14-lnl/lnl mice. Very few CD68-positive cells were detected in the brain stem of treated 
animals (Scale bars: low magnification 100μm; high magnification 60μm). B S1BF cortex; 
CA1/CA2 hippocampus; VPL/VPM thalamus, CENT2 cerebellum; Gi brain stem. The results of 
the immunostaining were supported by the quantification of immunoreactivity where IV treated 
mice showed a significant increase in the CD68-positive cells in the cortex and thalamus 
compared to the controls. Extensive CD68 expression was detected in the thalamic nuclei and in 
the brain stem of untreated K14-lnl/lnl mice (Data presented as average + SD. Statistical 
analysis: two-wayANOVA, Tukey’s multiple comparisons test; * p≤0.05, ** p≤0.01, *** 
p<0.001, **** p<0.0001). 
4.6.5. An analysis of neuronal loss and cortical thickness in IV treated 
K14-lnl/lnl mice 
Nissl staining is a widely used method to study anatomy, tissue architecture and 
pathology of the brain. The cresyl violet dye binds to the RNA present in the ER and 
ribosomes of cells. The characteristic cytoplasm of a neuron is rich in endoplasmic 
reticulum and ribosomes compared to other CNS cell populations, therefore it can be 
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specifically stained with the Nissl method allowing the distinction between neurons and 
other glial cells (Scott and Willett, 1966).  
The Nissl stained brain sections were analysed with the Stereo Investigator software. 
The stereological technique provides a quantitative and unbiased estimation of the 
number of neurons, thickness and volume of specific brain regions through the 
combination of an optical dissector and an optical fractionator (West et al., 1991). The 
optical dissector is a three-dimensional probe that creates a 3D model of the tissue 
sample from a series of two-dimensional measurements. This allows the accurate 
estimation of the number of neurons in the total volume of the analysed brain region. 
The optical fractionator relies on a systematic and random sampling scheme, so that 
each portion of the analysed brain region has the same probability of being sampled. 
The Cavalieri estimator is used to measure the dimension and volume of a specific brain 
region (Gundersen et al., 1999). 
The stereological analysis compared brains from IV treated K14-lnl/lnl animals and 
wild-type controls. The brain developmental stage of the younger end-stage P14 
untreated K14-lnl/lnl mice did not allow a direct age-related comparison with the older 
P55 animals, as different maturation time points are characterised by specific features, 
like brain size and number of neurons (Pressler and Auvin, 2013). 
It has been reported that affected brains of the K14-lnl/lnl mice are characterised by 
cerebral atrophy, particularly in the somatosensory regions (Farfel-Becker et al., 2011b). 
Decrease in the thickness of the cortical layer in treated mice was observed (Figure 
25A). The use of the Stereo Investigator software to determine the cortical thickness 
demonstrated that the atrophy in treated brains was significant (p<0.0001) compared to 
age-matched wild-type controls (Figure 25B). Furthermore, the lateral ventricles 
appeared enlarged (Figure 25A). Ventriculomegaly has been described in different 
types of lysosomal storage disorders (Wang et al., 2011) as a symptom of the 
progression of the neuropathology and accompanies cortical thinning. 
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Figure 25 - Nissl staining and stereology analysis. 
A Brain sections from wild-type controls and treated K14-lnl/lnl mice stained with the Nissl 
method. Treated brains were smaller, with enlarged ventricles and atrophic cortex (Scale bar: 
1mm). B Cortical thickness measurements in wild-type and IV treated knock-out mice. Treated 
K14-lnl/lnl mice showed significant cortical atrophy (Data presented as average + SD. 
Statistical analysis: unpaired t test, Welch’s correction; **** p<0.0001). C Neuron counts in 
cortex (S1BF), thalamus (VPM/VPL) and brain stem (Gi). IV treated K14-lnl/lnl mice showed a 
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significant reduction in the number of neurons compared to wild-type controls. No significant 
neuronal loss was identified in the brain stem compared to control wild-type mice (Data 
presented as average + SD. Statistical analysis: two-wayANOVA, Tukey’s multiple 
comparisons test; **** p<0.0001). 
Gaucher disease type II is characterised by acute and widespread neuronal loss  (Farfel-
Becker et al., 2014). The cortical area S1BF in treated brains was the most affected 
region, characterised by astrogliosis, intense microglial activation and atrophy. 
Stereological counts by optical fractionation revealed that the number of neurons in the 
cortical region of treated mice was significantly reduced (p<0.0001) compared to the 
wild-type controls (Figure 25C). Although the neuropathology was less accentuated in 
the thalamic nuclei, a significant neuronal loss was measured in the VPM/VPL region in 
IV treated K14-lnl/lnl brains (p<0.0001) compared to the wild-type controls. However, 
complete neuroprotection of the neuronal cells in the treated brain stem was measured 
with no significant difference in neuron counts compared to the wild-type control brain 
sections. 
4.7. An amelioration of visceral pathology in treated K14-
lnl/lnl mice 
Although Gaucher disease type II is mainly characterised by severe neuropathology 
patients develop extensive visceral pathology, affecting particularly the spleen, liver and 
lungs (Stirnemann et al., 2017). One of the aims of this study was to demonstrate 
whether the intravenous administration of the scAAV2/9.GUSB.hGBA1.bGHpA vector 
resulted in not only a therapeutic effect in the brain but also a widespread systemic 
delivery of the therapeutic GBA1 gene to the visceral organs. To assess the efficacy of 
the visceral therapy, organs harvested from P55 IV treated K14-lnl/lnl mice were 
compared to age-matched wild-type controls and P55 ICV treated knock-out mice. 
Spleen weight, presence of Gaucher cells and tissue architecture of spleen, liver and 
lung were analysed. The glucocerebrosidase enzymatic activity was measured in 
different visceral organs. Finally, a blood analysis was performed in order to evaluate 
the possible effects on anaemia and thrombocytopenia. 
129 
4.7.1. Normalisation of spleen weight and reduction of macrophage 
activation in IV treated K14-lnl/lnl mice 
K14-lnl/lnl mice that received intracerebroventricular administration of the 
scAAv2/9.GUSB.hGBA1.bGHpA vector developed splenomegaly. However, the 
systemic injection of the vector resulted in the reduction of spleen size (Figure 26A). 
While the spleen weight of ICV treated K14-lnl/lnl mice were observably increased 
compared to the age-matched wild-type controls (p=0.049), there was no statistically 
significant difference between ICV and IV treated mice (Figure 26B). However, the 
weight of the spleen in IV treated knock-out mice was comparable to the controls. 
 
Figure 26 - Amelioration of spleen pathology following systemic administration of the 
scAAv2/9.GUSB.hGBA1.bGHpA vector. 
A Spleens harvested from a IV treated K14-lnl/lnl mouse (P55) and an age-matched ICV treated 
animal (Scale bar: 0.5cm). B ICV treated knock-out mice developed splenomegaly, while IV 
treated animals did not show significant enlargement of the spleen, compared to the age-
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matched controls (Data presented as average + SD. Statistical analysis: one-wayANOVA, 
Tukey’s multiple comparions test; * p<0.05). C Images of spleen from wild-type, IV treated and 
ICV treated animals. Top panel: Immunoperoxidase using antibodies against CD68 showed 
increased macrophage activation in sections of spleen taken from ICV treated mice. Bottom 
panel: Hematoxylin and Eosin staining revealed the presence of Gaucher cells (indicated by 
white arrows) in spleen from ICV treated K14-lnl/lnl, while the intravenous administration 
resulted in correction of the pathology (Scale bar: 200μm). D Quantification of immunostaining 
against the CD68 macrophagic marker (Data presented as average + SD. Statistical analysis: 
one-wayANOVA, Tukey’s multiple comparisons test; * p<0.05, ** p<0.01). 
The immunostaining for CD68 on spleen sections to detect the accumulation of 
engorged macrophages showed that the pathology in the IV treated K14-lnl/lnl mice 
was reduced compared to the age-matched ICV treated animals, particularly in the white 
pulp regions (Figure 26C, top panel).  
The sections from the same organs were stained with Haematoxylin and Eosin (H&E) 
and the histological analysis was carried out (Figure 26C, bottom panel). H&E 
staining is widely used in histopathology, in order to assess cellular morphology and 
tissue architecture (Fischer et al., 2008). This staining technique labels the nucleic acids 
in the nucleus with a blue colour and the cytoplasmic proteins with a pink dye. The 
analysis of spleen section stained with H&E confirmed the previous findings: the tissue 
structure of the white pulp in the ICV treated mice was disrupted. The stain highlighted 
the presence of numerous enlarged Gaucher cells (indicated by white arrows), 
interfering with the physiological cell distribution. In the spleen from age-matched IV 
treated K14-lnl/lnl mice, the tissue architecture was better maintained similarly to the 
wild-type controls, and very few or no enlarged cells were detected. 
These results were corroborated by the quantification of the anti-CD68 
immunohistochemistry experiment. The analysis revealed that the activation of 
macrophages was substantial in the spleen of ICV treated K14-lnl/lnl mice compared to 
both the IV treated knock-out animals higher (p=0.015) and the K14-wt/wt controls 
(p<0.0001) (Figure 26D). However, an increase (p=0.005) in the levels of activated 
macrophages in spleens harvested from IV treated knock-out mice and wild-type 
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controls was also reported. 
4.7.2. Systemic administration of scAAV2/9.GUSB.hGBA1.bGHpA 
ameliorates pathology in the liver of treated Gba1 knock-out mice 
The analysis of the CD68 marker for macrophage activation in liver sections revealed 
that the IV treated K14-lnl/lnl mice did not develop pathology and the macrophage 
levels were comparable to the age-matched wild-type controls (Figure 27A). The 
activation of macrophages was more extensive in the livers of age-matched ICV treated 
animals, where numerous enlarged CD68-positive cells were identified by 
immunoperoxidase staining. In addition, the H&E stain demonstrated that the integrity 
of the tissue was profoundly disrupted in the ICV treated mice. However, the liver 
tissue from IV treated K14-lnl/lnl mice was observably improved in integrity of the 
architecture and only a few scattered Gaucher cells were detected.  
Quantification of the staining of the macrophagic marker CD68 (Figure 27B) 
confirmed that the K14-lnl/lnl mice that received ICV injections of the virus had 
significantly higher levels of CD68-positive cells compared to the age-matched IV 
treated knock-out mice (p=0.0007) and the wild-type control livers (p=0.003). Systemic 
administration of the vector resulted in drastic reduction of activated macrophages to 
physiological levels. 
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Figure 27 - Correction of the liver pathology in IV treated K14-lnl/lnl mice. 
A Immunostaining to the macrophagic marker CD68. IV treated Gba1 knock-out mice did not 
develop liver pathology, while ICV treated K14-lnl/lnl mice showed high macrophagic 
activation and disruption of the tissue architecture (Scale bar: 200μm). B The quantification of 
the immunoreactivity confirmed the profound macrophage activation in tissue from ICV treated 
animals. No statistically significant difference was found between wild-type controls and IV 
treated K14-lnl/lnl mice (Data presented as average + SD. Statistical analysis: one-
wayANOVA, Tukey’s multiple comparisons test; ** p<0.01, *** p<0.001). 
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4.7.3. Amelioration of lung pathology resulting from intravenous 
administration of scAAV2/9.GUSB.hGBA1.bGHp 
The analysis of macrophage activation and infiltration in lung tissue samples revealed a 
significant increase in CD68-positive cells in ICV treated K14-lnl/lnl mice (Figure 
28A).  Although the extent of activated macrophages in Gba1 knock-out mice that 
received systemic injection of the viral vector was clearly reduced to normal 
physiological level, few scattered CD68-positive enlarged cells could be detected. 
H&E histological analysis revealed that the architecture of the tissue from ICV treated 
mice was extremely compromised: the alveoli’s structure was disrupted and numerous 
engorged macrophages could be observed. The lung tissue from IV treated K14-lnl/lnl 
mice showed a regular tissue organisation, with open air sacs structures and the 
presence of only a few Gaucher cells. Overall, the sections from intravenously treated 
mice highly resembled the wild-type tissue. 
The thresholding of the immunoreactivity (Figure 28B) confirmed that the 
intracerebroventricular administration of the vector did not have a therapeutic effect on 
the lung pathology, as the ICV treated mice showed increased macrophage infiltration 
compared to both wild-type controls (p=0.0005) and IV treated K14-lnl/lnl mice 
(p<0.0001). In comparison the systemic administration of the 
scAAV2/9.GUSB.hGBA1.bGHp vector significantly reduced the accumulation of 
CD68-positive cells. 
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Figure 28 - Histological analysis of lung tissue from IV treated K14-lnl/lnl mice. 
A Accumulation of activated macrophages was present in the tissues from ICV treated Gba1 
knock-out mice, while only few CD68-positive cells were detected in the lung tissue from IV 
treated K14-lnl/lnl mice. In the tissue from ICV treated mice it was possible to identify 
numerous Gaucher cells (indicated with white arrows). The tissue samples from IV treated 
knock-out mice samples appeared healthy, and only a limited number of Gaucher cells was 
detected (Scale bar: 200μm). B The quantification of the immunoreactivity confirmed that IV 
treated mice had a significant decrease in macrophage activation and infiltration in the lungs 
(Data presented as average + SD. Statistical analysis: one-wayANOVA, Tukey’s multiple 
comparisons test; *** p<0.001, **** p<0.0001). 
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4.7.4. Blood parameters in Gba1 knock-out mice treated following 
systemic injection of scAAV2/9.GUSB.hGBA1.bGHp 
Anaemia, thrombocytopenia and leukopenia are characteristic of Gaucher disease 
(Nagral, 2014). This condition is mirrored in some of the murine models (Farfel-Becker 
et al., 2011a, Mistry et al., 2010), although in the literature there is no evidence of blood 
abnormalities in the K14-lnl/lnl model. The untreated knock-out mice die within the 
first two weeks of life, therefore might not be sufficiently old to develop severe 
anaemia. In order to establish whether adult 55 day-old treated animals developed blood 
pathology, samples from IV treated knock-out and age-matched wild-type mice were 
analysed (Figure 29). The results demonstrated that the number of erythrocytes, 
haemoglobin levels, platelet count and number of white blood cells in samples from IV 
treated K14-lnln/lnl were comparable to the wild-type physiological range. 
 
Figure 29 - Blood analysis. 
Blood samples from IV treated K14-lnl/lnl mice and age-matched wild-type controls were 
analysed. Red blood cells count, hemoglobin, platelets and leukocytes concentration were 
measured (Data presented as average + SD. Statistical analysis: unpaired t test, Welch’s 
correction; ns p>0.05). 
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4.7.5. Intravenous administration of scAAV2/9.GUSB.hGBA1.bGHp 
resulted in the increase of the β-glucocerebrosidase activity in some 
organs 
Although the Gba1 gene is knocked-out in the K14-lnl/lnl mouse model, low levels of 
mRNA are still produced (Enquist et al., 2007). This results in minimal β-
glucocerebrosidase activity in liver (ca. 10%) and spleen (ca. 2%). However, the 
residual enzymatic activity is not sufficient to clear the elevated glucosylceramide that 
accumulates in the organs. 
The analysis of enzymatic activity investigated whether the intravenous administration 
of the viral vector carrying the functional hGBA1 gene resulted in the production of 
active β-glucocerebrosidase enzyme in the visceral organs and if the physiological 
enzyme levels could be restored in treated mice. The enzymatic activity in tissues from 
IV treated K14-lnl/lnl mice was compared with samples from wild-type animals, ICV 
treated Gba1 knock-out mice, and untreated K14-lnl/lnl mice (Figure 30). 
The β-glucocerebrosidase activity in the spleen of both IV and ICV treated mice was 
decreased (ca. 42%) compared to the normal physiological level; however, the 
difference was not statistically significant. The enzyme levels in the liver tissue 
harvested from untreated K14-lnl/lnl were significantly reduced (p=0.018) compared to 
wild-type levels, confirming the results from Enquist’s study. Physiological enzyme 
levels in the spleen were very low and although the intravenous administration almost 
doubled (ca. 196%) the β-glucocerebrosidase activity compared to untreated mice, the 
overall difference was not significant. 
The response to the treatment in the lungs was encouraging: the intravenous 
administration of the vector resulted in the increase of the enzymatic activity compared 
to both untreated K14-lnl/lnl and ICV injected mice. In tissues from IV treated knock-
out mice the β-glucocerebrosidase residual activity raised to ca. 54% of the 
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physiological levels. However, there was no statistically significant difference between 
the two routes of administration. 
The systemic injection of the scAAV2/9.GUSB.hGBA1.bGHp caused a drastic increase 
(ca. 728%) of the enzymatic activity in the heart compared to wild-type levels 
(p<0.0001). The β-glucocerebrosidase residual activity in cardiac tissue from ICV 
treated mice was comparable to the normal physiological levels (ca. 67%). 
 
Figure 30 - Enzymatic activity in different visceral organs. 
The systemic injection of the scAAV2/9.GUSB.hGBA1.bGHp resulted in a general increase in 
the β-glucocerebrosidase residual activity in liver, spleen, lung and heart tissues. The 
enzymatic activity in organs from the intravenous administered mice was compared to the β-
glucocerebrosidase activity in organs from wild-type controls, ICV treated knock-out animals 
and untreated K14-lnl/lnl mice (Data presented as average + SD. Statistical analysis: two-
wayANOVA, Tukey’s multiple comparisons test; * p<0.05, ** p<0.01, **** p<0.0001). 
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4.8. Long-term study 
The intravenous administration of the scAAV2/9.GUSB.hGBA1.bGHp vector resulted 
in the extension of the lifespan, partial amelioration of the neuropathology and 
improvement in the visceral pathology K14-lnl/lnl mice at 55 days of age. The effects of 
gene therapy on lifespan over a longer period of time were investigated. 
Following neonatal injection of the viral vector, all treated mice (IV treated K14-lnl/lnl 
n=5; ICV treated K14-lnl/lnl n=9) were rescued from neonatal neurodegeneration-
associated death and survived up to at least 180 days of age (Figure 31A). At this point 
the animals were sacrificed.  
The therapeutic effect of the systemic treatment on the long-term survival mice was 
assessed. Since the most evident symptom of Gaucher disease in the viscera is the 
enlargement of the spleen, their weight was measured (Figure 31B). Encouragingly, 
there was no significant difference between the intravenously treated knock-out and the 
wild-type control samples. Whereas, the spleen size of the ICV treated K14-lnl/lnl 
animals was significantly higher (p=0.009) than the wild-type controls. Although the 
spleen size of the IV treated animals was reduced compared to the age-matched ICV 
treated mice, the difference was not statistically significant.  
The aforementioned results were supported by the analysis of immunostaining of spleen 
sections with the macrophagic marker CD68 (Figure 31C). In the samples obtained 
from ICV treated mice it was possible to detect intense macrophage activation, 
characterised by clusters of enlarged affected macrophages within the white pulp. 
However, the number of CD68-positive cells in the spleen form IV treated K14-lnl/lnl 
mice was significantly reduced, almost comparable to the wild-type controls. 
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Figure 31 - Effects of the intravenous administration of gene therapy in K14-lnl/lnl in a 
long-term study. 
A Gba1 knock-out mice usually die at 14 days of age, whereas K14-lnl/lnl mice treated with 
systemic gene therapy at day of birth lived for at least six months. Wild-type and ICV treated 
mice were used as controls (Statistical analysis: log rank (Mantel-Cox) test; p<0.001). B 
Average spleen weight. Statistical analysis revealed that the size of the spleen from ICV treated 
mice was significantly higher than wild-type controls. The spleen weight was reduced in K14-
lnl/lnl mice that received intravenous injection of the vector (Data presented as average + SD. 
Statistical analysis: one-wayANOVA, Tukey’s multiple comparisons test; ** p<0.01). C Anti-
CD68 staining on spleen sections. Aged ICV treated mice showed numerous enlarged Gaucher 
cells in the white pulp of the spleen. Spleens derived from IV treated knock-out mice did not 
develop macrophage activation (Scale bars: low magnification 100μm; high magnification 
60μm). 
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4.9. Conclusions 
This study demonstrated that a single intravenous injection of the 
scAAV2/9.GUSB.hGBA1.bGHpA vector resulted in a significant extension of the 
lifespan of Gba1 knock-out animals. For the duration of their life, the animals were 
monitored for pathological manifestations, however they did not develop significant 
neurological symptoms. Moreover, the body weight was maintained within the normal 
range. The mice were sacrificed at 55 days of age and an extensive neuropathological 
analysis was conducted. In general, the effect of the gene therapy on neuropathology 
was heterogeneous and varied from region to region. While the administration of the 
vector caused widespread overexpression of the β-glucocerebrosidase protein, some 
brain regions continued to present neuropathology. Extensive astrogliosis and 
microglial activation was detected in the cortical region S1BF. Whereas other areas, 
such as the brain stem, resulted in the prevention of activated astrocytes and microglia 
cells. Intense lysosome accumulation was found in the same cortical regions 
characterised by severe neuroinflammation. The somato-barrel field region was 
subjected to atrophy and neuronal loss. On the contrary, the Gi region in the brain stem 
was not affected by neuronal death, with neuron numbers comparable to healthy 
controls. 
Although the intravenous administration of the vector only partially ameliorated the 
neuropathology, treated mice were rescued up to at least 6 months of age with no 
observable neurological symptoms. 
In terms of the effect of gene therapy on the visceral organs, treated mice exhibited 
amelioration in macrophage activation in the liver, spleen and lungs, where only a 
limited number of Gaucher cells were identified. Moreover, the tissue architecture was 
preserved, as it highly resembled the cellular organisation of wild-type age-matched 
mouse samples. The positive effects of the treatment were confirmed by the analysis of 
the β-glucocerebrosidase activity in different organ samples. Overall, tissues derived 
from IV treated K14-lnl/lnl showed increased residual enzymatic activity compared to 
untreated knock-out mice. Even though the wild-type levels were not achieved in all 
considered tissues, the residual β-glucocerebrosidase activity was sufficient to 
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considerably ameliorate the visceral pathology in treated mice. This phenomenon has 
been already observed in the study on gene therapy for haemophilia, where a modest 
increase in the enzymatic levels led to a therapeutic effect (Nathwani et al., 2014). The 
blood analysis revealed that IV treated K14-lnl/lnl mice did not develop hematologic 
conditions typical of Gaucher disease. 
While gene therapy targeted to the brain via ICV administration did provide long-term 
rescue of the treated K14-lnl/lnl mice, they did develop the systemic visceral 
manifestations of Gaucher disease. The last part of the present study confirmed that the 
intravenous administration of the viral vector to neonatal Gba1 knock-out mice also 
allowed to extend the lifespan of treated animals up to six months. In addition, the 
animals did not develop splenomegaly. The histological analysis of the tissue confirmed 
that macrophage activation was not present in the samples derived from IV treated mice. 
Together these results provided evidence that the intravenous administration of 
scAAV2/9.GUSB.hGBA1.bGHpA at the day of birth led to amelioration of the 
neurodegeneration and visceral pathology in Gba1 knock-out mice. The lifespan of 
treated animals was extended from 14 days to at least 180 days.
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5. AAV9-mediated expression 
targeted to neurons enhances 
therapeutic efficacy in the brain of 
a neuronopathic Gaucher disease 
mouse model 
5.1. Introduction 
The administration of scAAV2/9.GUSB.hGBA1.bGHpA resulted in significant long-
term extension of the lifespan of K14-lnl/lnl knock-out mice. However, the 
neuropathology of treated animals was only partially ameliorated. This was thought to 
be caused by the low efficiency of the vector, particularly due to the expression driven 
by a relatively weak promoter. In the following chapter, the creation and testing of a 
new and improved vector is described. In comparison to the initial vector, the genome 
conformation of the second viral vector was single-stranded. This allowed the 
manipulation of the expression cassette and the insertion of transcription and 
transduction enhancing elements. Moreover, a strong neuron-specific promoter was 
used in order to improve transgene expression in the central nervous system following 
systemic administration. 
The first part of this chapter describes the design and production of the new viral vector 
carrying the eGFP reporter gene, and the subsequent study of vector specificity and 
distribution following intravenous administration of the vector to neonatal wild-type 
mice. Subsequently, a vector carrying the therapeutic GBA1 gene was designed and 
produced, and a safety analysis was conducted on wild-type mice injected with the 
vector at day of birth. Finally, this GBA1 vector was systemically administered to 
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neonatal Gba1 knock-out mice and the extension in lifespan was evaluated together 
with behavioural studies. The animals were also assessed for pathological 
manifestations. Once the mice were sacrificed, neuropathological analysis was 
conducted, where β-glucocerebrosidase overexpression, neuroinflammation, microglia 
activation and lysosome accumulation in the central nervous system was evaluated. A 
stereological study was also performed, investigating neuronal loss and brain atrophy. 
Finally the effect of gene therapy on the visceral pathology of treated mice was 
assessed. This included the evaluation of splenomegaly, the presence of activated 
macrophages and Gaucher cells, and β-glucocerebrosidase enzymatic activity 
measurement within the liver, spleen, lung and heart of treated mice. 
5.2. Reporter gene study 
5.2.1. ssAAV2/9.hSynI.eGFP.WPRE.hGHpA vector 
The AAV9 plasmid vector carrying the eGFP gene (Figure 32) was previously 
engineered in Dr. Rahim’s laboratory. Previous results showed that, although the 
intravenous administration of scAAV2/9.GUSB.hGBA1.bGHpA resulted in 
considerable extension of treated mice, the vector only partially ameliorated the 
neuropathology of the Gba1 knock-out mice. Therefore a series of steps were taken in 
order to enhance transgene expression, particularly within the central nervous system. 
The human synapsin promoter hSynI (Schoch et al., 1996) was cloned into the 
expression cassette, upstream of the eGFP reporter gene. In previous studies, it has been 
shown that synapsin I is a strong promoter that leads to neuron-specific eGFP 
transduction in the central nervous system of mice injected in the brain with an AAV9 
vector (McLean et al., 2014) and also following systemic administration (Jackson et al., 
2016). The new vector had a single-stranded conformation: the extra space in the 
expression cassette allowed for the insertion of additional expression enhancing 
sequences. The translation enhancing Kozak consensus sequence (Kozak, 2005) was 
added at the 5’ of the eGFP gene, while the WPRE element (Loeb et al., 1999) was 
cloned downstream the reporter gene. The polyA sequence was derived from the human 
growth hormone polyadenylation signal. Furthermore, previous studies have shown that 
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a single-stranded AAV9 vector that includes a WPRE sequence has an enhanced 
expression profile in various organs when compared to a self-complementary vector 
configuration that lacks a WPRE enhancing sequence (Mattar et al., 2015). 
 
Figure 32 - ssAAV2/9.hSynI.eGFP.WPRE.hGHpA vector.  
In the single-stranded AAV2/9 vector, eGFP expression was driven by the human synapsin I 
promoter. The Kozak sequence was added at the 5’ of the transgene and the enhancer viral 
element WPRE was cloned immediately downstream. 
The vector was produced following the triple transfection of HEK-293T cells and 
purification was completed by iodixanol gradient ultracentrifugation. The final viral 
titer was measured via both SDS-PAGE and alkaline gel electrophoresis, and 
subsequent densitometric analysis. The quantification of viral capsid protein VP3 
(Figure 33A) against bovine serum albumin standards of known concentrations resulted 
in a titer of 8.04 x 1012 viral particles per ml. From the analysis of genome content 
(Figure 33B), the resulting titre of the virus was 2.47 x 1012 viral genome copies per ml. 
Since the result obtained by the analysis of the alkaline gel was slightly lower than the 
quantification of the viral particles, an average value of 5.2 x 1012 vp/ml was assumed 
as the final titer of the ssAAV2/9.hSynI.eGFP.WPRE.hGHpA vector. 
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Figure 33 - Titration of ssAAV2/9.hSynI.eGFP.WPRE.hGHpA. 
A Capsid protein analysis by SDS-PAGE. Different dilution of the virus (15μl, 10μl, 5μl, 1μl) 
and BSA standard (250ng, 500ng, 750ng, 1000ng) were loaded in a polyacrylamide gel. 
Assuming that each viral particle contains 4.987 x 109 ng of VP3, the resulting titer of the virus 
was 8.04 x 1012 vp/ml. B Genome content analysis by alkaline gel electrophoresis. The DNA 
concentration of 15μl of the virus was measured against the HyperLadder. Assuming that the 
mass of one copy of vector is 2.916 x 109 ng, the resulting titer was determined to be 2.47 x 1012 
vg/ml. 
5.2.2. eGFP neuronal expression profile following intravenous 
administration of the ssAAV2/9.hSynI.eGFP.WPRE.hGHpA vector to 
neonatal mice 
Three wild-type CD1 mice were intravenously injected into the temporal vein on the 
day of birth with 40μl of the ssAAV2/9.hSynI.eGFP.WPRE.hGHpA vector, resulting in 
a total dose of 2 x 1011 vp. The animals were sacrificed at one month of age and eGFP 
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expression analysis was carried out. 
 
Figure 34 - Widespread neuronal expression following intravenous administration of 
ssAAV2/9.hSynI.eGFP.WPRE.hGHpA. 
A eGFP expression in brains from injected mice was assessed following immunohistochemical 
staining. Intravenous administration of the vector resulted in extensive and substantial rostro-
caudal eGFP expression in the brains of injected mice (WT + AAV) compared to controls (WT 
uninjected). B Light microscopy images of discrete brain regions. On the basis of cell 
morphology, the transgene expression appeared neuron-specific throughout the whole brain 
(Scale bars: low magnification 100μm; high magnification 60μm). 
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The systemic administration of the vector resulted in intense and widespread eGFP 
expression throughout the whole brain (Figure 34A). Light microscopy analysis 
revealed that high transduction was being achieved in the cortex, with particular 
efficiency in layer V of the cortex, in the CA1/CA2 region and the dentate gyrus of the 
hippocampus, in the thalamic nuclei, in the Purkinje cells of the cerebellum, and in the 
gigantocellular nuclei in the brain stem (Figure 34B). At higher magnification it was 
possible to appreciate that transduced cells had distinct neuronal morphology. 
In order to confirm that eGFP expression driven by the synapsin promoter was neuron-
specific, immunofluorescence was conducted using cell-specific antibodies together 
with imaging using confocal microscopy. Brain sections from injected mice and 
uninjected controls were co-stained with fluorescent antibodies against the eGFP 
protein and the neuronal marker NeuN or the astrocytic marker GFAP. The nucleic acid 
marker DAPI was used in order to identify cellular nuclei. In the brain of injected mice 
it was possible to identify cells positive for the neuronal marker NeuN which also 
showed positive eGFP protein expression (Figure 35A). In comparison, eGFP could not 
be detected in cells positively stained for the astrocytic marker GFAP (Figure 35B). 
These images demonstrated that the synapsin promoter resulted in transgene expression 
specifically in neurons and not in other macroglial cells within the central nervous 
system. 
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Figure 35 - Confocal microscopy imaging demonstrated neuronal-specific tropism of the 
vector. 
A Brain sections of injected mice (WT + ssAAV2/9.hSynI.eGFP.WPRE.hGHp) were co-
stained for the neuronal marker NeuN and the GFP reporter. eGFP expression in cells 
transduced by the virus showed specifically neuronal morphology (white arrows). Uninjected 
wild-type mice (WT) were used as control. Single channel pictures and merged images are 
shown (Scale bars: 20μm). B In order to confirm that the transgene expression was strictly 
limited to neurons, brain sections were stained for the astrocytic marker GFAP. Cells expressing 
eGFP did not co-localised with GFAP labelled cells (white arrow). 
5.2.3. Transduction of the visceral organs 
The use of neuron specific promoter did bring into a question its ability to mediate a 
systemic therapeutic effect for the treatment of Gaucher disease type II in the visceral 
organs. However, although hSynI is a neuron-specific promoter, it has been 
demonstrated that synapsin I protein is expressed in the trans-Golgi compartment of 
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epithelial cells in the liver of mice (Bustos et al., 2001). Therefore, a more detailed 
analysis of the visceral organs was performed to determine if the hSynI promoter was 
actually able to express eGFP in other non-neuronal cell types in the viscera. The liver 
tissue harvested from injected mice was analysed for eGFP expression (Figure 36). The 
administration of the vector resulted in transduction of liver cells in injected mice. 
Consequently the transduction efficiency in other cell types was assessed. Evidence of 
vector-mediated gene expression was found in the spleen, lung and heart. 
 
Figure 36 - Transduction of visceral organs following administration of the 
ssAAV2/9.hSynI.eGFP.WPRE.hGHpA vector. 
Strong transgene expression was found in the liver of injected mice. Scattered eGFP-positive 
cells were found in spleen, lung and heart (Scale bar: 100μm). 
5.3. ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA vector 
The reporter gene study demonstrated that the use of a strong neuronal promoter 
resulted in extensive brain transduction following intravenous administration to 
neonatal mice, with evidence of transgene expression within visceral organs. However, 
for the purpose of systemic gene delivery of the soluble protein β-glucocerebrosidase, 
the higher transduction observed in the liver and lower levels in the spleen, heart and 
lung could be sufficient for the synthesis and consequent uptake of the enzyme in other 
tissues through the cross-correction mechanism. 
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For these reasons, a GBA1 version of the viral vector carrying the functional human 
gene was manufactured. First, the plasmid expressing the human GBA1 gene was 
produced and tested in vitro.  Consequently the viral vector was produced and 
administered to neonatal wild-type mice, in order to (i) evaluate whether the GBA1 
transgene expression was comparable to the results obtained with the eGFP construct, 
and (ii) assess any possible neuroinflammatory reaction following overexpression of the 
β-glucocerebrosidase protein in the brain. 
5.3.1. Cloning of the hGBA1 gene and in vitro testing 
The GBA1 gene was amplified via PCR, using the GBA_BspEI_f and the 
GBA_EcoRI_r primers. Two restriction site sequences corresponding to the BspEI and 
EcoRI enzymes were introduced at the 5’ and 3’ of the gene, respectively. The eGFP 
gene was removed from the original pAAV.hSynI.eGFP.WPRE.hGHpA plasmid through 
restriction enzyme digest with the aforementioned enzymes and replaced with the 
hGBA1 sequence via ligation reaction (Figure 37A). Automated Sanger sequencing of 
the plasmid confirmed the successful introduction of the human GBA1 gene into the 
AAV construct. 
In order to verify whether the β-glucocerebrosidase protein was efficiently produced, 
HEK-293T cells were transfected with the pAAV.hSynI.hGBA1.WPRE.hGHpA plasmid. 
The amount of GCase protein produced in transfected cells and untreated control cells 
after 48 hours was measured through Western blot analysis (Figure 37B). The 
membrane stained with the antibody against β-glucocerebrosidase revealed that the 
transfection with the plasmid produced the correct size protein (59kDa). The 
quantification of the relative protein expression showed that transfection with the 
pAAV.hSynI.hGBA1.WPRE.hGHpA plasmid resulted in a significant 16-fold increase 
(p=0.04) in β-glucocerebrosidase expression compared to untransfected control cells 
(Figure 37C). This was despite using the neuron specific hSynI promoter and 
suggesting that it has the ability to express in non-neuronal cells such the kidney 
derived HEK-293T cells. These results demonstrated that the β-glucocerebrosidase 
protein was being efficiently produced and the transfection with the 
pAAV.hSynI.hGBA1.WPRE.hGHpA plasmid resulted in overexpression of the GCase 
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enzyme. To determine if the β-glucocerebrosidase produced following transfection was 
functional, the enzymatic activity of the protein was assessed. The enzyme was 
extracted from the cell lysate (Figure 37D) of transfected and control cells. Following 
incubation with the substrate 4-methylumbelliferyl-β-D-glucopyranoside, quantification 
of the enzymatic activity was carried out. Results confirmed that β-glucocerebrosidase 
was enzymatically active. The increase in the enzymatic activity (p=0.04) in treated 
samples reflected the overexpression of the protein following transfection. The β-
glucocerebrosidase enzymatic activity was also tested in the supernatant of transfected 
and control cells (Figure 37E), in order to establish whether the protein was correctly 
secreted. The quantification revealed that the secreted protein was enzymatically 
functional and displayed a catalytic activity similar to the control samples. 
 
Figure 37 - Cloning and in vitro testing of the pAAV.hSynI.eGFP.WPRE.hGHpA plasmid. 
A Map of the plasmid, showing the main elements of the expression cassette and the BspEI and 
EcoRI restriction enzyme sites. B Western blot result. HEK-293T cells transfected with the 
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pAAV.hSynI.eGFP.WPRE.hGHpA plasmid (hSynI.hGBA1) produced the GCase protein 
(59kDa). In transfected cells the protein levels were significantly higher than in the control 
(Loading control: β-actin). C Quantification of the Western blot analysis. Expression in 
transfected cells was 16-fold higher than control levels. D Enzymatic assay on cell lysate and E 
supernatant demonstrated that the β-glucocerebrosidase protein was enzymatically functional 
(Data presented as average + SD. Statistical analysis: unpaired t test, Welch’s correction; * 
p<0.05). 
5.3.2. Codon optimisation of the GBA1 sequence 
In order to further improve the expression of the human GBA1 gene, the sequence of the 
wild-type gene underwent codon-optimisation processing. The principle underlying 
codon-optimisation is based on the degenerative properties of the genetic code: optimal 
codon usage can contribute to increase translation rate and specificity, resulting in 
higher gene expression (Karlin and Mrazek, 1996). The OptimumGene™ algorithm 
(GenScript) was used to modify the GBA1 nucleotide sequence yet maintaining the 
same amino acid sequence (GBA1_CO). The Kozak sequence and the BspEI restriction 
enzyme site were synthesised upstream of the GBA1_CO sequence, while the EcoRI site 
was incorporated at the 3’ end, so that it was possible to clone the optimised sequence 
into the pAAV.hSynI.hGBA1.WPRE.hGHpA plasmid replacing the wild-type gene. The 
resulting pAAV.hSynI.GBA1_CO.WPRE.hGHpA plasmid was used to transfect HEK-
293T cells and the β-glucocerebrosidase protein expression was measured by Western 
blot analysis. The densitometric quantification of the GCase protein (Figure 38) 
showed that the transfection with the plasmid expressing the codon-optimized sequence 
resulted in an increase (p=0.019) of β-glucocerebrosidase protein expression compared 
to the untransfected control. Although there was no statistically significant difference 
between the two sets of samples, the transfection with the wild-type sequence produced 
higher levels of protein. For this reason, the original pAAV.hSynI.hGBA1.WPRE.hGHpA 
plasmid carrying the wild-type GBA1 sequence was chosen and consequently used to 
produce the viral vector. 
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Figure 38 - Codon optimisation of the GBA1 gene.  
Quantification of Western blot analysis. The use of the codon-optimized sequence (GBA1_CO) 
did not improve the β-glucocerebrosidase protein expression in transfected cells, compared to 
the wild-type sequence (WT GBA1) (Data presented as average + SD. Statistical analysis: 
unpaired t test, Welch’s correction; * p<0.05, ** p<0.01). 
5.3.3. ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA viral vector production 
The pAAV.hSynI.hGBA1.WPRE.hGHpA plasmid was used to produce the 
ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA viral vector (Figure 39A). The same triple 
transfection process employed to produce the eGFP version of the vector was carried 
out. The titer of the virus was measured by SDS-PAGE (Figure 39B) and consequent 
densitometric analysis (Figure 39C). The analysis of polyacrylamide gel showed that 
the virus was efficiently produced and the amount of VP3 protein was consequently 
determined. The average titer of the preparation was quantified to be 6 x 1013 vp/ml. 
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Figure 39 - ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA virus production. 
A Schematic of the expression cassette. The human GBA1 gene was under control of the 
synapsin I promoter. B SDS-PAGE gel. 5μl, 10μl and 15μl of the viral preparation were loaded 
and the amount of VP3 capsid protein was measured. C Titration of the preparation. The viral 
vector was produced with an average titer of 6 x 1013 vp/ml. 
5.3.4. Assessment of neuroinflammatory response  
In order to evaluate whether the injection of a high dose of the viral vector could result 
in toxicity within the central nervous system, the inflammatory response following 
administration was assessed. A total dose of 2.4 x 1012 vp was intravenously 
administered to three neonatal wild-type mice. The animals were sacrificed at one 
month of age and the brain was harvested and processed. The neuroinflammatory 
response following administration of the vector was assessed. Brain sections from 
injected mice and untreated controls were stained for the astrocytic marker GFAP 
(Figure 40A). Activated astrocytes were not visible in the tissue and the staining 
intensity levels throughout the whole brain of injected mice were comparable to the 
controls. Quantification of GFAP immunoreactivity in the cortical region S1BF, in the 
hippocampus and in the thalamic nuclei confirmed that mice injected with the vector did 
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not develop astrocytosis in any of these brain regions (Figure 40B). Hence it was 
concluded that the administration of the vector did not cause an astroglial-mediated 
inflammatory response in the brain of injected mice. 
 
Figure 40 - Analysis of neuroinflammation following administration of the vector to wild-
type mice.  
A Immunohistochemical staining for the marker GFAP did not show increase in astrocytosis in 
brains from injected mice (WT injected) compared to untreated controls (WT controls). B S1BF 
cortex; CA1/CA2 hippocampus; VPL/VPM thalamus. Quantification of the GFAP intensity 
confirmed normal levels of astrocytes in injected brains (Data presented as average + SD. 
Statistical analysis: two-wayANOVA, Tukey’s multiple comparisons test; ns p>0.05). 
5.4. Gene therapy in the mouse model for neuronopathic 
Gaucher disease 
Since the toxicological study carried out on wild-type mice did not show adverse effect 
following administration of the vector and the β-glucocerebrosidase expression was 
elevated in the brain of injected mice, the ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA viral 
vector was utilised to administer gene therapy to the Gaucher mouse model. Five K14-
lnl/lnl mice were intravenously injected on the day of birth via the temporal vein with 
40μl of the vector, resulting in a total dose of of 2.4 x 1012 viral particles. The animals 
were monitored for weight loss and neurological symptoms. Due to an undesired eye 
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infection spread in the animal facility, the mice were sacrificed at nine weeks of age and 
the neuropathological analysis was performed. Immunohistochemistry on brain sections 
was carried out, and possible neuronal loss was measured. The effects of gene therapy 
on the visceral organs were also evaluated through the analysis of macrophage 
accumulation and β-glucocerebrosidase enzymatic activity. 
5.4.1. Extension of lifespan and health monitoring 
While the untreated K14-lnl/lnl mice were collected at the humane endpoint at two 
weeks of age, the administration of gene therapy resulted in significant extension of the 
lifespan of the treated animals (Figure 41A). Gba1 knock-out mice that received 
intravenous injection of the ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA vector on the day 
of birth survived up to at least nine weeks of age. At that point, both treated animals and 
age-matched wild-type controls were sacrificed, as required from the UCL Home Office 
Veterinary because of an infection unrelated to the treatment. The body weight of the 
animals was constantly monitored. Treated animals did not show any significant 
difference in weight compared to wild-type littermates (Figure 41B). 
 
 
Figure 41 - Prolonged lifespan of treated K14-lnl/lnl animals.  
A Kaplan-Meier survival curve. Intravenous administration of the vector resulted in extended 
life of treated animals (IV treated K14-lnln/lnl) (Statistical analysis: log rank (Mantel-Cox) test; 
p<0.001). B Treated mice maintained body weight comparable to controls (Statistical analysis: 
two-way ANOVA, Tukey’s multiple comparisons test; ns p>0.05). 
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5.4.2. Assessment of neurological manifestations 
A series of behavioural tests were conducted in order to evaluate neurological 
symptoms in treated mice. As the untreated K14-lnl/lnl mice were not old enough to be 
trained and tested before being sacrificed at the humane end-point at P14, most of the 
analysis was carried out on treated animals and wild-type age-matched controls. Data 
shown in Figure 42 show the results of tests conducted on 60-day-old mice; except for 
the righting reflex test (Figure 42A), which was conducted on 14 day-old mice. 
K14-lnl/lnl mice rapidly developed neurological manifestations at two weeks of age. At 
the end-stage the animals were not able to right themselves when place in a supine 
position. Untreated Gba1 knock-out animals completely failed the righting reflex test 
(score 0), whereas all IV treated mice and wild-type controls returned to prone position 
in less than 1 second (score 1) at P14 (Figure 42A). 
IV treated K14-lnl/lnl and K14-wt/wt were tested for locomotor dysfunction on the 
rotarod apparatus (Figure 42B). The time at fall from the rod was recorded. Treated 
mice performed similarly to the controls, falling at an average time of 36.5s, compared 
to wild-type animals at 49.5s. Although the time achieved by treated knock-out mice on 
the rotarod was slightly shorter than duration of the controls the difference was not 
statistically significant. 
Similar results were obtained from the open field test, where mice were placed into a 
transparent chamber and movement was recorded for 4 minutes (Figure 42C). Several 
different parameters were analysed: distance travelled, average speed, time the animal 
was in motion and time it remained immobile. IV treated mice performed equally to the 
controls in all the examined tasks. Examples of resulting movement traces are also 
shown in Figure 42C. All animals showed exploratory behaviour. IV treated mice did 
not walk preferentially on the edge of the field, but crossed the centre of the chamber 
several times comparably to their wild-type littermate controls. 
Mice were also assessed for a clasping phenotype to evaluate eventual cerebellar ataxia 
(Figure 42D). IV treated K14-lnl/lnl displayed dissimilar phenotypes. Three of the five 
158 
animals showed a mild clasping behaviour, occasionally retracting one leg for less than 
30s (score 1). One animal exhibited a more severe phenotype, retracting both hind limbs 
for more than 50% of the experimental time (score 2). The last mouse did not show any 
pathological manifestation, extending all libs out from the body like wild-type controls 
(score 0). 
Motor coordination was measured by placing animals on a grid for 1 minute and 
counting the paw misplacements over the total number of steps (Figure 42E). Both IV 
treated K14-lnl/lnl and K14-wt/wt animals faulted a comparable number of front paw 
placements. However, treated mice performed worse than controls when specifically the 
back paw misplacements were measured (p=0.0039). 
Finally, an indicative gait evaluation was performed measuring stride length and base 
width (Figure 42F). The footprint analysis revealed that IV treated mice did not show 
overt motor deficits, maintaining a good coordination and balance similar to the wild-
type controls. 
Combined these behavioural analyses indicated that K14-lnl/lnl mice that received gene 
therapy on the day of birth did not develop severe neurological symptoms nine weeks 
after the administration. One isolate animal showed moderate clasping phenotype. 
Overall, however IV treated mice showed higher back paw misplacement in the foot 
faults test, treated mice performed similarly to the wild-type controls in all the tests, 
demonstrating that motor coordination deficits were largely prevented following the 
treatment. 
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Figure 42 - Behavioural assessment of treated mice. 
A Righting reflex test. Untreated K14-lnl/lnl mice were unable to right themselves when place 
in supine position (score=0), while treated mice showed fast latency to turn (score=1) 
(Statistical analysis: one-way ANOVA, Holm-Sidak’s multiple comparisons test; **** 
p<0.0001). B Rotarod. Treated mice did not show loco-motor impairments when positioned on 
the rotarod (Data presented as average + SD. Statistical analysis: unpaired t test, Welch’s 
correction; ns p>0.05). C Open field test (traces and data analysis). Mice were assessed for 
distance walked, speed, time of mobility and immobility when placed into the open field box. 
Overall, treated animals performed as the wild-type controls (Data presented as average + SD. 
Statistical analysis: unpaired t test, Welch’s correction; ns p>0.05). D Tail suspension. Treated 
mice showed different phenotypes, from moderate clasping (score=2) to normal behavior 
(score=0) (Statistical analysis: unpaired t-test, Welch’s correction; ns p>0.05). E Foot faults 
test. Paw misplacement was counted over the total number of steps. Treated mice showed 
increased back foot misplacement compared to controls (Data presented as average + SD. 
Statistical analysis: two-way ANOVA, Tukey’s multiple comparisons test; * p<0.05). F 
Footprint test (Traces and data analysis). Stride length and base width of the steps were 
analysed. Treated knock-out mice maintained good coordination skills and performed similarly 
to wild-type controls (Data presented as average + SD. Statistical analysis: two-way ANOVA, 
Tukey’s multiple comparisons test; ns p>0.05). 
5.4.3. Widespread overexpression of β-glucocerebrosidase in the brain 
of treated K14-lnl/lnl mice 
Untreated K14-lnl/lnl, IV treated K14-lnl/lnl and wild-type mice were sacrificed and an 
extensive histological analysis of the brain was performed. 
The intravenous injection of the ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA vector to 
neonatal wild-type mice resulted in intense and widespread overexpression of β-
glucocerebrosidase in the brain. In order to evaluate whether the administration of the 
vector to Gba1 knock-out animals caused an increase in the expression of the protein, 
brain sections of treated mice underwent immunohistochemical staining against the 
GCase protein (Figure 43A) and the most affected brain regions observed in Gaucher 
patients were analysed. The systemic administration of the vector resulted in widespread 
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β-glucocerebrosidase expression. Exceptionally high transduction was observed in the 
thalamic nuclei of treated brains. In other regions the concentration of GCase-positive 
neurons was lower; nevertheless in the cortex, hippocampus, cerebellum and brain stem 
it was still possible to detect many stained cells. The quantification of the 
immunoreactivity (Figure 43B) confirmed the significant β-glucocerebrosidase 
overexpression in treated brains compared to the wild-type controls, while untreated 
K14-lnl/lnl mice expressed minimal amount of protein.
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Figure 43 - Overexpression of β-glucocerebrosidase in treated brains. 
A Brain sections from wild-type, treated K14-lnl/lnl mice and untreated K14-lnl/lnl mice were 
stained for β-glucocerebrosidase. Intense neuronal staining was observed throughout the whole 
brain of treated mice (Scale bars: low magnification 100μm; high magnification 60μm). B S1BF 
cortex; CA1/CA2 hippocampus; VPM/VPL thalamus, 10Cb cerebellum; Gi brain stem. 
Quantification of immunoreactivity confirmed the widespread overexpression of GBA1 in 
different regions of the brain (Data presented as average + SD. Statistical analysis: two-way 
ANOVA, Tukey’s multiple comparisons test; ns p>0.05). C Enzymatic assay. Administration of 
the vector resulted in increase of the enzymatic activity in the brain of treated mice (Data 
presented as average + SD. Statistical analysis: one-way ANOVA, Tukey’s multiple 
comparisons test; * p<0.05). 
To determine whether transduced cells produced enzymatically functional β-
glucocerebrosidase, frozen brain samples were homogenised and the catalytic activity of 
the enzyme was measured (Figure 43C). Results showed that the overexpression of the 
GBA1 gene normalized the β-glucocerebrosidase enzymatic activity into wild-type 
levels. GCase residual activity in treated brains was 68% that of the normal range, while 
the untreated Gba1 knock-out brains maintained only minimal reduced (p=0.04) 
enzymatic activity. No significant difference was found between control and treated 
samples. 
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5.4.4. Reduction of neuroinflammation in Gba1 knock-out mice 
following vector administration 
The presence of numerous and diffuse activated astrocytes in many brain regions, 
particularly within cortical areas is characteristic of Gba1 knock-out mice. Brain 
sections form untreated Gba1 knock-out (14 day-old), treated mice (60 day-old), and 
age-matched wild-type controls (60 day-old) were stained for the GFAP marker. The 
administration of the ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA cleared the presence of 
activated astrocytes within the cortical layers and the thalamic nuclei of treated mice 
compared to the untreated animals (Figure 44A). A notable amelioration in 
neuroinflammation was observed in the brain stem and cerebellum, although the GFAP 
intensity was still not comparable to the wild-type control levels. The quantification of 
the anti-GFAP staining (Figure 44B) demonstrated that neuroinflammation levels were 
completely normalised in the somato-barrel field region S1BF and the thalamic nuclei 
VPM/VPL in treated brains. GFAP-positive cells were found in the CA1/CA2 layers of 
the hippocampus and in the cerebellum, however the difference with wild-type control 
was not statistically significant. In the gigantocellular nuclei region of the cerebellum 
the immunoreactivity was markedly elevated (p=0.017) in treated brains compared to 
controls. However, GFAP levels in brains harvested from IV treated K14-lnl/lnl mice 
were lower (p=0.0005) than the average astrocytic activation in the untreated Gba1 
knock-out samples. 
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Figure 44 - Reduction of astrocytosis in treated mice.  
A Light microscopy imaging of immunohistochemical staining for the astrocytic marker GFAP. 
Neuroinflammation was normalised in the cortex, thalamus and cerebellum of treated K14-
lnl/lnl mice (Scale bars: low magnification 100μm; high magnification 60μm). B S1BF cortex; 
CA1/CA2 hippocampus; VPM/VPL thalamus, 10Cb cerebellum; Gi brain stem. Significant 
reduction in astrocytosis was observed in the S1BF cortical region, the thalamic nuclei and brain 
stem of treated mice, while untreated knock-out animals developed intense and extensive 
astrocytic activation (Data presented as average + SD. Statistical analysis: two-wayANOVA, 
Tukey’s multiple comparisons test; * p<0.05, *** p<0.001, **** p<0.0001). 
5.4.5. Normalisation of microglia activation in treated K14-lnl/lnl mice 
The previous chapter demonstrated that the administration of the 
scAAV2/9.GUSB.hGBA1.bGHpA vector resulted in only partial amelioration of 
microglial activation in treated brains, limited to restricted regions. Intense CD68-
positive staining was detected in the cortex and in the hippocampus of the previously 
treated mice. However, the treatment with ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA 
provided more promising results. Brains from mice treated with this second vector did 
not develop microglia activation (Figure 45A). The brain sections stained for the 
microglial marker CD68 resulted in the complete clearance of positive cells, comparable 
to wild-type samples. This result was confirmed by quantification of the 
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immunoreactivity (Figure 45B). In all analysed regions it was not possible to identify 
enlarged CD68-positive cells in brain sections from both IV treated and wild-type 
control mice. Immunohistochemistry on untreated K14-lnl/lnl brains showed diffuse 
and intense microglia activation throughout the whole brain, demonstrating the 
beneficial effect of gene therapy on treated mice. 
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Figure 45 - Reduction of microglia activation in treated K14-lnl/lnl mice. 
A Brain sections stained for the microglial marker CD68. Samples from treated mice resulted in 
the complete clearance of CD68-positive cells (Scale bars: low magnification 100μm; high 
magnification 60μm). B S1BF cortex; CA1/CA2 hippocampus; VPM/VPL thalamus, 10Cb 
cerebellum; Gi brain stem. Quantification of immunoreactivity confirmed that gene therapy 
normalised microglia activation levels in treated brains (Data presented as average + SD. 
Statistical analysis: two-way ANOVA, Tukey’s multiple comparisons test; * p<0.05, **** 
p<0.0001). 
5.4.6. Administration of the ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA 
vector prevented accumulation of lysosomes in the brain 
In order to determine if the systemic treatment with the 
ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA vector ameliorated the accumulation of 
disrupted lysosomes within the brain of affected mice, brain sections were incubated 
with anti-LAMP1 antibody (Figure 46A). The analysis of the lysosomal marker 
distribution showed that the build-up in treated brains was reduced compared to 
untreated K14-lnl/lnl sections. The improvement was confirmed by quantification of the 
average immunoreactivity (Figure 46B). Lysosome marker levels were normalised to 
control levels in all the analysed brain areas in tissue from IV treated animals. Thus, it 
was demonstrated that the overexpression of β-glucocerebrosidase in the brain 
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prevented the accumulation of lysosomes in the brain of treated mice. 
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Figure 46 - Normalisation of lysosome accumulation levels following gene therapy 
administration. 
A Reduction of lysosome accumulation in treated brains compared to untreated Gba1 knock-out 
samples (Scale bars: low magnification 100μm; high magnification 60μm). B S1BF cortex; 
CA1/CA2 hippocampus; VPM/VPL thalamus, 10Cb cerebellum; Gi brain stem. The 
administration of the vector resulted in complete normalisation of lysosomal marker LAMP1 in 
all the analysed regions of treated brains (Data presented as average + SD. Statistical analysis: 
two-wayANOVA, Tukey’s multiple comparisons test; * p<0.05, ** p<0.01). 
5.4.7. Gene therapy prevents neuronal loss 
Brain tissue from IV treated mice and age-matched wild-type controls were stained with 
cresyl violet Nissl and an analysis of neuronal counts was performed using stereology 
software. Previous results showed that although the intravenous administration of 
scAAV2/9.GUSB.hGBA1.bGHpA extended the lifespan of treated K14-lnl/lnl, the mice 
developed widespread neuropathology characterised by neuronal loss, ventriculomegaly 
and brain atrophy. In order to establish whether the treatment with 
ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA ameliorated the neuropathology, cortical 
thickness measurements were carried out (Figure 47B). Statistical analysis revealed 
that, although the difference was minimal, the cortex of IV treated mice brain had 
reduced cortical thickness (p=0.0013) compared to the wild-type controls. Despite the 
shrinkage of the cortical regions, the anatomy of the brains harvested from treated mice 
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was not disrupted, and there was no sign of pathological enlargement of the lateral 
ventricles (Figure 47A). 
The number of neurons in the somato-barrel field cortical region, the thalamic nuclei 
and the Gi region in the brain stem was evaluated (Figure 47C). In all analysed areas, 
the neuron count in treated samples was comparable to the age-matched wild type 
controls. The systemic administration of the ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA 
vector resulted in efficient neuron-specific transduction and prevented 
neurodegeneration and cell loss in 9 weeks old treated mice.  
A non-quantitative analysis on neuron loss in the cerebellum was also performed. 
Calbindin is an established marker specific for Purkinje cells (Kim et al., 2009). 
Cerebellar sections of brains from wild-type controls, IV treated K14-lnl/lnl mice and 
P14 untreated Gba1 knock-out animals were stained for calbindin and light microscopy 
images were taken (Figure 47D). The pictures showed that while wild-type brain was 
characterized by ordered elongating Purkinje cells, in the treated brain neurons 
displayed a more arborising phenotype. There was no evident loss of neuron loss in 
cerebellar tissue form treated animals, however only few dispersed Purkinje cells were 
identified in the brain of untreated mice. 
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Figure 47 - Analysis of neurodegeneration following gene therapy.  
A Brain sections from wild-type controls and treated K14-lnl/lnl mice stained with the Nissl 
method. Treated brains did not display ventriculomegaly (Scale bar: 1mm). B Cortical thickness 
measurements in wild-type and IV treated knock-out mice. Treated K14-lnl/lnl mice showed 
mild, although significant cortical atrophy compared to controls (Data presented as average + 
SD. Statistical analysis: unpaired t test, Welch’s correction; ** p<0.01). C Neuron count 
showed that K14-lnl/lnl treated mice did not develop significant neurodegeneration. The 
number of neurons in cortex, thalamus and brain stem demonstrated that treated brains were not 
subject to neuronal loss (Data presented as average + SD. Statistical analysis: two-wayANOVA, 
Tukey’s multiple comparisons test; ns p>0.05). D Calbindin staining of cerebellar sections. In 
IV treated brains there was no significant Purkinje neuron loss, as opposed to samples form 
untreated K14-lnl/lnl (Scale bars: low magnification 100μm; high magnification 60μm). 
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5.4.8. Effects of gene therapy on the visceral pathology 
The results of the reported gene study on visceral transduction following administration 
of the ssAAV2/9.hSynI.eGFP.WPRE.hGHpA vector showed that the transgene 
expression under control of a neuron-specific promoter is not extremely efficient. 
Although many transduced cells were identified in the liver of injected mice, much 
lower levels were detected in the heart, spleen and lungs. In order to evaluate if the 
visceral pathology in K14-lnl/lnl mice was ameliorated, possibly through the cross-
correction mechanism, liver, spleen, lung and heart tissues were examined. 
As splenomegaly is one of the first and most common systemic manifestations, the size 
of the spleen of nine weeks old treated mice was measured (Figure 48A). The animals 
that received gene therapy did not develop organomegaly, as the average weight of the 
spleens from treated mice was comparable to the spleen size of wild-type controls. 
The administration of the ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA vector to neonatal 
mice improved both the spleen and the liver pathology. The immunohistochemical 
staining of the macrophagic marker CD68 (Figure 48C) showed that tissues from IV 
treated K14-lnl/lnl mice were not characterised by the accumulation of enlarged 
macrophages. The amelioration of the pathology in spleen and liver of treated mice was 
more evident when tissue from nine-weeks-old treated animals where compared to 
young P14 Gba1 knock-out mice: in fact, samples from untreated K14-lnl/lnl mice were 
characterised by extensive infiltration of activated macrophages. Gaucher cells were 
widely present in heart sections from knock-out mice. Administration of the vector 
resulted in partial amelioration of macrophage activation: few enlarged macrophages 
were observed in the heart from IV treated K14-lnl/lnl mice. Unfortunately, gene 
therapy did not have substantial beneficial effect on the lungs of treated mice, as many 
CD68 positive cells were identified in the tissue sections. 
The improvement of the visceral pathology in treated mice was then confirmed by 
quantitative threshold imaging of the CD68 staining on serial sections of the organs 
(Figure 48B). The reduction of CD68-positive cells in treated liver (p=0.02) and spleen 
(p=0.0002) tissues was significant compared to younger untreated Gba1 knock-out 
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samples. Although the difference in macrophagic activation in the lung was not 
statistically significant when comparing wild-type controls and treated mice, an increase 
in CD68 staining was observed under the light microscope in treated tissue (Figure 
48C). Finally, statistical evaluation did not highlight any significant difference in the 
analysis of heart tissue. 
Tissue integrity and architecture was assessed on tissue sections stained with 
hematoxilyn and eosin dye (Figure 48D). While liver tissue from wild-type controls 
and IV treated K14-lnl/lnl mice appeared very similar, liver sections from untreated 
knock-out mice were characterised by extensive infiltration of Gaucher cells. These 
enlarged cells presented expanded cytoplasmic compartment and interfere with tissue 
structure. Although the staining of CD68 underlined the presence of many activated 
macrophages in the spleen of untreated mice, H&E staining did not reveal the presence 
of engorged Gaucher cells. On the contrary, enlarged macrophages were identified in 
lung sections from IV treated Gba1 knock-out mice. This result confirmed the previous 
finding, demonstrating that the administration of the vector resulted in insufficient 
transduction of lung tissue. Heart sections did not appear to be characterised by Gaucher 
cells. 
Finally, the enzymatic activity of β-glucocerebrosidase in the viscera following 
administration of the ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA vector was measured 
(Figure 48E). Although the enzymatic activity was not normalised to the wild-type 
levels, β-glucocerebrosidase activity increased in treated mice compared to untreated 
Gba1 knock-out animals. GCase residual activity remained significantly lower 
(p<0.0001) than the normal range in livers of treated mice (8%), while β-
glucocerebrosidase activity in spleen samples was 43% of the wild-type level. 
Inefficient transduction of lung and heart following administration of the vector resulted 
in low residual enzymatic activity (7%) in organs harvested from treated mice. 
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Figure 48 - Analysis of visceral pathology following gene therapy administration. 
A Spleen weight. IV treated mice did not develop splenomegaly at 9 weeks of age (Data 
presented as average + SD. Statistical analysis: unpaired t test, Welch’s correction; ns p>0.05). 
B Quantification of immunohistochemical staining for the macrophagic marker CD68. Tissues 
from treated mice were not characterized by infiltration of activated macrophages. No 
significant difference between treated and untreated K14-lnl/lnl mice was found in heart tissue 
(Data presented as average + SD. Statistical analysis: two-wayANOVA, Tukey’s multiple 
comparisons test; * p<0.05, ** p<0.01, *** p<0.001). C CD68 staining of tissue sections. Lung 
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samples from treated mice presented numerous activated macrophages (indicated by white 
arrow), while spleen and liver samples resulted in the clearance from engorged macrophages 
(Scale bar: 200μm). D H&E staining. Gaucher cells were found in lung tissue harvested from 
treated mice. The other tissues were not characterized by Gaucher cells infiltration (Scale bar: 
200μm). E GCase enzymatic activity was measured in tissue samples. Although β-
glucocerebrosidase activity in treated animals was increased compared to untreated K14-lnl/lnl 
mice, the residual enzymatic levels were not restored to physiological values (Data presented as 
average + SD. Statistical analysis: two-wayANOVA, Tukey’s multiple comparisons test; * 
p<0.05, **** p<0.0001). 
5.5. Conclusions 
The work presented in this chapter described the design, testing and administration of a 
novel adeno-associated viral vector suitable for the treatment of neuronopatic Gaucher 
disease. 
First, a novel single-stranded vector was designed and a reporter gene study was 
conducted. In the expression cassette the eGFP gene was cloned downstream the human 
synapsin I promoter sequence. The Kozak sequence was incorporated at the 5’ end of 
the gene, while the viral enhancer element WPRE was cloned at the 3’ end in order to 
amplify the efficiency of transgene expression in in vivo studies. The 
ssAAV2/9.hSynI.eGFP.WPRE.hGHpA vector was successfully produced at a titre of 
5.2 x 1012 vp/ml. Consequently, the vector was intravenously administered at a dose of 
2 x 1011 vp to neonatal wild-type mice. The animals were sacrificed one month after in 
order to study the transgene expression in the central nervous system and the visceral 
organs. The administration of the viral vector resulted in widespread and intense 
expression of the eGFP protein throughout the whole brain. In addition, confocal 
images demonstrated that synapsin is a strong neuron-specific promoter. The systemic 
administration of the ssAAV2/9.hSynI.eGFP.WPRE.hGHpA vector provided 
transduction of hepatocytes and transgene expression in the spleen, lung and heart of 
injected mice, albeit at much lower levels. 
The results of the reporter gene study were sufficient to confirm the potential use of the 
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viral vector for the treatment of Gaucher disease. Therefore the human GBA1 gene was 
cloned into the cassette and the expression plasmid was tested in vitro with the aim of 
determine whether (i) the synapsin promoter could efficiently drive the expression of 
the β-glucocerebrosidase gene and (ii) the resulting protein was catalytically active. Cell 
transfection with the plasmid resulted in considerable overexpression of the 
enzymatically active β-glucocerebrosidase protein. In order to further increase the 
transgene expression, the codon optimised version of the GBA1 gene was cloned into 
the vector plasmid and the efficiency of expression was tested in vitro. Western blot 
analysis showed that the use of the codon optimised sequence did not improve gene 
expression in transfected cells. Therefore the initial expression plasmid carrying the 
wild-type sequence of the GBA1 gene was used to produce the 
ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA adeno-associated viral vector. The virus was 
injected intravenously into wild-type mice at day of birth and any toxic effect of β-
glucocerebrosidase overexpression in the brain was assessed. One month after injection 
the animals were sacrificed and the brain was analysed for pathology. The widespread 
overexpression of β-glucocerebrosidase did not cause a neuroinflammatory response in 
injected mice.  
At this point the ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA vector was demonstrated to 
be efficient and safe, therefore a high dose of 2.4 x 1012 viral particles was administered 
to neonatal K14-lnl/lnl Gba1 knock-out mice. Gene therapy resulted in a significant 
extension in the lifespan of treated animals, normalisation of body weight and 
amelioration of most of the locomotor and behavioural indexes. The mice were 
sacrificed at 63 days of age, for reasons unrelated to the treatment. Consequently, the 
brain was extensively analysed. The administration of the vector caused widespread 
overexpression of β-glucocerebrosidase in neurons of treated mice. This resulted in 
complete prevention of a microglia-mediated inflammatory response. Lysosomal 
accumulation was also normalised. In addition, significant reduction of astrocyte-
mediated inflammatory response was observed in the cortex and thalamus, while the 
cerebellum and brain stem showed only a partial amelioration in astrocyte activation. 
The overall positive effect of gene therapy in the brain of treated mice was evident 
when the neuron count was measured. In fact, the number of neurons in the cortical 
region S1BF, the thalamic nuclei area and the brain stem were comparable to those 
numbers measured in age-matched wild-type control mice. Moreover, no evident 
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reduction in the number of Purkinje neurons in the cerebellum of treated mice was 
observed. However, atrophy of the cortical layer was detected.  
Finally, the effects of the systemic administration of gene therapy on the viscera were 
assessed. As expected, the pathology was reverted in liver and spleen. The tissues did 
not present enlarged Gaucher cells and the levels of activated macrophages were 
reduced to the wild-type levels. Also, treated mice did not develop splenomegaly. 
However, lung tissue was characterised by the presence of many activated 
macrophages. These results were supported by the analysis of the β-glucocerebrosidase 
activity in the homogenised tissues. High levels of residual enzymatic activity were 
found in the spleen of treated mice. In the liver samples the β-glucocerebrosidase 
activity was 8% of the wild-type normal level; however, this minimal residual activity 
was sufficient to improve the pathology in the organs of treated Gba1 knock-out mice. 
Although enzyme levels in lung and heart tissue were relatively low, the enzymatic 
activity in tissue from treated animals was still greater than the untreated knock-out 
controls.
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6. Discussion 
6.1. Overview 
Loss-of-function mutations in the GBA1 gene lead to Gaucher disease. The more severe 
mutations result in the neuronopathic type II and type III forms of the disease. There is 
currently no treatment for the lethal neurodegeneration observed in these patients. Type 
II is acute and children may die at any time between the perinatal period to a maximum 
of 2 years of age. A host of visceral manifestations of the disease are also present, the 
most prominent being hepatosplenomegaly. There is an overwhelming need to develop 
a novel therapy that addresses the lethal neurodegeneration and preferably also the 
visceral symptoms. 
The aim of the present work is to develop a comprehensive pre-clinical study on 
intravenously administered gene therapy for neuronopathic Gaucher disease. The 
rationale behind the study is based on the hypothesis that a single intravenous 
administration of a viral vector carrying the functional human GBA1 gene to a knock-
out mouse model can potentially improve both the visceral and neurological pathology. 
This study provides proof-of-concept that intravenously administered AAV9 vectors 
that carry a therapeutic copy of the GBA1 gene can cross the blood-brain barrier and (i) 
rescue the mouse model from neonatal lethality, (ii) ameliorate neurolopathology, (iii) 
provide significant increase in lifespan, from 14 days to at least 180 days old and (iv) 
improve visceral symptoms and pathology. 
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6.2. Intravenously administered AAV9 gene therapy can 
rescue an acute neonatal lethal mouse model of 
neurodegeneration 
The mouse model used in this preclinical study does faithfully recapitulate many of the 
neurological and visceral manifestations of the disease. The neurological component is 
lethal and while the administration of the AAV9 vectors used in this study does not 
represent a ‘cure’, the therapeutic effect is significant, as there is amelioration of the 
brain pathology sufficient to provide significant long-term extension on lifespan and 
indices of quality of life. 
The only other therapeutic strategy that has shown effect in this K14-lnl/lnl mouse 
model has been employed in other studies investigating the effects of the administration 
of a glusosylceramide synthase inhibitor on survival and neuropathology (Cabrera-
Salazar et al., 2012). 12 Gba1 knock-out mice were injected into the peritoneal cavity 
daily from P4, and 13 were injected into the lateral ventricles at P1, P2 and P3, in 
combination with intraperitoneal administration from P4. The treatment resulted in 
reduction of the substrate accumulation, microglial activation and astrogliosis in the 
central nervous system of administered mice. However the average lifespan of the 
treated mice increased only by 4 days when the compound was injected 
intraperitoneally, and 12 days following combination therapy.  Therefore, a minimally 
invasive intravenously administered gene therapy that extends the lifespan of the mice 
from 14 days to at least 180 days is a major step forward towards developing a 
treatment for neuronopathic Gaucher disease. 
A further consideration is that the K14-lnl/lnl mouse model is one of the most severe 
and aggressive viable mouse models of a metabolic neurodegenerative disease. To date, 
it is the most severe mouse model of any neurodegenerative disease to be treated with 
gene therapy. Any therapeutic success in this model is significant and does suggest that 
this approach will be beneficial in any number of less acute neurological conditions. 
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6.3. Amelioration of neuropathology in the K14-lnl/lnl mouse 
model following intravenous AAV9-mediated gene therapy 
The neuropathological analysis on treated mice confirmed that it was possible to 
ameliorate the acute neurological symptoms in the brain of K14-lnl/lnl mice. The 
intravenous administration of the vector resulted in overexpression of the human GBA1 
gene in widespread brain regions. Of particular interest is the significant improvement 
of the brain stem in the pathological markers considered in the study. This brain region 
is responsible for the conduction of nerve signals between the spinal cord and the brain. 
It collects the projections originating from the midbrain and provides the motor and 
sensory innervation to the body through the cranial nerves (Kandel, 2012). The brain 
stem, and in particular the gigantocellular nuclei region (Gi), plays a fundamental role 
in the control of swallowing and breathing reflexes. While amelioration in the pathology 
in a variety of brain regions may cumulatively contribute to preventing 
neurodegeneration-associated death, the restoration of the endogenous levels of 
functional glucocerebrosidase in the Gi and prevention of pathology may play a major 
role in contributing to the increase in lifespan of the animals. Indeed, while a number of 
factors may contribute, brainstem degeneration leading to aspiration and subsequent 
pneumonia is one of the ultimate cause of death in type II Gaucher Disease patients 
(Gupta et al., 2011). 
6.4. A single-stranded AAV9 vector that includes the synapsin 
promoter and the WPRE element is the preferred construct 
for treating type II neuronopathic Gaucher disease 
The first part of the current work demonstrated that the administration of an adeno-
associated virus carrying the functional GBA1 gene increased lifespan of treated animals 
and improved the visceral pathology. However, the scAAV2/9.GUSB.hGBA1.bGHpA 
vector did not completely address the widespread and acute neurodegeneration when 
administered systemically. Therefore, a more efficient vector with specific neuronal 
tropism was designed in order to improve the transgene expression in the central 
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nervous system. It is well established that neuronopathic forms of Gaucher disease are 
characterised by widespread neuronal loss (Wong et al., 2004). The involvement of 
neurons as cause of brain pathology has been also demonstrated in a Gaucher mouse 
model (Enquist et al., 2007). For this reason, specific targeting of neuronal cells in the 
affected brains was thought to be essential to improve the efficiency of the treatment. 
The human synapsin I promoter has been successfully used in gene delivery studies and 
it was proven to mediate strong and neuron-specific gene expression (Jackson et al., 
2016). The use of a neuronal promoter in combination with the inclusion of enhancing 
sequences like the Kozak fragment and the WPRE element, made the 
ssAAV2/9.hSynI.eGFP.WPRE.hGHpA the optimal vector for gene delivery to neurons 
and the central nervous system. Although self-complementary adeno-associated viruses 
mediate a more rapid transduction than the single-stranded vectors (McCarty et al., 
2001), the introduction of enhancing elements compensates for the reduced  efficiency 
of ssAAVs. The WPRE element was already known to enhance transgene expression in 
vitro (Loeb et al., 1999). More recently, it has been demonstrated that the intravenous 
administration of a single-stranded adeno-associated virus expressing eGFP and 
carrying the WPRE sequence resulted in increase of transgene expression (Mattar et al., 
2015). 
The systemic administration of the ssAAV2/9.hSynI.eGFP.WPRE.hGHpA to neonatal 
wild-type mice resulted in widespread and intense transduction of the central nervous 
system, demonstrating that the vector was able to efficiently deliver the transgene to the 
brain when injected intravenously. The virus tropism was neuron-specific and eGFP 
expression was detected throughout the whole brain. 
The advantage of the systemic route of administration relies on the ability of AAV to 
cross the blood-brain barrier. Since neuronopathic forms of Gaucher disease are 
characterised by both brain and visceral pathology, a single intravenous injection could 
address both manifestations. The administration of 
ssAAV2/9.hSynI.eGFP.WPRE.hGHpA resulted in efficient liver transduction and more 
moderate transgene expression in the spleen, lung and heart. These results were not 
surprising, considering the facts that (i) the synapsin I protein is expressed in 
hepatocytes (Bustos et al., 2001) and (ii) the transgene expression was driven by a 
neuron-specific sequence and not a ubiquitous promoter. The liver-directed gene 
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therapy for haemophilia demonstrated that targeting of hepatocytes results in the 
increase of enzyme levels in the blood stream, since the liver is a crucial organ for the 
major metabolic pathways. Efficient transduction of liver tissue could therefore be 
beneficial for increasing β-glucocerebrosidase levels in other visceral organs. 
The systemic administration of the ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA vector to 
Gba1 knock-out mice successfully rescued the ultimately fatal neuropathology, 
resulting in an extension of lifespan and improvement in behaviour and quality of life in 
the treated mice. The overexpression of glucocerebrosidase in neurons resulted in the 
reduction of astrogliosis and the microglia-mediated inflammatory response. This 
observation might seem to contrast the pathological mechanism proposed by Vardi and 
colleagues (Vardi et al., 2016). In fact, the study demonstrated that in the chemical-
induced Gaucher mouse model neuroinflammation precedes neuronal loss. However, 
our study shows that the rescue of neurons alone has a therapeutic effect on both 
astrocytes and microglia. In light of these findings, two hypotheses on the therapeutic 
mechanism of the gene therapy treatment can be proposed: (i) correcting the genetic 
defect in neurons could prevent the fatal neurodegeneration and neuronal loss, 
consequently averting the activation of neuroinflammatory responses; (ii) neighbouring 
cells can uptake the secreted glucocerebrosidase enzyme following GBA1 
overexpression in neurons through the cross-correction mechanism, and this results in 
amelioration of neuroinflammation and microglia activation. 
The brain-targeted gene therapy only partially ameliorated the visceral manifestations. 
Although the liver could serve as metabolic factory for the production of 
glucocerebrosidase following ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA administration, 
the levels of circulating enzyme were not sufficient to appreciate a significant 
amelioration of the pathology in other organs. 
Overall, although the treatment might not completely cure the visceral symptoms, a 
possible clinical use of the vector should be taken in consideration. There is currently no 
available therapy for the devastating neurodegeneration in Gaucher patients, while the 
visceral pathology characteristic of type I is successfully rescued by enzyme 
replacement therapy. Evidently, further research is needed in order to improve the gene 
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delivery treatment; nonetheless a combination therapy with ERT or another vector may 
be extremely beneficial and should be considered. 
6.5. Clinical precedent for intravenously administered AAV9 
gene therapy for neurological diseases 
AAV9 is known to be highly efficient at transducing neurons (Foust et al., 2009). 
However, the finding that it also has the ability to cross the blood-brain barrier has 
already had a significant impact on the neurological gene therapy field. Since the 
original pre-clinical studies of intravenously administered AAV9 to rescue a mouse 
model of spinal muscular atrophy, a clinical trial has been initiated at the Nationwide 
Children’s Hospital in the USA (NCT02122952). While this study is ongoing, the initial 
reports have been remarkable with significant improvements in locomotor function in 
treated children (unpublished work (Mendell, 2016a)). 
Like Gaucher disease, CLN3 Batten disease is a neurodegenerative lysosomal storage 
disorder. A recent pre-clinical study published in 2016 reported partial correction of 
pathology in a mouse model following intravenous administration of an AAV9 vector 
(Bosch et al., 2016). Abeona Therapeutics have recently been granted FDA Orphan 
Drug designation to start a clinical trial for this condition. Therefore, there is clinical 
precedent for intravenously administered AAV9 in the clinic and this is being pursued 
by other studies. Gaucher disease is, arguably, an easier target than CLN3 Batten 
disease. This is on the basis that the CLN3 protein is membrane bound within the cell 
and so there is no real possibility for cross-correction of surrounding cells and much 
higher levels of gene delivery efficiency may be required. Glucocerebrosidase is a 
soluble enzyme that could mediate cross-correction of untransduced neighbouring cells 
and so amplifying the therapeutic efficacy. 
Although the main focus of this study has been on developing an intravenous approach 
for systemic effect, the data show that a direct intracerebroventricular injection of vector 
also rescues the Gaucher disease mouse model from neonatal lethality. However, the 
visceral pathology persists and splenomegaly is observed. While there is a case for 
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combining intracerebroventricular mediated gene therapy to treat the brain and also 
administering enzyme replacement therapy for the duration of the patients life to treat 
the visceral organs, this would be hugely expensive. The cost of intravenous gene 
therapy will be high, but as a one-time treatment it is very likely to be more economical 
in the long-term than a lifetime of enzyme replacement therapy. 
The two different routes of administration used in this study may have consequences for 
potential clinical trial design. At present, there is debate in the gene therapy community 
as to whether IV administration of therapeutic AAV vectors is preferable over direct 
administration to the CSF in clinical trials for other neurodegenerative lysosomal 
storage diseases. In those diseases where the defective protein is membrane-bound or 
structural, and so no cross-correction is available, is the ability of AAV9 to cross the 
BBB efficient enough in humans to have a significant effect? An example of this is a 
future clinical trial for neurodegenerative CLN3 Batten disease in which the patients 
will receive an intravenous administration of an AAV9 vector. In contrast, a clinical 
trial for neurodegenerative CLN6 Batten disease, that also involves a defective 
membrane bound protein, the patients will receive the AAV9 vector delivered to the 
CSF via intrathecal administration (NCT02725580). The case for intravenous 
administration in any future translation of this gene therapy study for neuronopathic 
Gaucher disease is stronger due to the added advantage of the soluble nature of the 
glucocerebrosidase protein, allowing for cross-correction. In addition, the systemic 
administration can address the more profound visceral diseases that accompanies the 
neurological pathology. 
6.6. Final considerations 
The first part of the present work showed that, while improvements to the central 
nervous system transduction were needed, the intravenous administration of the vector 
had a clear benefit of targeting both the brain and the visceral organs. The reduction in 
spleen weight and the substantial amelioration of cytopathology in the spleen, liver and 
lungs were encouraging results. The improvements in the visceral pathology were 
further demonstrated in the long-term study, where the systemic disease progressed with 
time in ICV treated mice, resulting in splenomegaly and severe accumulation of 
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Gaucher cells in the tissues. 
The use of a neuron-specific promoter prevented neurodegeneration and rescued the 
mice from the deadly neuropathology. Conversely, the effects on the visceral pathology 
were less evident. Unfortunately, because of the scarce availability of Gba1 knock-out 
mice, it was not possible to administer the ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA 
vector into the brain of neonatal mice and perform a comparative analysis. Arguably, 
the direct injection of the neuronal-specific vector would result in reversion of the 
neurodegeneration, while simultaneously allowing the progression of the visceral 
symptoms. 
Taken together these data have provided a critical insight on the effects of systemic 
gene therapy for the treatment of neuronapathic Gaucher disease. The intravenous 
administration of a vector expressing a strong yet ubiquitous promoter could result in 
widespread enzyme activity, sufficient to ameliorate both the critical neurodegeneration 
and the visceral pathology. As already mentioned, the possibility of combination 
therapy administration should also be considered. This could offer two different 
therapeutic options. First, an intravenous administration of vector with a neuron specific 
promoter like synapsin to treat the brain and partially treat the visceral organs but with 
additional supplementation of reduced doses of ERT. This could partially reduce the 
cost of enzyme replacement therapy. Second, the possibility of using two different viral 
vectors can be explored. The systemic administration of one viral vector with wide 
tropism utilising a ubiquitous promoter could be used to treat the visceral 
manifestations, while a second strong neuron vector injected into the lateral ventricles 
can rescue the severe neuropathology. Although the double administration would be 
simultaneous, a possible host immune response should be taken in consideration. 
The positive effects of gene therapy on the visceral pathology may also be beneficial for 
type I patients. As previously mentioned, the current treatment for Gaucher disease type 
I patients are a considerable burden. On the contrary, a single injection of the viral 
vector may result in an efficient and definitive amelioration of the disease. In addition, 
the ability of the AAV2/9 vector to transduce the bones when administered systemically 
(Rahim et al., 2011) could improve the mild effects of enzyme replacement therapy on 
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bone crisis pathology and pain in type I patients (Charrow et al., 2007). 
The partial clearance of Gaucher cells in the organs demonstrated the potential 
beneficial effects of systemic gene therapy in the viscera.  However, the histological 
analysis did not entirely reflect the evaluation of the enzymatic activity. With the 
iteration of the current protocol, the assay can efficiently detect a significant difference 
in the GCase activity in the blood of knock-out animals compared to wild-type or 
heterozygote mice, yet it is not able to differentiate with certainty more subtle 
dissimilarities. This might be improved with a higher powered study and further 
optimisation of the assay. 
While the pathology presented by the K14-lnl/lnl mice reflects the human symptoms, 
the premature death of the animals due to the acute and rapid neurodegeneration 
required an early intervention. Since the time window for treatment was narrow, the 
administration to neonates was necessary. Although a prenatal diagnosis test to identify 
autosomal founder mutations has been recently proposed (Zeevi et al., 2015), in the 
current clinical practise an accurate diagnosis is frequently delayed and subjects might 
not be identified before the first few months of age (Grabowski, 2008). Therefore, the 
administration of the treatment at day of birth is currently not reliably feasible in human 
patients in the absence of a national/international new born screening programme, or 
unless there is a family history of the disease with an already affected sibling. However, 
the purpose of this study was to provide proof-of-concept evidence on the viability of 
systemic gene therapy for the treatment of neuronopathic Gaucher disease. The use of 
subsequent animal models may be useful to determine whether a later intervention can 
lead to equally promising outputs.  Different mouse models, such as the CBE induced 
model present the advantage of potentially inducing the disease later and assessing 
intervention in older animals (Vardi et al., 2016).  
6.7. Future perspective  
The optimisation of novel vectors would be a main objective of future studies. Different 
vectors carrying powerful ubiquitous promoters will be produced and their effects on 
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the neurological and visceral pathology of knock-out mice will be assessed. Two 
potential candidates are the chicken β-actin promoter which has also being used in 
clinical trials for Batten Disease (NCT02725580), and the CAG promoter which is used 
in the spinal muscular atrophy clinical trial (NCT02122952) and is known to mediate 
high levels and long-term transgene expression (Gray et al., 2011). The synthetic 
sequence is 1.6kb long and comprises the cytomegalovirus enhancer element, the first 
part of the chicken β-actin promoter and the 3’ splice sequence of the rabbit β-globin 
gene (Miyazaki et al., 1989). 
Recent advances in capsid engineering have allowed the creation of novel viral particles 
with enhanced tropism to specific cell types. In one prominent example, Deverman and 
colleagues have developed a cell-type-specific capsid selection technique and thereby 
identified engineered AAV capsids that transduce the brain and the spinal cord of adult 
mice following systemic administration with high efficiency (Deverman et al., 2016, 
Chan et al., 2017). The two AAV-PHP.B and AAV-PHP.eB variants showed high 
efficiency in transducing the CNS following intravenous injection of low dose vector, 
resulting in improved CNS tropism and 40-fold increase in gene expression, compare to 
standard AAV9. The use of these novel vectors will significantly enhance brain 
transduction while substantially reducing the viral load. It is evident that this could have 
major impact on the availability of the vector and production costs. 
The optimisation of the capsid selection system is based on the transduction efficiency 
of neurons in adult mice. However, these novel AAV variants have not been tested on 
non-human primates yet. The prediction of cellular tropism and transduction efficiency 
in humans based on pre-clinical animal studies has not always met the expectations in 
the clinical application. An example of this is the use of an AAV8-based vector for the 
treatment of haemophilia (Lisowski et al., 2015). While AAV8 is able to transduce 
almost 100% of liver cells when administered to mice and non-human primates, only a 
small percentage of the human hepatocytes expresses the transgene. Although the low 
dose of reconstituted enzyme is sufficient to provide a therapeutic effect on treated 
patients, a more specific human tropism needs to be achieved. Therefore, novel capsid 
variants require further investigation in other species before being applied to the clinical 
practice. 
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6.8. Conclusion 
The results reported in this work demonstrated that viral gene delivery is a potential 
therapeutic option for the treatment of neuronapathic Gaucher disease. The advantage of 
this approach is that a single systemic injection of the vector can ameliorate both the 
visceral pathology and the fatal neuropathology of the K14-lnl/lnl mouse model. Two 
different adeno-associated viral vectors have been tested, the administration of which 
resulted in significant extension of the lifespan of treated mice. The different design of 
each vector reflected their distinctive therapeutic characteristics. The 
scAAV2/9.GUSB.hGBA1.bGHpA vector mediated the ubiquitous expression of the 
GBA1 gene following intravenous administration to neonatal mice. While the 
neuropathology was only partially ameliorated, the visceral manifestations noticeably 
benefited from the treatment. A second vector was produced with the intent of improve 
the central nervous system transduction following systemic administration, since there 
is currently no available cure for the devastating neuropathology that characterises 
Gaucher disease type II. As expected, the administration of the neuron-specific 
ssAAV2/9.hSynI.hGBA1.WPRE.hGHpA vector successfully prevented the 
neurodegeneration and rescued the mice from premature death. 
The present work, together with the significant and recent advances in the field, 
validated the use of viral gene therapy for the treatment of genetic diseases for which 
there is currently no cure. Although it is an extremely long and challenging process, the 
unmet need of a life-saving treatment for rare neurological lysosomal storage disorders 
has to be addressed. Further enhancement in gene therapy will improve the translation 
from academic research to clinic application. However, the major obstacles in 
developing a gene therapy treatment remain the prohibitive cost of the production 
process and the availability of highly specialised centres. More research needs to be 
carried out in order to facilitate the development of novel and efficacious therapies. This 
will possibly result in reduction of the manufacture and commercialisation costs, 
rendering gene therapy an attractive treatment option for a wider range of diseases.
192 
Bibliography 
ADACHI, M., WALLACE, B. J., SCHNECK, L. & VOLK, B. W. 1967. Fine structure 
of central nervous system in early infantile Gaucher's disease. Arch Pathol, 83, 
513-26. 
BADDELEY, A. J., GUNDERSEN, H. J. & CRUZ-ORIVE, L. M. 1986. Estimation of 
surface area from vertical sections. J Microsc, 142, 259-76. 
BAILEY, K. R. C., J. N. 2009. Anxiety-related behaviors in mice. In: JJ, B. (ed.) 
Methods of behavior analysis in neuroscience. Boca Ranton (FL): CRC 
Press/Taylor & Francis. 
BARNEVELD, R. A., KEIJZER, W., TEGELAERS, F. P., GINNS, E. I., GEURTS 
VAN KESSEL, A., BRADY, R. O., BARRANGER, J. A., TAGER, J. M., 
GALJAARD, H., WESTERVELD, A. & REUSER, A. J. 1983. Assignment of 
the gene coding for human beta-glucocerebrosidase to the region q21-q31 of 
chromosome 1 using monoclonal antibodies. Hum Genet, 64, 227-31. 
BARTON, N. W., BRADY, R. O., DAMBROSIA, J. M., DI BISCEGLIE, A. M., 
DOPPELT, S. H., HILL, S. C., MANKIN, H. J., MURRAY, G. J., PARKER, R. 
I., ARGOFF, C. E. & ET AL. 1991. Replacement therapy for inherited enzyme 
deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N 
Engl J Med, 324, 1464-70. 
BARTUS, R. T., WEINBERG, M. S. & SAMULSKI, R. J. 2014. Parkinson's disease 
gene therapy: success by design meets failure by efficacy. Mol Ther, 22, 487-97. 
BELMATOUG, N. S., J. 2012. Gaucher Disease [Online]. Available: 
http://www.orpha.net/consor4.01/www/cgi-
bin/OC_Exp.php?lng=EN&Expert=355. 
BERNS, K. I. & GIRAUD, C. 1996. Biology of adeno-associated virus. Curr Top 
Microbiol Immunol, 218, 1-23. 
BITTON, A., ETZELL, J., GRENERT, J. P. & WANG, E. 2004. Erythrophagocytosis 
in Gaucher cells. Arch Pathol Lab Med, 128, 1191-2. 
BLOM, S. & ERIKSON, A. 1983. Gaucher disease--Norrbottnian type. 
Neurodevelopmental, neurological, and neurophysiological aspects. Eur J 
Pediatr, 140, 316-22. 
BOHLEGA, S., KAMBOURIS, M., SHAHID, M., AL HOMSI, M. & AL SOUS, W. 
2000. Gaucher disease with oculomotor apraxia and cardiovascular calcification 
(Gaucher type IIIC). Neurology, 54, 261-3. 
BOSCH, M. E., ALDRICH, A., FALLET, R., ODVODY, J., BURKOVETSKAYA, M., 
SCHUBERTH, K., FITZGERALD, J. A., FOUST, K. D. & KIELIAN, T. 2016. 
Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology 
Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3). J Neurosci, 
36, 9669-82. 
BOSCH, M. E. & KIELIAN, T. 2015. Neuroinflammatory paradigms in lysosomal 
storage diseases. Front Neurosci, 9, 417. 
BOUSTANY, R. M. 2013. Lysosomal storage diseases--the horizon expands. Nat Rev 
Neurol, 9, 583-98. 
BOUSTANY, R. M. M., T. 2007. . In: RIMOIN, D. (ed.) Emery and Rimoin's 
Principles and Practice of Medical Genetics Elsevier. 
193 
BOUTIN, S., MONTEILHET, V., VERON, P., LEBORGNE, C., BENVENISTE, O., 
MONTUS, M. F. & MASURIER, C. 2010. Prevalence of serum IgG and 
neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 
9 in the healthy population: implications for gene therapy using AAV vectors. 
Hum Gene Ther, 21, 704-12. 
BRADBURY, A. M., GRAY-EDWARDS, H. L., SHIRLEY, J. L., MCCURDY, V. J., 
COLACO, A. N., RANDLE, A. N., CHRISTOPHERSON, P. W., BIRD, A. C., 
JOHNSON, A. K., WILSON, D. U., HUDSON, J. A., DE POMPA, N. L., 
SORJONEN, D. C., BRUNSON, B. L., JEYAKUMAR, M., PLATT, F. M., 
BAKER, H. J., COX, N. R., SENA-ESTEVES, M. & MARTIN, D. R. 2015. 
Biomarkers for disease progression and AAV therapeutic efficacy in feline 
Sandhoff disease. Exp Neurol, 263, 102-12. 
BRADY, R. O. 2006. Enzyme replacement for lysosomal diseases. Annu Rev Med, 57, 
283-96. 
BROOKS, S. P. & DUNNETT, S. B. 2009. Tests to assess motor phenotype in mice: a 
user's guide. Nat Rev Neurosci, 10, 519-29. 
BUSTOS, R., KOLEN, E. R., BRAITERMAN, L., BAINES, A. J., GORELICK, F. S. 
& HUBBARD, A. L. 2001. Synapsin I is expressed in epithelial cells: 
localization to a unique trans-Golgi compartment. J Cell Sci, 114, 3695-704. 
CABRERA-SALAZAR, M. A., DERISO, M., BERCURY, S. D., LI, L., LYDON, J. T., 
WEBER, W., PANDE, N., CROMWELL, M. A., COPELAND, D., LEONARD, 
J., CHENG, S. H. & SCHEULE, R. K. 2012. Systemic delivery of a 
glucosylceramide synthase inhibitor reduces CNS substrates and increases 
lifespan in a mouse model of type 2 Gaucher disease. PLoS One, 7, e43310. 
CAN, A., DAO, D. T., TERRILLION, C. E., PIANTADOSI, S. C., BHAT, S. & 
GOULD, T. D. 2012. The tail suspension test. J Vis Exp, e3769. 
CASTELHANO-CARLOS, M. J., SOUSA, N., OHL, F. & BAUMANS, V. 2010. 
Identification methods in newborn C57BL/6 mice: a developmental and 
behavioural evaluation. Lab Anim, 44, 88-103. 
CASTLE, M. J., GERSHENSON, Z. T., GILES, A. R., HOLZBAUR, E. L. & WOLFE, 
J. H. 2014. Adeno-associated virus serotypes 1, 8, and 9 share conserved 
mechanisms for anterograde and retrograde axonal transport. Hum Gene Ther, 
25, 705-20. 
CEARLEY, C. N. & WOLFE, J. H. 2006. Transduction characteristics of adeno-
associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse 
brain. Mol Ther, 13, 528-37. 
CHAN, K. Y., JANG, M. J., YOO, B. B., GREENBAUM, A., RAVI, N., WU, W. L., 
SANCHEZ-GUARDADO, L., LOIS, C., MAZMANIAN, S. K., DEVERMAN, 
B. E. & GRADINARU, V. 2017. Engineered AAVs for efficient noninvasive 
gene delivery to the central and peripheral nervous systems. Nat Neurosci, 20, 
1172-1179. 
CHANDLER, R. J., LAFAVE, M. C., VARSHNEY, G. K., TRIVEDI, N. S., 
CARRILLO-CARRASCO, N., SENAC, J. S., WU, W., HOFFMANN, V., 
ELKAHLOUN, A. G., BURGESS, S. M. & VENDITTI, C. P. 2015. Vector 
design influences hepatic genotoxicity after adeno-associated virus gene therapy. 
J Clin Invest, 125, 870-80. 
CHANDLER, R. J., SANDS, M. S. & VENDITTI, C. P. 2017. Recombinant Adeno-
Associated Viral Integration and Genotoxicity: Insights from Animal Models. 
Hum Gene Ther, 28, 314-322. 
194 
CHARROW, J., DULISSE, B., GRABOWSKI, G. A. & WEINREB, N. J. 2007. The 
effect of enzyme replacement therapy on bone crisis and bone pain in patients 
with type 1 Gaucher disease. Clin Genet, 71, 205-11. 
CHENNA, R., SUGAWARA, H., KOIKE, T., LOPEZ, R., GIBSON, T. J., HIGGINS, 
D. G. & THOMPSON, J. D. 2003. Multiple sequence alignment with the Clustal 
series of programs. Nucleic Acids Res, 31, 3497-500. 
CODERCH, L., LOPEZ, O., DE LA MAZA, A. & PARRA, J. L. 2003. Ceramides and 
skin function. Am J Clin Dermatol, 4, 107-29. 
CONRADI, N. G., SOURANDER, P., NILSSON, O., SVENNERHOLM, L. & 
ERIKSON, A. 1984. Neuropathology of the Norrbottnian type of Gaucher 
disease. Morphological and biochemical studies. Acta Neuropathol, 65, 99-109. 
COX, T., LACHMANN, R., HOLLAK, C., AERTS, J., VAN WEELY, S., 
HREBICEK, M., PLATT, F., BUTTERS, T., DWEK, R., MOYSES, C., GOW, 
I., ELSTEIN, D. & ZIMRAN, A. 2000. Novel oral treatment of Gaucher's 
disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate 
biosynthesis. Lancet, 355, 1481-5. 
COX, T. M. 2001. Gaucher disease: understanding the molecular pathogenesis of 
sphingolipidoses. J Inherit Metab Dis, 24 Suppl 2, 106-21; discussion 87-8. 
COX, T. M. 2010. Gaucher disease: clinical profile and therapeutic developments. 
Biologics, 4, 299-313. 
COX, T. M. & CACHON-GONZALEZ, M. B. 2012. The cellular pathology of 
lysosomal diseases. J Pathol, 226, 241-54. 
CRAWLEY, A. C. & WALKLEY, S. U. 2007. Developmental analysis of CNS 
pathology in the lysosomal storage disease alpha-mannosidosis. J Neuropathol 
Exp Neurol, 66, 687-97. 
DAHL, M., DOYLE, A., OLSSON, K., MANSSON, J. E., MARQUES, A. R. A., 
MIRZAIAN, M., AERTS, J. M., EHINGER, M., ROTHE, M., MODLICH, U., 
SCHAMBACH, A. & KARLSSON, S. 2015. Lentiviral gene therapy using 
cellular promoters cures type 1 Gaucher disease in mice. Mol Ther, 23, 835-844. 
DAVIDSON, B. L., STEIN, C. S., HETH, J. A., MARTINS, I., KOTIN, R. M., 
DERKSEN, T. A., ZABNER, J., GHODSI, A. & CHIORINI, J. A. 2000. 
Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of 
variant cell types and regions in the mammalian central nervous system. Proc 
Natl Acad Sci U S A, 97, 3428-32. 
DAYA, S. & BERNS, K. I. 2008. Gene therapy using adeno-associated virus vectors. 
Clin Microbiol Rev, 21, 583-93. 
DAYTON, R. D., WANG, D. B. & KLEIN, R. L. 2012. The advent of AAV9 expands 
applications for brain and spinal cord gene delivery. Expert Opin Biol Ther, 12, 
757-66. 
DEACON, R. M. 2013. Measuring motor coordination in mice. J Vis Exp, e2609. 
DEEGAN, P. B. & COX, T. M. 2012. Imiglucerase in the treatment of Gaucher disease: 
a history and perspective. Drug Des Devel Ther, 6, 81-106. 
DEKKER, N., VAN DUSSEN, L., HOLLAK, C. E., OVERKLEEFT, H., SCHEIJ, S., 
GHAUHARALI, K., VAN BREEMEN, M. J., FERRAZ, M. J., GROENER, J. 
E., MAAS, M., WIJBURG, F. A., SPEIJER, D., TYLKI-SZYMANSKA, A., 
MISTRY, P. K., BOOT, R. G. & AERTS, J. M. 2011. Elevated plasma 
glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell 
markers, and therapeutic response. Blood, 118, e118-27. 
DESNICK, R. J. & SCHUCHMAN, E. H. 2012. Enzyme replacement therapy for 
lysosomal diseases: lessons from 20 years of experience and remaining 
challenges. Annu Rev Genomics Hum Genet, 13, 307-35. 
195 
DEVEBER, G. A., SCHWARTING, G. A., KOLODNY, E. H. & KOWALL, N. W. 
1992. Fabry disease: immunocytochemical characterization of neuronal 
involvement. Ann Neurol, 31, 409-15. 
DEVERMAN, B. E., PRAVDO, P. L., SIMPSON, B. P., KUMAR, S. R., CHAN, K. 
Y., BANERJEE, A., WU, W. L., YANG, B., HUBER, N., PASCA, S. P. & 
GRADINARU, V. 2016. Cre-dependent selection yields AAV variants for 
widespread gene transfer to the adult brain. Nat Biotechnol, 34, 204-9. 
DEVI, A. R., GOPIKRISHNA, M., RATHEESH, R., SAVITHRI, G., 
SWARNALATA, G. & BASHYAM, M. 2006. Farber lipogranulomatosis: 
clinical and molecular genetic analysis reveals a novel mutation in an Indian 
family. J Hum Genet, 51, 811-4. 
DISEASE, A. W. G. O. M. O. P., KISHNANI, P. S., STEINER, R. D., BALI, D., 
BERGER, K., BYRNE, B. J., CASE, L. E., CROWLEY, J. F., DOWNS, S., 
HOWELL, R. R., KRAVITZ, R. M., MACKEY, J., MARSDEN, D., 
MARTINS, A. M., MILLINGTON, D. S., NICOLINO, M., O'GRADY, G., 
PATTERSON, M. C., RAPOPORT, D. M., SLONIM, A., SPENCER, C. T., 
TIFFT, C. J. & WATSON, M. S. 2006. Pompe disease diagnosis and 
management guideline. Genet Med, 8, 267-88. 
DONSANTE, A., MILLER, D. G., LI, Y., VOGLER, C., BRUNT, E. M., RUSSELL, 
D. W. & SANDS, M. S. 2007. AAV vector integration sites in mouse 
hepatocellular carcinoma. Science, 317, 477. 
DUQUE, S., JOUSSEMET, B., RIVIERE, C., MARAIS, T., DUBREIL, L., DOUAR, 
A. M., FYFE, J., MOULLIER, P., COLLE, M. A. & BARKATS, M. 2009. 
Intravenous administration of self-complementary AAV9 enables transgene 
delivery to adult motor neurons. Mol Ther, 17, 1187-96. 
DVIR, H., HAREL, M., MCCARTHY, A. A., TOKER, L., SILMAN, I., FUTERMAN, 
A. H. & SUSSMAN, J. L. 2003. X-ray structure of human acid-beta-
glucosidase, the defective enzyme in Gaucher disease. EMBO Rep, 4, 704-9. 
ENQUIST, I. B., LO BIANCO, C., OOKA, A., NILSSON, E., MANSSON, J. E., 
EHINGER, M., RICHTER, J., BRADY, R. O., KIRIK, D. & KARLSSON, S. 
2007. Murine models of acute neuronopathic Gaucher disease. Proc Natl Acad 
Sci U S A, 104, 17483-8. 
ENQUIST, I. B., NILSSON, E., MANSSON, J. E., EHINGER, M., RICHTER, J. & 
KARLSSON, S. 2009. Successful low-risk hematopoietic cell therapy in a 
mouse model of type 1 Gaucher disease. Stem Cells, 27, 744-52. 
ENQUIST, I. B., NILSSON, E., OOKA, A., MANSSON, J. E., OLSSON, K., 
EHINGER, M., BRADY, R. O., RICHTER, J. & KARLSSON, S. 2006. 
Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl 
Acad Sci U S A, 103, 13819-24. 
ESCH, S. W., WILLIAMS, T. D., BISWAS, S., CHAKRABARTY, A. & LEVINE, S. 
M. 2003. Sphingolipid profile in the CNS of the twitcher (globoid cell 
leukodystrophy) mouse: a lipidomics approach. Cell Mol Biol (Noisy-le-grand), 
49, 779-87. 
EYAL, N., WILDER, S. & HOROWITZ, M. 1990. Prevalent and rare mutations among 
Gaucher patients. Gene, 96, 277-83. 
FARFEL-BECKER, T., VITNER, E. B. & FUTERMAN, A. H. 2011a. Animal models 
for Gaucher disease research. Dis Model Mech, 4, 746-52. 
FARFEL-BECKER, T., VITNER, E. B., KELLY, S. L., BAME, J. R., DUAN, J., 
SHINDER, V., MERRILL, A. H., JR., DOBRENIS, K. & FUTERMAN, A. H. 
2014. Neuronal accumulation of glucosylceramide in a mouse model of 
196 
neuronopathic Gaucher disease leads to neurodegeneration. Hum Mol Genet, 23, 
843-54. 
FARFEL-BECKER, T., VITNER, E. B., PRESSEY, S. N., EILAM, R., COOPER, J. D. 
& FUTERMAN, A. H. 2011b. Spatial and temporal correlation between neuron 
loss and neuroinflammation in a mouse model of neuronopathic Gaucher 
disease. Hum Mol Genet, 20, 1375-86. 
FERRARI, F. K., SAMULSKI, T., SHENK, T. & SAMULSKI, R. J. 1996. Second-
strand synthesis is a rate-limiting step for efficient transduction by recombinant 
adeno-associated virus vectors. J Virol, 70, 3227-34. 
FINK, J. K., CORRELL, P. H., PERRY, L. K., BRADY, R. O. & KARLSSON, S. 
1990. Correction of glucocerebrosidase deficiency after retroviral-mediated gene 
transfer into hematopoietic progenitor cells from patients with Gaucher disease. 
Proc Natl Acad Sci U S A, 87, 2334-8. 
FISCHER, A. H., JACOBSON, K. A., ROSE, J. & ZELLER, R. 2008. Hematoxylin 
and eosin staining of tissue and cell sections. CSH Protoc, 2008, pdb prot4986. 
FOUST, K. D., NURRE, E., MONTGOMERY, C. L., HERNANDEZ, A., CHAN, C. 
M. & KASPAR, B. K. 2009. Intravascular AAV9 preferentially targets neonatal 
neurons and adult astrocytes. Nat Biotechnol, 27, 59-65. 
FRANCO, L. M., SUN, B., YANG, X., BIRD, A., ZHANG, H., SCHNEIDER, A., 
BROWN, T., YOUNG, S. P., CLAY, T. M., AMALFITANO, A., CHEN, Y. T. 
& KOEBERL, D. D. 2005. Evasion of immune responses to introduced human 
acid alpha-glucosidase by liver-restricted expression in glycogen storage disease 
type II. Mol Ther, 12, 876-84. 
FUKUDA, T., EWAN, L., BAUER, M., MATTALIANO, R. J., ZAAL, K., RALSTON, 
E., PLOTZ, P. H. & RABEN, N. 2006. Dysfunction of endocytic and autophagic 
pathways in a lysosomal storage disease. Ann Neurol, 59, 700-8. 
FUTERMAN, A. H. & HARDY, J. 2016. Perspective: Finding common ground. 
Nature, 537, S160-1. 
FUTERMAN, A. H. & VAN MEER, G. 2004. The cell biology of lysosomal storage 
disorders. Nat Rev Mol Cell Biol, 5, 554-65. 
GAN-OR, Z., AMSHALOM, I., KILARSKI, L. L., BAR-SHIRA, A., GANA-WEISZ, 
M., MIRELMAN, A., MARDER, K., BRESSMAN, S., GILADI, N. & ORR-
URTREGER, A. 2015. Differential effects of severe vs mild GBA mutations on 
Parkinson disease. Neurology, 84, 880-7. 
GIROD, A., WOBUS, C. E., ZADORI, Z., RIED, M., LEIKE, K., TIJSSEN, P., 
KLEINSCHMIDT, J. A. & HALLEK, M. 2002. The VP1 capsid protein of 
adeno-associated virus type 2 is carrying a phospholipase A2 domain required 
for virus infectivity. J Gen Virol, 83, 973-8. 
GOKER-ALPAN, O., LOPEZ, G., VITHAYATHIL, J., DAVIS, J., HALLETT, M. & 
SIDRANSKY, E. 2008. The spectrum of parkinsonian manifestations associated 
with glucocerebrosidase mutations. Arch Neurol, 65, 1353-7. 
GOKER-ALPAN, O., SCHIFFMANN, R., PARK, J. K., STUBBLEFIELD, B. K., 
TAYEBI, N. & SIDRANSKY, E. 2003. Phenotypic continuum in neuronopathic 
Gaucher disease: an intermediate phenotype between type 2 and type 3. J 
Pediatr, 143, 273-6. 
GOKER-ALPAN, O., STUBBLEFIELD, B. K., GIASSON, B. I. & SIDRANSKY, E. 
2010. Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body 
disorders. Acta Neuropathol, 120, 641-9. 
GOMBASH LAMPE, S. E., KASPAR, B. K. & FOUST, K. D. 2014. Intravenous 
injections in neonatal mice. J Vis Exp, e52037. 
197 
GRABOWSKI, G. A. 2008. Phenotype, diagnosis, and treatment of Gaucher's disease. 
Lancet, 372, 1263-71. 
GRABOWSKI, G. A. 2012. Gaucher disease and other storage disorders. Hematology 
Am Soc Hematol Educ Program, 2012, 13-8. 
GRABOWSKI, G. A., GATT, S. & HOROWITZ, M. 1990. Acid beta-glucosidase: 
enzymology and molecular biology of Gaucher disease. Crit Rev Biochem Mol 
Biol, 25, 385-414. 
GRABOWSKI, G. A. P., G.A.; KOLODNY, E.H. 2010. The Online Metabolic and 
Molecular Bases of Inherited disease. New York: Mc Graw Hill. 
GRAEBER, M. B., STREIT, W. J., KIEFER, R., SCHOEN, S. W. & KREUTZBERG, 
G. W. 1990. New expression of myelomonocytic antigens by microglia and 
perivascular cells following lethal motor neuron injury. J Neuroimmunol, 27, 
121-32. 
GRAVES, P. N., GRABOWSKI, G. A., EISNER, R., PALESE, P. & SMITH, F. I. 
1988. Gaucher disease type 1: cloning and characterization of a cDNA encoding 
acid beta-glucosidase from an Ashkenazi Jewish patient. DNA, 7, 521-8. 
GRAY, S. J., FOTI, S. B., SCHWARTZ, J. W., BACHABOINA, L., TAYLOR-
BLAKE, B., COLEMAN, J., EHLERS, M. D., ZYLKA, M. J., MCCOWN, T. J. 
& SAMULSKI, R. J. 2011. Optimizing promoters for recombinant adeno-
associated virus-mediated gene expression in the peripheral and central nervous 
system using self-complementary vectors. Hum Gene Ther, 22, 1143-53. 
GRIMM, D. & KAY, M. A. 2003. From Virus Evolution to Vector Revolution: Use of 
Naturally Occurring Serotypes of Adeno-associated Virus (AAV) as Novel 
Vectors for Human Gene Therapy. Curr Gene Ther., 3, 281-304. 
GUERTL, B., NOEHAMMER, C. & HOEFLER, G. 2000. Metabolic 
cardiomyopathies. Int J Exp Pathol, 81, 349-72. 
GUNDERSEN, H. J., JENSEN, E. B., KIEU, K. & NIELSEN, J. 1999. The efficiency 
of systematic sampling in stereology--reconsidered. J Microsc, 193, 199-211. 
GUPTA, N., OPPENHEIM, I. M., KAUVAR, E. F., TAYEBI, N. & SIDRANSKY, E. 
2011. Type 2 Gaucher disease: phenotypic variation and genotypic 
heterogeneity. Blood Cells Mol Dis, 46, 75-84. 
HADDAD, S. E., KHOURY, M., DAOUD, M., KANTAR, R., HARATI, H., 
MOUSALLEM, T., ALZATE, O., MEYER, B. & BOUSTANY, R. M. 2012. 
CLN5 and CLN8 protein association with ceramide synthase: biochemical and 
proteomic approaches. Electrophoresis, 33, 3798-809. 
HALBERT, C. L., MILLER, A. D., MCNAMARA, S., EMERSON, J., GIBSON, R. L., 
RAMSEY, B. & AITKEN, M. L. 2006. Prevalence of neutralizing antibodies 
against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and 
normal populations: Implications for gene therapy using AAV vectors. Hum 
Gene Ther, 17, 440-7. 
HARRIS, C. M., TAYLOR, D. S. & VELLODI, A. 1999. Ocular motor abnormalities 
in Gaucher disease. Neuropediatrics, 30, 289-93. 
HOLLAK, C. E., VAN WEELY, S., VAN OERS, M. H. & AERTS, J. M. 1994. 
Marked elevation of plasma chitotriosidase activity. A novel hallmark of 
Gaucher disease. J Clin Invest, 93, 1288-92. 
HOLLERAN, W. M., ZIEGLER, S. G., GOKER-ALPAN, O., EBLAN, M. J., ELIAS, 
P. M., SCHIFFMANN, R. & SIDRANSKY, E. 2006. Skin abnormalities as an 
early predictor of neurologic outcome in Gaucher disease. Clin Genet, 69, 355-7. 
HONG, Y. B., KIM, E. Y., YOO, H. W. & JUNG, S. C. 2004. Feasibility of gene 
therapy in Gaucher disease using an adeno-associated virus vector. J Hum 
Genet, 49, 536-43. 
198 
HOROWITZ, M., WILDER, S., HOROWITZ, Z., REINER, O., GELBART, T. & 
BEUTLER, E. 1989. The human glucocerebrosidase gene and pseudogene: 
structure and evolution. Genomics, 4, 87-96. 
HRUSKA, K. S., LAMARCA, M. E., SCOTT, C. R. & SIDRANSKY, E. 2008. 
Gaucher disease: mutation and polymorphism spectrum in the 
glucocerebrosidase gene (GBA). Hum Mutat, 29, 567-83. 
HUIZING, M., HELIP-WOOLEY, A., WESTBROEK, W., GUNAY-AYGUN, M. & 
GAHL, W. A. 2008. Disorders of lysosome-related organelle biogenesis: clinical 
and molecular genetics. Annu Rev Genomics Hum Genet, 9, 359-86. 
HUSAIN, T., PASSINI, M. A., PARENTE, M. K., FRASER, N. W. & WOLFE, J. H. 
2009. Long-term AAV vector gene and protein expression in mouse brain from 
a small pan-cellular promoter is similar to neural cell promoters. Gene Ther, 16, 
927-32. 
JACKSON, K. L., DAYTON, R. D., DEVERMAN, B. E. & KLEIN, R. L. 2016. Better 
Targeting, Better Efficiency for Wide-Scale Neuronal Transduction with the 
Synapsin Promoter and AAV-PHP.B. Front Mol Neurosci, 9, 116. 
JARDIM, L. B., VILLANUEVA, M. M., DE SOUZA, C. F. & NETTO, C. B. 2010. 
Clinical aspects of neuropathic lysosomal storage disorders. J Inherit Metab Dis, 
33, 315-29. 
JEYAKUMAR, M., DWEK, R. A., BUTTERS, T. D. & PLATT, F. M. 2005. Storage 
solutions: treating lysosomal disorders of the brain. Nat Rev Neurosci, 6, 713-25. 
JMOUDIAK, M. & FUTERMAN, A. H. 2005. Gaucher disease: pathological 
mechanisms and modern management. Br J Haematol, 129, 178-88. 
KANDEL, E. S., J. H.; JESSEL, T. 2012. Principles of Neural Science, McGraw-Hill 
Education. 
KARLIN, S. & MRAZEK, J. 1996. What drives codon choices in human genes? J Mol 
Biol, 262, 459-72. 
KIM, B. J., LEE, S. Y., KIM, H. W., PARK, E. J., KIM, J., KIM, S. J., SO, I. & JEON, 
J. H. 2009. Optimized immunohistochemical analysis of cerebellar purkinje cells 
using a specific biomarker, calbindin d28k. Korean J Physiol Pharmacol, 13, 
373-8. 
KIM, J. Y., GRUNKE, S. D., LEVITES, Y., GOLDE, T. E. & JANKOWSKY, J. L. 
2014. Intracerebroventricular viral injection of the neonatal mouse brain for 
persistent and widespread neuronal transduction. J Vis Exp, 51863. 
KO, D. C., MILENKOVIC, L., BEIER, S. M., MANUEL, H., BUCHANAN, J. & 
SCOTT, M. P. 2005. Cell-autonomous death of cerebellar purkinje neurons with 
autophagy in Niemann-Pick type C disease. PLoS Genet, 1, 81-95. 
KOIKE, M., SHIBATA, M., WAGURI, S., YOSHIMURA, K., TANIDA, I., 
KOMINAMI, E., GOTOW, T., PETERS, C., VON FIGURA, K., 
MIZUSHIMA, N., SAFTIG, P. & UCHIYAMA, Y. 2005. Participation of 
autophagy in storage of lysosomes in neurons from mouse models of neuronal 
ceroid-lipofuscinoses (Batten disease). Am J Pathol, 167, 1713-28. 
KOPRIVICA, V., STONE, D. L., PARK, J. K., CALLAHAN, M., FRISCH, A., 
COHEN, I. J., TAYEBI, N. & SIDRANSKY, E. 2000. Analysis and 
classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher 
disease. Am J Hum Genet, 66, 1777-86. 
KOTIN, R. M., SINISCALCO, M., SAMULSKI, R. J., ZHU, X. D., HUNTER, L., 
LAUGHLIN, C. A., MCLAUGHLIN, S., MUZYCZKA, N., ROCCHI, M. & 
BERNS, K. I. 1990. Site-specific integration by adeno-associated virus. Proc 
Natl Acad Sci U S A, 87, 2211-5. 
199 
KOTTERMAN, M. A. & SCHAFFER, D. V. 2014. Engineering adeno-associated 
viruses for clinical gene therapy. Nat Rev Genet, 15, 445-51. 
KOZAK, M. 2005. Regulation of translation via mRNA structure in prokaryotes and 
eukaryotes. Gene, 361, 13-37. 
LAL, T. R. & SIDRANSKY, E. 2017. The Spectrum of Neurological Manifestations 
Associated with Gaucher Disease. Diseases, 5. 
LEONE, P., SHERA, D., MCPHEE, S. W., FRANCIS, J. S., KOLODNY, E. H., 
BILANIUK, L. T., WANG, D. J., ASSADI, M., GOLDFARB, O., GOLDMAN, 
H. W., FREESE, A., YOUNG, D., DURING, M. J., SAMULSKI, R. J. & 
JANSON, C. G. 2012. Long-term follow-up after gene therapy for canavan 
disease. Sci Transl Med, 4, 165ra163. 
LEVINE, B. & KLIONSKY, D. J. 2004. Development by self-digestion: molecular 
mechanisms and biological functions of autophagy. Dev Cell, 6, 463-77. 
LISOWSKI, L., DANE, A. P., CHU, K., ZHANG, Y., CUNNINGHAM, S. C., 
WILSON, E. M., NYGAARD, S., GROMPE, M., ALEXANDER, I. E. & KAY, 
M. A. 2014. Selection and evaluation of clinically relevant AAV variants in a 
xenograft liver model. Nature, 506, 382-6. 
LISOWSKI, L., TAY, S. S. & ALEXANDER, I. E. 2015. Adeno-associated virus 
serotypes for gene therapeutics. Curr Opin Pharmacol, 24, 59-67. 
LIU, G., MARTINS, I., WEMMIE, J. A., CHIORINI, J. A. & DAVIDSON, B. L. 2005. 
Functional correction of CNS phenotypes in a lysosomal storage disease model 
using adeno-associated virus type 4 vectors. J Neurosci, 25, 9321-7. 
LIU, Y., SUZUKI, K., REED, J. D., GRINBERG, A., WESTPHAL, H., HOFFMANN, 
A., DORING, T., SANDHOFF, K. & PROIA, R. L. 1998. Mice with type 2 and 
3 Gaucher disease point mutations generated by a single insertion mutagenesis 
procedure. Proc Natl Acad Sci U S A, 95, 2503-8. 
LLOYD-EVANS, E., PELLED, D., RIEBELING, C., BODENNEC, J., DE-MORGAN, 
A., WALLER, H., SCHIFFMANN, R. & FUTERMAN, A. H. 2003. 
Glucosylceramide and glucosylsphingosine modulate calcium mobilization from 
brain microsomes via different mechanisms. J Biol Chem, 278, 23594-9. 
LOEB, J. E., CORDIER, W. S., HARRIS, M. E., WEITZMAN, M. D. & HOPE, T. J. 
1999. Enhanced expression of transgenes from adeno-associated virus vectors 
with the woodchuck hepatitis virus posttranscriptional regulatory element: 
implications for gene therapy. Hum Gene Ther, 10, 2295-305. 
LUKINA, E., WATMAN, N., ARREGUIN, E. A., DRAGOSKY, M., IASTREBNER, 
M., ROSENBAUM, H., PHILLIPS, M., PASTORES, G. M., KAMATH, R. S., 
ROSENTHAL, D. I., KAPER, M., SINGH, T., PUGA, A. C. & 
PETERSCHMITT, M. J. 2010. Improvement in hematological, visceral, and 
skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate 
(Genz-112638) treatment: 2-year results of a phase 2 study. Blood, 116, 4095-8. 
MANFREDSSON, F. P., RISING, A. C. & MANDEL, R. J. 2009. AAV9: a potential 
blood-brain barrier buster. Mol Ther, 17, 403-5. 
MANNO, C. S., CHEW, A. J., HUTCHISON, S., LARSON, P. J., HERZOG, R. W., 
ARRUDA, V. R., TAI, S. J., RAGNI, M. V., THOMPSON, A., OZELO, M., 
COUTO, L. B., LEONARD, D. G., JOHNSON, F. A., MCCLELLAND, A., 
SCALLAN, C., SKARSGARD, E., FLAKE, A. W., KAY, M. A., HIGH, K. A. 
& GLADER, B. 2003. AAV-mediated factor IX gene transfer to skeletal muscle 
in patients with severe hemophilia B. Blood, 101, 2963-72. 
MANNO, C. S., PIERCE, G. F., ARRUDA, V. R., GLADER, B., RAGNI, M., 
RASKO, J. J., OZELO, M. C., HOOTS, K., BLATT, P., KONKLE, B., DAKE, 
M., KAYE, R., RAZAVI, M., ZAJKO, A., ZEHNDER, J., RUSTAGI, P. K., 
200 
NAKAI, H., CHEW, A., LEONARD, D., WRIGHT, J. F., LESSARD, R. R., 
SOMMER, J. M., TIGGES, M., SABATINO, D., LUK, A., JIANG, H., 
MINGOZZI, F., COUTO, L., ERTL, H. C., HIGH, K. A. & KAY, M. A. 2006. 
Successful transduction of liver in hemophilia by AAV-Factor IX and 
limitations imposed by the host immune response. Nat Med, 12, 342-7. 
MARSHALL, J., SUN, Y., BANGARI, D. S., BUDMAN, E., PARK, H., NIETUPSKI, 
J. B., ALLAIRE, A., CROMWELL, M. A., WANG, B., GRABOWSKI, G. A., 
LEONARD, J. P. & CHENG, S. H. 2016. CNS-accessible Inhibitor of 
Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic 
Gaucher Disease. Mol Ther, 24, 1019-1029. 
MARTINEZ-ARIAS, R., CALAFELL, F., MATEU, E., COMAS, D., ANDRES, A. & 
BERTRANPETIT, J. 2001. Sequence variability of a human pseudogene. 
Genome Res, 11, 1071-85. 
MATTAR, C. N., WADDINGTON, S. N., BISWAS, A., JOHANA, N., NG, X. W., 
FISK, A. S., FISK, N. M., TAN, L. G., RAHIM, A. A., BUCKLEY, S. M., 
TAN, M. H., LU, J., CHOOLANI, M. & CHAN, J. K. 2013. Systemic delivery 
of scAAV9 in fetal macaques facilitates neuronal transduction of the central and 
peripheral nervous systems. Gene Ther, 20, 69-83. 
MATTAR, C. N., WONG, A. M., HOEFER, K., ALONSO-FERRERO, M. E., 
BUCKLEY, S. M., HOWE, S. J., COOPER, J. D., WADDINGTON, S. N., 
CHAN, J. K. & RAHIM, A. A. 2015. Systemic gene delivery following 
intravenous administration of AAV9 to fetal and neonatal mice and late-
gestation nonhuman primates. FASEB J, 29, 3876-88. 
MAZZULLI, J. R., XU, Y. H., SUN, Y., KNIGHT, A. L., MCLEAN, P. J., 
CALDWELL, G. A., SIDRANSKY, E., GRABOWSKI, G. A. & KRAINC, D. 
2011. Gaucher disease glucocerebrosidase and alpha-synuclein form a 
bidirectional pathogenic loop in synucleinopathies. Cell, 146, 37-52. 
MCCARTY, D. M. 2008. Self-complementary AAV vectors; advances and 
applications. Mol Ther, 16, 1648-56. 
MCCARTY, D. M., MONAHAN, P. E. & SAMULSKI, R. J. 2001. Self-
complementary recombinant adeno-associated virus (scAAV) vectors promote 
efficient transduction independently of DNA synthesis. Gene Ther, 8, 1248-54. 
MCEACHERN, K. A., NIETUPSKI, J. B., CHUANG, W. L., ARMENTANO, D., 
JOHNSON, J., HUTTO, E., GRABOWSKI, G. A., CHENG, S. H. & 
MARSHALL, J. 2006. AAV8-mediated expression of glucocerebrosidase 
ameliorates the storage pathology in the visceral organs of a mouse model of 
Gaucher disease. J Gene Med, 8, 719-29. 
MCLEAN, J. R., SMITH, G. A., ROCHA, E. M., HAYES, M. A., BEAGAN, J. A., 
HALLETT, P. J. & ISACSON, O. 2014. Widespread neuron-specific transgene 
expression in brain and spinal cord following synapsin promoter-driven AAV9 
neonatal intracerebroventricular injection. Neurosci Lett, 576, 73-8. 
MEHTA, A. 2006. Epidemiology and natural history of Gaucher's disease. Eur J Intern 
Med, 17 Suppl, S2-5. 
MELCHIORRI, D., PANI, L., GASPARINI, P., COSSU, G., ANCANS, J., BORG, J. 
J., DRAI, C., FIEDOR, P., FLORY, E., HUDSON, I., LEUFKENS, H. G., 
MULLER-BERGHAUS, J., NARAYANAN, G., NEUGEBAUER, B., 
POKROTNIEKS, J., ROBERT, J. L., SALMONSON, T. & SCHNEIDER, C. K. 
2013. Regulatory evaluation of Glybera in Europe - two committees, one 
mission. Nat Rev Drug Discov, 12, 719. 
201 
MENDELL, J. R., ET AL. 2016a. Gene Therapy for Spinal Muscular Atrophy Type 1 
Shows Potential to Improve Survival and Motor Functional Outcomes. In: INC., 
E. (ed.). The American Society of Gene & Cell Therapy. 
MENDELL, J. R. A.-Z., S.; SHELL, R.; ARNOLD, W. D.; RODINO-KLAPAC, L.; 
KISSEL, J. T.; PRIOR, T.; MIRANDA, C; LOWES, L.; ALFANO, L.; BERRY, 
K.; PETEK, C.; CHURCH, K.; BRAUN, L.; CORCORAN, S.; MEYER, K.; 
LIKHITE, S.; BURGHES, A.; FOUST, K. D.; KASPAR, B. K. 2016b. Gene 
Therapy for Spinal Muscular Atrophy Type 1 Shows Potential to Improve 
Survival and Motor Functional Outcomes. In: THERAPY, M. (ed.) The 
American Society of Gene & Cell Therapy. Elsevier. 
MIGNOT, C., DOUMMAR, D., MAIRE, I., DE VILLEMEUR, T. B. & FRENCH 
TYPE 2 GAUCHER DISEASE STUDY, G. 2006. Type 2 Gaucher disease: 15 
new cases and review of the literature. Brain Dev, 28, 39-48. 
MISTRY, P. K., LIU, J., YANG, M., NOTTOLI, T., MCGRATH, J., JAIN, D., 
ZHANG, K., KEUTZER, J., CHUANG, W. L., MEHAL, W. Z., ZHAO, H., 
LIN, A., MANE, S., LIU, X., PENG, Y. Z., LI, J. H., AGRAWAL, M., ZHU, L. 
L., BLAIR, H. C., ROBINSON, L. J., IQBAL, J., SUN, L. & ZAIDI, M. 2010. 
Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease 
displaying cellular and molecular dysregulation beyond the macrophage. Proc 
Natl Acad Sci U S A, 107, 19473-8. 
MISTRY, P. K., SIRRS, S., CHAN, A., PRITZKER, M. R., DUFFY, T. P., GRACE, 
M. E., MEEKER, D. P. & GOLDMAN, M. E. 2002. Pulmonary hypertension in 
type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and 
response to therapy. Mol Genet Metab, 77, 91-8. 
MIYAZAKI, J., TAKAKI, S., ARAKI, K., TASHIRO, F., TOMINAGA, A., 
TAKATSU, K. & YAMAMURA, K. 1989. Expression vector system based on 
the chicken beta-actin promoter directs efficient production of interleukin-5. 
Gene, 79, 269-77. 
MORISOT, C., MILLAT, G., COESLIER, A., BOURGOIS, B., FONTENOY, E., 
DOBBELAERE, D., VEROT, L., HAOUARI, N., VAILLANT, C., 
GOTTRAND, F., BOGAERT, E., THELLIEZ, P., KLOSOWSKI, S., 
DJEBARA, A., BACHIRI, A., MANOUVRIER, S. & VANIER, M. T. 2005. 
[Fatal neonatal respiratory distress in Niemann-Pick C2 and prenatal diagnosis 
with mutations in gene HE1/NPC2]. Arch Pediatr, 12, 434-7. 
MORRISON, C. 2015. $1-million price tag set for Glybera gene therapy. Nat 
Biotechnol, 33, 217-8. 
NAGRAL, A. 2014. Gaucher disease. J Clin Exp Hepatol, 4, 37-50. 
NALDINI, L. 2015. Gene therapy returns to centre stage. Nature, 526, 351-60. 
NARITA, A., SHIRAI, K., ITAMURA, S., MATSUDA, A., ISHIHARA, A., 
MATSUSHITA, K., FUKUDA, C., KUBOTA, N., TAKAYAMA, R., 
SHIGEMATSU, H., HAYASHI, A., KUMADA, T., YUGE, K., WATANABE, 
Y., KOSUGI, S., NISHIDA, H., KIMURA, Y., ENDO, Y., HIGAKI, K., 
NANBA, E., NISHIMURA, Y., TAMASAKI, A., TOGAWA, M., SAITO, Y., 
MAEGAKI, Y., OHNO, K. & SUZUKI, Y. 2016. Ambroxol chaperone therapy 
for neuronopathic Gaucher disease: A pilot study. Ann Clin Transl Neurol, 3, 
200-15. 
NASO, M. F., TOMKOWICZ, B., PERRY, W. L., 3RD & STROHL, W. R. 2017. 
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 
NATHWANI, A. C., REISS, U. M., TUDDENHAM, E. G., ROSALES, C., 
CHOWDARY, P., MCINTOSH, J., DELLA PERUTA, M., LHERITEAU, E., 
PATEL, N., RAJ, D., RIDDELL, A., PIE, J., RANGARAJAN, S., BEVAN, D., 
202 
RECHT, M., SHEN, Y. M., HALKA, K. G., BASNER-TSCHAKARJAN, E., 
MINGOZZI, F., HIGH, K. A., ALLAY, J., KAY, M. A., NG, C. Y., ZHOU, J., 
CANCIO, M., MORTON, C. L., GRAY, J. T., SRIVASTAVA, D., NIENHUIS, 
A. W. & DAVIDOFF, A. M. 2014. Long-term safety and efficacy of factor IX 
gene therapy in hemophilia B. N Engl J Med, 371, 1994-2004. 
NATHWANI, A. C., TUDDENHAM, E. G., RANGARAJAN, S., ROSALES, C., 
MCINTOSH, J., LINCH, D. C., CHOWDARY, P., RIDDELL, A., PIE, A. J., 
HARRINGTON, C., O'BEIRNE, J., SMITH, K., PASI, J., GLADER, B., 
RUSTAGI, P., NG, C. Y., KAY, M. A., ZHOU, J., SPENCE, Y., MORTON, C. 
L., ALLAY, J., COLEMAN, J., SLEEP, S., CUNNINGHAM, J. M., 
SRIVASTAVA, D., BASNER-TSCHAKARJAN, E., MINGOZZI, F., HIGH, K. 
A., GRAY, J. T., REISS, U. M., NIENHUIS, A. W. & DAVIDOFF, A. M. 
2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia 
B. N Engl J Med, 365, 2357-65. 
NAULT, J. C., DATTA, S., IMBEAUD, S., FRANCONI, A., MALLET, M., 
COUCHY, G., LETOUZE, E., PILATI, C., VERRET, B., BLANC, J. F., 
BALABAUD, C., CALDERARO, J., LAURENT, A., LETEXIER, M., 
BIOULAC-SAGE, P., CALVO, F. & ZUCMAN-ROSSI, J. 2015. Recurrent 
AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat 
Genet, 47, 1187-93. 
NEUMANN, J., BRAS, J., DEAS, E., O'SULLIVAN, S. S., PARKKINEN, L., 
LACHMANN, R. H., LI, A., HOLTON, J., GUERREIRO, R., PAUDEL, R., 
SEGARANE, B., SINGLETON, A., LEES, A., HARDY, J., HOULDEN, H., 
REVESZ, T. & WOOD, N. W. 2009. Glucocerebrosidase mutations in clinical 
and pathologically proven Parkinson's disease. Brain, 132, 1783-94. 
NIH, G. H. R. 2017. What is gene therapy? [Online]. MD 20894, USA: National 
Institute of Health. Available: 
https://ghr.nlm.nih.gov/primer/therapy/genetherapy. 
NILSSON, O. & SVENNERHOLM, L. 1982. Accumulation of glucosylceramide and 
glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and 
juvenile Gaucher disease. J Neurochem, 39, 709-18. 
NIXON, G. F. 2009. Sphingolipids in inflammation: pathological implications and 
potential therapeutic targets. Br J Pharmacol, 158, 982-93. 
O'NEILL, R. R., TOKORO, T., KOZAK, C. A. & BRADY, R. O. 1989. Comparison of 
the chromosomal localization of murine and human glucocerebrosidase genes 
and of the deduced amino acid sequences. Proc Natl Acad Sci U S A, 86, 5049-
53. 
ORVISKY, E., SIDRANSKY, E., MCKINNEY, C. E., LAMARCA, M. E., SAMIMI, 
R., KRASNEWICH, D., MARTIN, B. M. & GINNS, E. I. 2000. 
Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher 
disease begins early in gestation. Pediatr Res, 48, 233-7. 
PAN, C., NELSON, M. S., REYES, M., KOODIE, L., BRAZIL, J. J., STEPHENSON, 
E. J., ZHAO, R. C., PETERS, C., SELLECK, S. B., STRINGER, S. E. & 
GUPTA, P. 2005. Functional abnormalities of heparan sulfate in 
mucopolysaccharidosis-I are associated with defective biologic activity of FGF-
2 on human multipotent progenitor cells. Blood, 106, 1956-64. 
PANDEY, M. K., RANI, R., ZHANG, W., SETCHELL, K. & GRABOWSKI, G. A. 
2012. Immunological cell type characterization and Th1-Th17 cytokine 
production in a mouse model of Gaucher disease. Mol Genet Metab, 106, 310-
22. 
203 
PARENTI, G., ANDRIA, G. & VALENZANO, K. J. 2015. Pharmacological Chaperone 
Therapy: Preclinical Development, Clinical Translation, and Prospects for the 
Treatment of Lysosomal Storage Disorders. Mol Ther, 23, 1138-48. 
PARENTI, G., MORACCI, M., FECAROTTA, S. & ANDRIA, G. 2014. 
Pharmacological chaperone therapy for lysosomal storage diseases. Future Med 
Chem, 6, 1031-45. 
PARFITT, D. A., AGUILA, M., MCCULLEY, C. H., BEVILACQUA, D., MENDES, 
H. F., ATHANASIOU, D., NOVOSELOV, S. S., KANUGA, N., MUNRO, P. 
M., COFFEY, P. J., KALMAR, B., GREENSMITH, L. & CHEETHAM, M. E. 
2014. The heat-shock response co-inducer arimoclomol protects against retinal 
degeneration in rhodopsin retinitis pigmentosa. Cell Death Dis, 5, e1236. 
PASSINI, M. A., WATSON, D. J., VITE, C. H., LANDSBURG, D. J., 
FEIGENBAUM, A. L. & WOLFE, J. H. 2003. Intraventricular brain injection of 
adeno-associated virus type 1 (AAV1) in neonatal mice results in 
complementary patterns of neuronal transduction to AAV2 and total long-term 
correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J 
Virol, 77, 7034-40. 
PASTORES, G. M. & HUGHES, D. A. 2015. Gaucher Disease. In: PAGON, R. A., 
ADAM, M. P., ARDINGER, H. H., WALLACE, S. E., AMEMIYA, A., BEAN, 
L. J. H., BIRD, T. D., FONG, C. T., MEFFORD, H. C., SMITH, R. J. H. & 
STEPHENS, K. (eds.) GeneReviews(R). Seattle (WA). 
PASTORES, G. M. & MAEGAWA, G. H. 2013. Clinical neurogenetics: neuropathic 
lysosomal storage disorders. Neurol Clin, 31, 1051-71. 
PASTORES, G. M., PATEL, M. J. & FIROOZNIA, H. 2000. Bone and joint 
complications related to Gaucher disease. Curr Rheumatol Rep, 2, 175-80. 
PAXINOS, G. F., K. 2012. Paxinos and Franklin's the Mouse Brain in Stereotaxic 
Coordinates, Academic Press. 
PELLED, D., LLOYD-EVANS, E., RIEBELING, C., JEYAKUMAR, M., PLATT, F. 
M. & FUTERMAN, A. H. 2003. Inhibition of calcium uptake via the 
sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff 
disease and prevention by treatment with N-butyldeoxynojirimycin. J Biol 
Chem, 278, 29496-501. 
PEREIRA, D. J., MCCARTY, D. M. & MUZYCZKA, N. 1997. The adeno-associated 
virus (AAV) Rep protein acts as both a repressor and an activator to regulate 
AAV transcription during a productive infection. J Virol, 71, 1079-88. 
PLATT, F. M. 2014. Sphingolipid lysosomal storage disorders. Nature, 510, 68-75. 
PLATT, F. M. & LACHMANN, R. H. 2009. Treating lysosomal storage disorders: 
current practice and future prospects. Biochim Biophys Acta, 1793, 737-45. 
PLATT, F. M., NEISES, G. R., DWEK, R. A. & BUTTERS, T. D. 1994. N-
butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol 
Chem, 269, 8362-5. 
POLGREEN, L. E., TOLAR, J., PLOG, M., HIMES, J. H., ORCHARD, P. J., 
WHITLEY, C. B., MILLER, B. S. & PETRYK, A. 2008. Growth and endocrine 
function in patients with Hurler syndrome after hematopoietic stem cell 
transplantation. Bone Marrow Transplant, 41, 1005-11. 
PRESSLER, R. & AUVIN, S. 2013. Comparison of Brain Maturation among Species: 
An Example in Translational Research Suggesting the Possible Use of 
Bumetanide in Newborn. Front Neurol, 4, 36. 
PRINETTI, A., PRIONI, S., CHIRICOZZI, E., SCHUCHMAN, E. H., CHIGORNO, V. 
& SONNINO, S. 2011. Secondary alterations of sphingolipid metabolism in 
lysosomal storage diseases. Neurochem Res, 36, 1654-68. 
204 
RAHIM, A. A., WONG, A. M., HOEFER, K., BUCKLEY, S. M., MATTAR, C. N., 
CHENG, S. H., CHAN, J. K., COOPER, J. D. & WADDINGTON, S. N. 2011. 
Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to 
differential targeting of CNS cell types and extensive transduction of the 
nervous system. FASEB J, 25, 3505-18. 
RASTALL, D. P. & AMALFITANO, A. 2015. Recent advances in gene therapy for 
lysosomal storage disorders. Appl Clin Genet, 8, 157-69. 
RECZEK, D., SCHWAKE, M., SCHRODER, J., HUGHES, H., BLANZ, J., JIN, X., 
BRONDYK, W., VAN PATTEN, S., EDMUNDS, T. & SAFTIG, P. 2007. 
LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting 
of beta-glucocerebrosidase. Cell, 131, 770-83. 
REINER, O. & HOROWITZ, M. 1988. Differential expression of the human 
glucocerebrosidase-coding gene. Gene, 73, 469-78. 
ROTH, P., SKLOWER BROOKS, S., POTAZNIK, D., COOMA, R. & SAHDEV, S. 
2005. Neonatal Gaucher disease presenting as persistent thrombocytopenia. J 
Perinatol, 25, 356-8. 
SANDHOFF, K. 2013. Metabolic and cellular bases of sphingolipidoses. Biochem Soc 
Trans, 41, 1562-8. 
SARAIVA, J., NOBRE, R. J. & PEREIRA DE ALMEIDA, L. 2016. Gene therapy for 
the CNS using AAVs: The impact of systemic delivery by AAV9. J Control 
Release, 241, 94-109. 
SCHMIDT, M., VOUTETAKIS, A., AFIONE, S., ZHENG, C., MANDIKIAN, D. & 
CHIORINI, J. A. 2008. Adeno-associated virus type 12 (AAV12): a novel AAV 
serotype with sialic acid- and heparan sulfate proteoglycan-independent 
transduction activity. J Virol, 82, 1399-406. 
SCHOCH, S., CIBELLI, G. & THIEL, G. 1996. Neuron-specific gene expression of 
synapsin I. Major role of a negative regulatory mechanism. J Biol Chem, 271, 
3317-23. 
SCHOLZ, S. W. & JEON, B. S. 2015. GBA mutations and Parkinson disease: when 
genotype meets phenotype. Neurology, 84, 866-7. 
SCHUELER, U. H., KOLTER, T., KANESKI, C. R., BLUSZTAJN, J. K., 
HERKENHAM, M., SANDHOFF, K. & BRADY, R. O. 2003. Toxicity of 
glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model 
system for assessing neuronal damage in Gaucher disease type 2 and 3. 
Neurobiol Dis, 14, 595-601. 
SCOTT, J. E. & WILLETT, I. H. 1966. Binding of cationic dyes to nucleic acids and 
ther biological polyanions. Nature, 209, 985-7. 
SEHARA, Y., FUJIMOTO, K. I., IKEGUCHI, K., KATAKAI, Y., ONO, F., TAKINO, 
N., ITO, M., OZAWA, K. & MURAMATSU, S. I. 2017. Persistent Expression 
of Dopamine-Synthesizing Enzymes 15 Years After Gene Transfer in a Primate 
Model of Parkinson's Disease. Hum Gene Ther Clin Dev, 28, 74-79. 
SHACHAR, T., LO BIANCO, C., RECCHIA, A., WIESSNER, C., RAAS-
ROTHSCHILD, A. & FUTERMAN, A. H. 2011. Lysosomal storage disorders 
and Parkinson's disease: Gaucher disease and beyond. Mov Disord, 26, 1593-
604. 
SHELTON, S. B., PETTIGREW, D. B., HERMANN, A. D., ZHOU, W., SULLIVAN, 
P. M., CRUTCHER, K. A. & STRAUSS, K. I. 2008. A simple, efficient tool for 
assessment of mice after unilateral cortex injury. J Neurosci Methods, 168, 431-
42. 
SIDRANSKY, E. 2004. Gaucher disease: complexity in a "simple" disorder. Mol Genet 
Metab, 83, 6-15. 
205 
SIDRANSKY, E., FARTASCH, M., LEE, R. E., METLAY, L. A., ABELLA, S., 
ZIMRAN, A., GAO, W., ELIAS, P. M., GINNS, E. I. & HOLLERAN, W. M. 
1996. Epidermal abnormalities may distinguish type 2 from type 1 and type 3 of 
Gaucher disease. Pediatr Res, 39, 134-41. 
SIDRANSKY, E. & LOPEZ, G. 2012. The link between the GBA gene and 
parkinsonism. Lancet Neurol, 11, 986-98. 
SIEGL, G., BATES, R. C., BERNS, K. I., CARTER, B. J., KELLY, D. C., KURSTAK, 
E. & TATTERSALL, P. 1985. Characteristics and taxonomy of Parvoviridae. 
Intervirology, 23, 61-73. 
SIMONARO, C. M., D'ANGELO, M., HASKINS, M. E. & SCHUCHMAN, E. H. 
2005. Joint and bone disease in mucopolysaccharidoses VI and VII: 
identification of new therapeutic targets and biomarkers using animal models. 
Pediatr Res, 57, 701-7. 
SINHA, G. 2014. Gaucher's disease oral therapy gets nod from FDA. Nat Biotechnol, 
32, 970-1. 
SNYDER, B. R., GRAY, S. J., QUACH, E. T., HUANG, J. W., LEUNG, C. H., 
SAMULSKI, R. J., BOULIS, N. M. & FEDERICI, T. 2011. Comparison of 
adeno-associated viral vector serotypes for spinal cord and motor neuron gene 
delivery. Hum Gene Ther, 22, 1129-35. 
SORRENTINO, N. C., D'ORSI, L., SAMBRI, I., NUSCO, E., MONACO, C., 
SPAMPANATO, C., POLISHCHUK, E., SACCONE, P., DE LEONIBUS, E., 
BALLABIO, A. & FRALDI, A. 2013. A highly secreted sulphamidase 
engineered to cross the blood-brain barrier corrects brain lesions of mice with 
mucopolysaccharidoses type IIIA. EMBO Mol Med, 5, 675-90. 
SPIEGEL, S. & MERRILL, A. H., JR. 1996. Sphingolipid metabolism and cell growth 
regulation. FASEB J, 10, 1388-97. 
SRIVASTAVA, A., LUSBY, E. W. & BERNS, K. I. 1983. Nucleotide sequence and 
organization of the adeno-associated virus 2 genome. J Virol, 45, 555-64. 
STARETZ-CHACHAM, O., LANG, T. C., LAMARCA, M. E., KRASNEWICH, D. & 
SIDRANSKY, E. 2009. Lysosomal storage disorders in the newborn. Pediatrics, 
123, 1191-207. 
STEPHENS, M. C., BERNATSKY, A., BURACHINSKY, V., LEGLER, G. & 
KANFER, J. N. 1978. The Gaucher mouse: differential action of conduritol B 
epoxide and reversibility of its effects. J Neurochem, 30, 1023-7. 
STIRNEMANN, J., BELMATOUG, N., CAMOU, F., SERRATRICE, C., 
FROISSART, R., CAILLAUD, C., LEVADE, T., ASTUDILLO, L., 
SERRATRICE, J., BRASSIER, A., ROSE, C., BILLETTE DE VILLEMEUR, 
T. & BERGER, M. G. 2017. A Review of Gaucher Disease Pathophysiology, 
Clinical Presentation and Treatments. Int J Mol Sci, 18. 
STONE, D. L., GINNS, E. I., KRASNEWICH, D. & SIDRANSKY, E. 2000a. Life-
threatening splenic hemorrhage in two patients with Gaucher disease. Am J 
Hematol, 64, 140-2. 
STONE, D. L. & SIDRANSKY, E. 1999. Hydrops fetalis: lysosomal storage disorders 
in extremis. Adv Pediatr, 46, 409-40. 
STONE, D. L., TAYEBI, N., ORVISKY, E., STUBBLEFIELD, B., MADIKE, V. & 
SIDRANSKY, E. 2000b. Glucocerebrosidase gene mutations in patients with 
type 2 Gaucher disease. Hum Mutat, 15, 181-8. 
SUMMERFORD, C. & SAMULSKI, R. J. 1998. Membrane-associated heparan sulfate 
proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol, 72, 
1438-45. 
206 
TAMARGO, R. J., VELAYATI, A., GOLDIN, E. & SIDRANSKY, E. 2012. The role 
of saposin C in Gaucher disease. Mol Genet Metab, 106, 257-63. 
TARDIEU, M., ZERAH, M., HUSSON, B., DE BOURNONVILLE, S., DEIVA, K., 
ADAMSBAUM, C., VINCENT, F., HOCQUEMILLER, M., BROISSAND, C., 
FURLAN, V., BALLABIO, A., FRALDI, A., CRYSTAL, R. G., BAUGNON, 
T., ROUJEAU, T., HEARD, J. M. & DANOS, O. 2014. Intracerebral 
administration of adeno-associated viral vector serotype rh.10 carrying human 
SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA 
disease: results of a phase I/II trial. Hum Gene Ther, 25, 506-16. 
TESSITORE, A., DEL, P. M. M., SANO, R., MA, Y., MANN, L., INGRASSIA, A., 
LAYWELL, E. D., STEINDLER, D. A., HENDERSHOT, L. M. & D'AZZO, A. 
2004. GM1-ganglioside-mediated activation of the unfolded protein response 
causes neuronal death in a neurodegenerative gangliosidosis. Mol Cell, 15, 753-
66. 
TRONCHE, F., KELLENDONK, C., KRETZ, O., GASS, P., ANLAG, K., ORBAN, P. 
C., BOCK, R., KLEIN, R. & SCHUTZ, G. 1999. Disruption of the 
glucocorticoid receptor gene in the nervous system results in reduced anxiety. 
Nat Genet, 23, 99-103. 
TSUJI, S., MARTIN, B. M., BARRANGER, J. A., STUBBLEFIELD, B. K., 
LAMARCA, M. E. & GINNS, E. I. 1988. Genetic heterogeneity in type 1 
Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic 
individuals. Proc Natl Acad Sci U S A, 85, 2349-52. 
US FOOD AND DRUG ADMINISTRATION 2016. Cellular & Gene Therapy 
Guidances [Online]. MD 20993, USA. Available: 
https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryI
nformation/Guidances/CellularandGeneTherapy/default.htm. 
US FOOD AND DRUG ADMINISTRATION 2017. FDA approves first treatment for a 
form of Batten disease [Online]. Available: 
https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm555613.ht
m. 
VARDI, A., ZIGDON, H., MESHCHERIAKOVA, A., KLEIN, A. D., YAACOBI, C., 
EILAM, R., KENWOOD, B. M., RAHIM, A. A., MASSARO, G., MERRILL, 
A. H., JR., VITNER, E. B. & FUTERMAN, A. H. 2016. Delineating 
pathological pathways in a chemically induced mouse model of Gaucher 
disease. J Pathol, 239, 496-509. 
VELLODI, A. 2014. Bone marrow transplantation for lysosomal storage disorders. 
Expert Review of Endocrinology & Metabolism, 1, 425-438. 
VITNER, E. B., DEKEL, H., ZIGDON, H., SHACHAR, T., FARFEL-BECKER, T., 
EILAM, R., KARLSSON, S. & FUTERMAN, A. H. 2010. Altered expression 
and distribution of cathepsins in neuronopathic forms of Gaucher disease and in 
other sphingolipidoses. Hum Mol Genet, 19, 3583-90. 
VITNER, E. B., FARFEL-BECKER, T., EILAM, R., BITON, I. & FUTERMAN, A. H. 
2012. Contribution of brain inflammation to neuronal cell death in 
neuronopathic forms of Gaucher's disease. Brain, 135, 1724-35. 
VITNER, E. B. & FUTERMAN, A. H. 2013. Neuronal forms of Gaucher disease. 
Handb Exp Pharmacol, 405-19. 
VITNER, E. B., SALOMON, R., FARFEL-BECKER, T., MESHCHERIAKOVA, A., 
ALI, M., KLEIN, A. D., PLATT, F. M., COX, T. M. & FUTERMAN, A. H. 
2014. RIPK3 as a potential therapeutic target for Gaucher's disease. Nat Med, 
20, 204-8. 
207 
WALKLEY, S. U. 2009. Pathogenic cascades in lysosomal disease-Why so complex? J 
Inherit Metab Dis, 32, 181-9. 
WALTER, J., YOU, Q., HAGSTROM, J. N., SANDS, M. & HIGH, K. A. 1996. 
Successful expression of human factor IX following repeat administration of 
adenoviral vector in mice. Proc Natl Acad Sci U S A, 93, 3056-61. 
WAN, L., HSU, C. M., TSAI, C. H., LEE, C. C., HWU, W. L. & TSAI, F. J. 2006. 
Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the 
RecNciI and L444P mutations. Blood Cells Mol Dis, 36, 422-5. 
WANG, D. B., DAYTON, R. D., HENNING, P. P., CAIN, C. D., ZHAO, L. R., 
SCHROTT, L. M., ORCHARD, E. A., KNIGHT, D. S. & KLEIN, R. L. 2010. 
Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral 
sclerosis relevant sequelae when TDP-43 is overexpressed. Mol Ther, 18, 2064-
74. 
WANG, R. Y., BODAMER, O. A., WATSON, M. S., WILCOX, W. R. & DISEASES, 
A. W. G. O. D. C. O. L. S. 2011. Lysosomal storage diseases: diagnostic 
confirmation and management of presymptomatic individuals. Genet Med, 13, 
457-84. 
WATAKABE, A., OHTSUKA, M., KINOSHITA, M., TAKAJI, M., ISA, K., 
MIZUKAMI, H., OZAWA, K., ISA, T. & YAMAMORI, T. 2015. Comparative 
analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, 
mouse and macaque cerebral cortex. Neurosci Res, 93, 144-57. 
WEI, R. R., HUGHES, H., BOUCHER, S., BIRD, J. J., GUZIEWICZ, N., VAN 
PATTEN, S. M., QIU, H., PAN, C. Q. & EDMUNDS, T. 2011. X-ray and 
biochemical analysis of N370S mutant human acid beta-glucosidase. J Biol 
Chem, 286, 299-308. 
WEST, M. J., SLOMIANKA, L. & GUNDERSEN, H. J. 1991. Unbiased stereological 
estimation of the total number of neurons in thesubdivisions of the rat 
hippocampus using the optical fractionator. Anat Rec, 231, 482-97. 
WONG, K., SIDRANSKY, E., VERMA, A., MIXON, T., SANDBERG, G. D., 
WAKEFIELD, L. K., MORRISON, A., LWIN, A., COLEGIAL, C., ALLMAN, 
J. M. & SCHIFFMANN, R. 2004. Neuropathology provides clues to the 
pathophysiology of Gaucher disease. Mol Genet Metab, 82, 192-207. 
WORGALL, S., SONDHI, D., HACKETT, N. R., KOSOFSKY, B., KEKATPURE, M. 
V., NEYZI, N., DYKE, J. P., BALLON, D., HEIER, L., GREENWALD, B. M., 
CHRISTOS, P., MAZUMDAR, M., SOUWEIDANE, M. M., KAPLITT, M. G. 
& CRYSTAL, R. G. 2008. Treatment of late infantile neuronal ceroid 
lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus 
expressing CLN2 cDNA. Hum Gene Ther, 19, 463-74. 
WU, J., ZHAO, W., ZHONG, L., HAN, Z., LI, B., MA, W., WEIGEL-KELLEY, K. A., 
WARRINGTON, K. H. & SRIVASTAVA, A. 2007. Self-complementary 
recombinant adeno-associated viral vectors: packaging capacity and the role of 
rep proteins in vector purity. Hum Gene Ther, 18, 171-82. 
XU, Y. H., REBOULET, R., QUINN, B., HUELSKEN, J., WITTE, D. & 
GRABOWSKI, G. A. 2008. Dependence of reversibility and progression of 
mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity 
levels. Mol Genet Metab, 94, 190-203. 
XU, Y. H., WENSTRUP, R. & GRABOWSKI, G. A. 1995. Effect of cellular type on 
expression of acid beta-glucosidase: implications for gene therapy in Gaucher 
disease. Gene Ther, 2, 647-54. 
YOUNG-GQAMANA, B., BRIGNOL, N., CHANG, H. H., KHANNA, R., SOSKA, 
R., FULLER, M., SITARAMAN, S. A., GERMAIN, D. P., GIUGLIANI, R., 
208 
HUGHES, D. A., MEHTA, A., NICHOLLS, K., BOUDES, P., LOCKHART, D. 
J., VALENZANO, K. J. & BENJAMIN, E. R. 2013. Migalastat HCl reduces 
globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma 
of Fabry patients. PLoS One, 8, e57631. 
ZEEVI, D. A., ALTARESCU, G., WEINBERG-SHUKRON, A., ZAHDEH, F., 
DINUR, T., CHICCO, G., HERSKOVITZ, Y., RENBAUM, P., ELSTEIN, D., 
LEVY-LAHAD, E., ROLFS, A. & ZIMRAN, A. 2015. Proof-of-principle rapid 
noninvasive prenatal diagnosis of autosomal recessive founder mutations. J Clin 
Invest, 125, 3757-65. 
ZHANG, H., YANG, B., MU, X., AHMED, S. S., SU, Q., HE, R., WANG, H., 
MUELLER, C., SENA-ESTEVES, M., BROWN, R., XU, Z. & GAO, G. 2011. 
Several rAAV vectors efficiently cross the blood-brain barrier and transduce 
neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther, 
19, 1440-8. 
ZHANG, S., TANG, M. B., LUO, H. Y., SHI, C. H. & XU, Y. M. 2017. Necroptosis in 
neurodegenerative diseases: a potential therapeutic target. Cell Death Dis, 8, 
e2905. 
ZIEGLER, R. J., CHERRY, M., BARBON, C. M., LI, C., BERCURY, S. D., 
ARMENTANO, D., DESNICK, R. J. & CHENG, S. H. 2007. Correction of the 
biochemical and functional deficits in fabry mice following AAV8-mediated 
hepatic expression of alpha-galactosidase A. Mol Ther, 15, 492-500. 
ZIMRAN, A. 2011. How I treat Gaucher disease. Blood, 118, 1463-71. 
 
